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Chapter 1
Introduction
Molecular characterization of tumor tissue by omics technologies has been extensively
used to unravel the underlying biological mechanisms of cancer and to identify novel
predictive biological markers (`biomarkers'), expecting that biomarker-guided treat-
ment decisions for individual patients improve the eﬀectiveness of these treatments.
This development imposes the need for new design and analysis concepts of clinical
trials that test multiple experimental medical interventions according to the molecular
phenotype of a patient in parallel.
1.1 Incorporation of biomarkers into clinical trial
design
Traditionally, clinical trials are subdivided into phases I, II, and III. After each phase a
decision is made whether the experimental treatment performed well enough to move
on to the next phase or, after phase III, if it can be approved for clinical use. However,
during the past decade the requirements for clinical trials have started to expand, indu-
cing a development away from the traditional trial setups such as a simple randomized
design (Fig. 1.1). New design concepts are being developed that aim to keep up with
the rapidly increasing number of potential biomarker-guided medical interventions that
1
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need to be evaluated. This poses several challenges and diﬃculties for the design of
clinical trials. The traditional study designs require long time lines and usually only
evaluate one experimental treatment at a time. To evaluate the increasing amount
of potential medical interventions more eﬃciently, various modiﬁed trial designs have
been proposed that also address issues that can arise when incorporating biomarkers
into clinical trials.
Patients R
Exp
Std
Figure 1.1: Standard randomized design
1.1.1 What is a `biomarker'?
A biomarker is, as deﬁned by the National Institutes of Health Biomarkers Deﬁnitions
Working Group, a characteristic that is objectively measured and evaluated as an indi-
cator of normal biological processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention (Downing 2001). A biomarker can be something as sim-
ple as a patient's blood pressure or it can be more complex, like a certain mutation in
a cancer cell, or other characteristics which need elaborate laboratory testing (Strimbu
and Tavel 2010). A distinction is made between prognostic and predictive biomarkers.
Both are baseline characteristics, but while a prognostic biomarker categorizes patients
by the degree of the outcome of interest, a predictive biomarker categorizes patients
by the degree of response to a certain treatment or therapy (Gosho et al. 2012).
Prognostic biomarkers are associated with the outcome of a disease regardless of
the therapy which was used. While they make it possible to group patients by likely
outcome after treatment with standard therapy, they cannot be used to guide the
choice of treatment for a particular patient (Gosho et al. 2012). The validation of
prognostic biomarkers is rather straightforward and can usually be done retrospectively
(Mandrekar and Sargent 2009a). Predictive biomarkers, on the other hand, should
be validated through a prospective study. They are associated with the response to
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a certain treatment and hence, ideally, oﬀer the possibility to prospectively identify
patients who are likely to beneﬁt from a certain treatment (Mandrekar and Sargent
2009b). The goal of validating predictive biomarkers is to ultimately be able to select
an optimal therapy from several options (Mandrekar and Sargent 2009a).
Mandrekar and Sargent (2009b) state that if time and money are sparse, a retrospective
validation of a predictive biomarker can be considered. However, it is crucial to use
data from a randomized controlled trial (RCT) to ensure comparability of biomarker-
positive and biomarker-negative patients. Data from a non-randomized trial (e.g.
cohort or single-arm studies) are not suitable for this purpose, since causal eﬀects
of the biomarker of interest on the treatment eﬀect cannot be isolated from other
potentially confounding factors (Mandrekar and Sargent 2009b). The focus in this
thesis will be on prospective validation of predictive biomarkers.
1.1.2 Recent design approaches
Various design approaches have been proposed for predictive biomarker validation and
oftentimes, there is more than one term for a speciﬁc study design. For consistency
purposes, the following sections will use the terminology and deﬁnitions used by Mand-
rekar and Sargent (2009b).
One possibility to incorporate biomarkers into a clinical trial design and to investigate
a biomarker-guided therapeutic intervention are so-called enrichment designs. In
this type of design patients are screened for their biomarker proﬁle as they enter the
study. If they test positive for the biomarker of interest they are included in the study,
otherwise they are excluded (cf. Figure 1.2). After this screening and selection step,
the study proceeds with the biomarker-positive patients only, who are then randomized
between an experimental therapy and standard of care. Hence, enrichment designs are
essentially simple randomized designs within a subpopulation with an added screening
step in the beginning of the study to identify patients belonging to the subpopulation
of interest.
The primary hypothesis of enrichment designs typically tests the clinical beneﬁt of
the investigated treatment in the biomarker-positive subpopulation only. Hence, this
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design should only be used if there is reliable evidence that only a subgroup of patients
will beneﬁt from the experimental treatment. Otherwise, a beneﬁt for the remainder
of the patient population may go undetected. An enrichment design is appropriate
Patients
Biomarker
assessment
B+
B−
R
Exp
Std
oﬀ-study
Figure 1.2: Enrichment design
and ethical if an experimental therapy only has a moderate beneﬁt for the entire
population but a high toxicity or if inclusion of biomarker-negative patients is ethically
impossible based on ﬁndings of previous studies. Additionally, the assay reproducibility
and accuracy should be well established, i.e. the determination of a patient's biomarker
status should be reliable and reproducible (Mandrekar and Sargent 2009b).
Besides enrichment designs, there are also all-comers designs, where all patients
meeting the (non biomarker related) eligibility criteria are included in the study, in-
dependent of their biomarker status. There are diﬀerent types of all-comers designs,
including the biomarker-based strategy design, biomarker-by-treatment interaction de-
sign, hybrid design, and sequential testing strategy design (Mandrekar and Sargent
2009b).
Just as the name biomarker-based strategy design suggests, this type of design
aims to compare the strategy of a biomarker-guided treatment against randomizing
between experimental therapy and standard of care, independent of biomarker status
(cf. Figure 1.3). For this purpose, patients are randomized between biomarker-guided
and non-biomarker-guided strategy in the beginning of the study. Here, biomarker-
guided treatment strategy means that biomarker-positive patients are treated with the
experimental therapy and biomarker-negative patients with standard of care. This is
based on the assumption that only biomarker-positive patients beneﬁt from the expe-
rimental treatment under investigation. Patients in the non-biomarker-guided group
are randomized between experimental therapy and standard of care, without assessing
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their biomarker status.
Patients R
Marker-based
Non-marker-based
Biomarker
assessment
B+
B−
R
Exp
Std
Exp
Std
Figure 1.3: Biomarker-based strategy design
The biomarker-based strategy design primarily tests the diﬀerence in treatment out-
come between the two treatment strategies. There are some discussions regarding
the drawbacks of this type of design. In both arms there are biomarker-positive and
biomarker-negative patients receiving one of the two on-study treatments. This causes
an overlap of patient groups receiving the same treatment within the biomarker-guided
and non-biomarker-guided arms. Thus, this type of design is usually less eﬃcient than
other randomized designs (Mandrekar and Sargent 2009b). Additionally, the treatment
eﬀect of the therapy and the prognostic eﬀect of the biomarker cannot be distinguished
(Gosho et al. 2012).
An alternative design, which does not have this overlap issue, is the biomarker-
by-treatment interaction design, also called biomarker-stratiﬁed design. This
design compares the beneﬁt of the experimental therapy in the biomarker-positive
population against the beneﬁt in the biomarker-negative population. Just as for an
enrichment design, the patients are screened for their biomarker status upon entering
the study and are assigned to a biomarker-positive or a biomarker-negative group ac-
cordingly. Within these groups, patients are randomized between experimental therapy
and standard of care.
This type of design can be used if there is not enough evidence that the investigated
therapy only beneﬁts the biomarker-positive population, as it investigates the experi-
mental therapy within the entire population, stratiﬁed by biomarker status (Mandrekar
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and Sargent 2010). The primary hypothesis of the biomarker-by-treatment interaction
Patients
Biomarker
assessment
B+
B−
R
R
Exp
Std
Exp
Std
Figure 1.4: Biomarker by treatment interaction design
design usually either tests the interaction between biomarker and treatment, or alter-
natively, it tests the treatment beneﬁt separately in each biomarker-group (An et al.
2012).
If it is not possible to treat biomarker-negative patients with the experimental therapy
due to ethical constraints, but one still wishes to collect data for these patients, one
could use a hybrid design, which is a mixture of the enrichment design and the
biomarker-by-treatment interaction design. This hybrid design randomizes biomarker-
positive patients between treatments, but rather than excluding the biomarker-negative
patients, they are kept in the study and treated with standard of care (cf. Figure 1.5).
Patients
Biomarker
assessment
B+ R
B−
Exp
Std
Std
Figure 1.5: Hybrid design
Mandrekar and Sargent (2009b) describe this design as similar to an enrichment design,
but providing additional value by including and collecting specimens and follow-up from
all patients. This allows using the collected data for retrospective testing for other
prognostic biomarkers later on. However, like the enrichment design, the primary
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hypothesis of the hybrid design only tests the beneﬁt of the investigated treatment in
the biomarker-positive population, and hence it is only powered to detect diﬀerences
in outcomes in this subpopulation (Mandrekar and Sargent 2009b).
In their paper, Mandrekar and Sargent (2009b) discuss another type of design to
investigate the treatment eﬀect within the entire population as well as the biomarker-
positive subpopulation: the sequential testing strategy design. Its general design
is similar to a biomarker-by-treatment interaction design, but it allows testing in the
overall population as well as in the subpopulation and it is usually based on one of
two diﬀerent testing strategy options. If the experimental treatment is expected to be
broadly eﬀective, it is tested in the entire population ﬁrst and afterwards in the (pro-
spectively deﬁned) biomarker-positive subpopulation. If there is strong prior evidence
that the eﬀect of the experimental treatment is much stronger in the biomarker-positive
population, the treatment is tested in the subpopulation ﬁrst (given that the investi-
gated biomarker has a suﬃcient prevalence). If the analysis within the subpopulation
yields signiﬁcant results, the entire population is tested as well (Mandrekar and Sargent
2009b). These strategies for testing in the overall as well as the subpopulation can
help to avoid that a subpopulation that beneﬁts from a new treatment may go un-
identiﬁed. This could happen when a new treatment is tested in the overall population
but only the biomarker-positive patients beneﬁt from the treatment, or if the treat-
ment is only tested in the biomarker-positive subpopulation but it would also beneﬁt the
biomarker-negative patients. For analysis strategies where two (or more) hypotheses
are tested, the issue of multiple testing can be addressed by utilizing so-called closed
testing procedures (Mandrekar and Sargent 2009b, Millen and Dmitrienko 2012).
1.1.3 Clinical trial designs with multiple biomarkers
The next step after incorporating a single biomarker into a clinical trial is to incor-
porate multiple biomarkers. The motivation behind trials testing multiple biomarkers
simultaneously is saving resources compared to running separate trials for each of the
biomarkers. Additionally, multiple biomarker trials oﬀer treatment options to a larger
percentage of patients who undergo a biomarker-screening, which makes the trial more
attractive to potential participants.
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Renfro and Sargent (2016) describe three diﬀerent approaches to multiple biomarker
trials, which they refer to as master protocols: trials that view biomarkers as a reﬁne-
ment of a certain tumor type (umbrella trials) and trials that understand biomarkers
as a replacement of the tumor type and which therefore recruit patients independent
of histology (basket trials). Master protocols that ﬁt neither of these descriptions are
referred to as platform trials. The detailed deﬁnitions of these three trial concepts can
slightly diﬀer, sometimes leading to a certain trial being classiﬁed diﬀerently, depending
on the author. For consistency purposes, the following sections will use the deﬁnitions
of Renfro and Sargent (2016).
In their paper, Renfro and Sargent (2016) deﬁne basket trials as trials which are
based on the hypothesis that certain biomarkers predict the response to a corresponding
treatment better than the tumor type. Therefore, patient eligibility is independent of
histology and the `baskets' patients are assigned to are deﬁned solely by biomarkers
(Figure 1.6). Nevertheless, basket trials are typically not entirely independent of tumor
type - they can, for example, be restricted to solid tumor types.
Tumor A
Tumor B
Tumor C
Tumor D
Biomarker 1
Biomarker 2
Biomarker 3
Biomarker 4
Patients screened
Drug 1
Drug 2
1
Figure 1.6: Study scheme for a basket trial 1.
1
Adapted from https://www.bhdsyndrome.org/forum/bhd-research-blog/genetic-sequencing-approaches-to-cancer-clinical-trials
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Due to diﬀerent standard treatments across tumor types, basket trials usually do not
include randomization to a standard arm. Examples for basket trials are NCI MATCH
(Mullard 2015) and SIGNATURE (Kang et al. 2015), which are both still ongoing
(Renfro and Sargent 2016).
Basket trials can be described as an eﬃcient way of screening experimental therapeu-
tics across multiple patient populations in early-phase drug development (Mandrekar
et al. 2015). Hence, one advantage discussed by Renfro and Sargent (2016) is that
these trials oﬀer biomarker-guided treatment for a great variety of tumor types, often
even for rare tumor types for which a standalone (randomized) clinical trial would not
be possible.
While these advantages sound compelling, Mandrekar et al. (2015) criticize the un-
certainty that prevails regarding the statistical planning and analysis of basket trials.
Their main point of criticism is the lack of justiﬁcation of sample sizes, but they also
demand taking more measures to take into account the inter-patient and inter-tumor
heterogeneity. Additionally, they call for more awareness regarding multiple testing
issues. However, above all there is the major limitation as pointed out by Renfro and
Sargent (2016): The underlying assumption that biomarkers can predict response to a
targeted therapy independent of the tumor type is still just a hypothesis; not a proven
concept.
Umbrella trials on the other hand do not rely on this hypothesis, as enrollment is
generally restricted to one tumor type (Figure 1.7). Patients are centrally screened
and assigned to one of several biomarker-deﬁned subtrials, which can be randomized
or single-arm. Examples for umbrella trials include FOCUS4 (Kaplan et al. 2013),
ALCHEMIST (Gerber et al. 2015), and LUNG-MAP (Ferrarotto et al. 2015). Again,
all of these studies are still ongoing (Renfro and Sargent 2016).
An advantage over basket trials that Renfro and Sargent (2016) point out is that
the restriction to a speciﬁc tumor type makes umbrella trials less susceptible to inter-
tumor heterogeneity. Additionally, inference regarding the considered tumor type can
be drawn more easily and, given there is randomization between the experimental
and standard treatments, prognostic and predictive eﬀects of the biomarkers can be
investigated.
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Tumor A
Tumor B
Tumor C
Tumor D
Biomarker 1
Biomarker 2
Biomarker 3
Biomarker 4
Patients screened
Tumor B
Drug 1
Drug 2
Drug 3
Trial 1
Trial 2
Tumor C Drug 1
Drug 3
Drug 4
1Figure 1.7: Study scheme for an umbrella trial
2.
However, the restriction to a single tumor type can also be a disadvantage: if a rare
tumor is subdivided into even smaller biomarker-groups, there could be issues with
suﬃcient accrual and overall progress of the trial (Renfro and Sargent 2016).
Master protocols that do not ﬁt either the basket or the umbrella type trials are referred
to as platform trials by Renfro and Sargent (2016). According to their deﬁnition,
platform trials typically comprise a randomized study design with common control arm
and many experimental treatment arms that are dynamically added to the study and
which can be closed again based on futility or eﬃcacy. Examples for platform trials are
SHIVA (Le Tourneau et al. 2015), NCI-MPACT (Do et al. 2015), the BATTLE trials
(Liu and Lee 2015), I-SPY2 (Park et al. 2016), and CUSTOM (Lopez-Chavez et al.
2015).
Unlike the aforementioned basket and umbrella trials, some of the listed platform trials
have already been completed. One of these trials is the SHIVA trial, whose design was
similar to a basket trial, i.e. patient accrual across diﬀerent tumor types, but it addi-
tionally included a randomized comparison between targeted therapy and physician's
2
Adapted from https://www.bhdsyndrome.org/forum/bhd-research-blog/genetic-sequencing-approaches-to-cancer-clinical-trials
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choice. The results of the SHIVA trial were published in 2015 by Le Tourneau et al.
(2015). They reported that they were not able to detect a signiﬁcant diﬀerence in
progression free survival of the targeted treatment strategy versus treatment with phy-
sician's choice. In their paper, they identify four key issues of their trial. Three are of
a more logistical nature: usage only of targeted agents marketed in France, treatment
with mostly single agents instead of combination therapy, and ﬁnally, not being able
to revise the assigned therapy (to react to developments/mutations within a patients'
tumor). Beyond these three issues, they criticize that the treatment algorithm used was
`unidimensional', meaning that it did not take into account the potential interaction
of coexisting biomarkers with the assigned treatment (Le Tourneau et al. 2015).
Another completed platform trial is the CUSTOM trial, again with recruitment across
tumor types, where patients were assigned to one of several experimental therapies
according to their basket (Lopez-Chavez et al. 2015). Patients that could not be
assigned to one of the baskets were treated with standard of care and followed up until
death. Each basket was treated as an independent phase II trial, with at least 40%
response rate as primary endpoint. Lopez-Chavez et al. (2015) reported that one of
the investigated drugs achieved its primary endpoint, one other did not. For all other
drugs, completion of accrual was deemed unfeasible. According to the authors, the
main weaknesses of the CUSTOM study were the low patient numbers due to the low
prevalence of the chosen biomarkers and the lack of an adaptive design. In particular,
they would have liked to be able to react to the latest developments by adding new
biomarker-arms and/or new treatments to the ongoing study (Lopez-Chavez et al.
2015).
All types of master protocols discussed in this section are quite challenging to plan
and execute, since they require a close collaboration between multiple industry, aca-
demic, regulatory, and community oncology stakeholders, often including participation
by multiple pharmaceutical companies providing drugs to the same trial (Renfro and
Sargent 2016). The results of the screening need to be suﬃciently reliable and the
screening process should be ﬁnancially feasible. Still, the overall number of patients
that can be screened is usually limited, simultaneously limiting the number of patients
in the individual biomarker-groups. Therefore, it is advantageous to be able to oﬀer
experimental treatment to as many patients as possible. If available, oﬀering an ex-
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perimental therapy to the biomarker-negative patients may help with accrual (Renfro
and Sargent 2016).
In summary, attention should be paid to expected sample sizes in the biomarker-
positive groups and inclusion of biomarker-negative patients should be considered when
appropriate. Another issue with master protocols, as discussed by Le Tourneau et al.
(2015) regarding the SHIVA trial, is that patients may qualify for more than one of the
biomarker-groups. Therefore, for these cases there should be clear rules regarding the
allocation to the biomarker-groups, possibly taking into consideration known interacti-
ons between biomarkers and treatments. Finally, due to the rapid developments in the
area of biomarkers and targeted therapies, master protocols should be ﬂexible enough
to react accordingly, as Lopez-Chavez et al. (2015) concluded from their CUSTOM
study.
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Aims of this PhD Thesis
The goal of this thesis is to develop and examine the design and analysis of an umbrella-
type cancer clinical trial with a time-to-event outcome as primary endpoint. This
trial should comprise multiple biomarker-deﬁned subgroups, each testing a distinct
experimental therapy versus standard-of care. The design should be ﬂexible enough
to accommodate new biomarker-based subgroups as new information (from internal or
external data as well as from expert knowledge) emerges. Of primary interest is a proof
of eﬃcacy of the biomarker guided strategy versus standard of care, and evaluation
of speciﬁc multi-arm subgroups, which may be deﬁned by prognostic risk or biological
functioning. The focus will be on three issues which arise in multiple biomarker trials.
The ﬁrst issue considered is low prevalence of the biomarkers. As more and more
biomarkers are discovered, patient populations are further and further subdivided into
biomarker-deﬁned subpopulations. Hence, the biomarkers of interest may have a preva-
lence that is too low to analyze the data for these subpopulations individually. For this
situation, it is aimed to investigate the evaluation of the biomarker-guided treatment
strategy rather than evaluating each group separately.
As a consequence of the low prevalence of the biomarkers, a large number of biomarker-
negative patients should be expected at the screening stage, which is the second
issue considered in this thesis. It is aimed to investigate whether inclusion of these
patients in the trial and the analysis provides additional beneﬁt, such as improvement
of power or reduction of bias.
The third issue considered is the constant discovery of new biomarkers and corre-
sponding biomarker-guided experimental therapies. It is aimed to be able to react to
these continuous developments by investigating options to add new biomarkers and
corresponding therapies to an ongoing study.
For this purpose an umbrella-type study design is proposed, where enrollment is re-
stricted to a single tumor type. Upon entering the study, each patients' biomarker
status is assessed with regard to the biomarkers included in the study (cf. Figure
1.8). According to these results, the patients are assigned to the respective biomarker-
deﬁned groups or to a biomarker-negative group, if they cannot be matched with any
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Figure 1.8: Proposed biomarker-guided study design
of the biomarker-groups. If a patient is matched with more than one of the biomarker-
deﬁned groups, guidelines should be available on how to proceed, possibly by assigning
diﬀerent priorities to the biomarkers, e.g. based on their prevalence or expected treat-
ment outcomes. Within the biomarker-deﬁned subgroups, patients are randomized
between an experimental, i.e. biomarker-guided, therapy and standard of care. The
experimental therapies can diﬀer for each group. Due to the restriction to one tumor
type, standard of care is assumed to be the same across the biomarker-groups. The
biomarker-negative group can either simply be assigned to standard of care or may also
be randomized between an experimental treatment and standard of care. During the
course of the study, biomarker-arms may be added as new information and biomarkers
become available.
Chapter 2
Fundamental Methods
2.1 Survival analysis
This Section is largely part of a paper that has already been published. The relevant
passages have been taken verbatim from Beisel et al. (2017). Section 2.1.1.4 has
already been published in Habermehl et al. (2017).
For data arising from oncological clinical trials, the endpoint of interest is commonly a
survival- or time-to-event endpoint, such as overall survival or progression free survival.
Hence, survival analysis is an often used tool. Time-to-event means that a time until
a certain event happens is observed. A key diﬀerence to other types of data is the
so-called `censoring'. Censoring occurs when the event of interest has not occurred
by the time the follow-up ends or if a patient leaves the study prematurely. A patient
who was censored at time t is known to not having had the event until time t, but it
is not known if or when the event occurred after time t. The survival function, i.e.
the probability that a patient survives longer than time t, is commonly denoted by
S(t) = P (T > t). The hazard function or hazard rate
h(t) = lim
∆t→0
P (t ≤ T < t+ ∆t|T ≥ t)
∆t
is the instantaneous rate of experiencing the event of interest at time t given that the
patient has survived until time t (e.g. see Kleinbaum and Klein 1996).
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2.1.1 Cox proportional hazards model
In 1972, Cox suggested a proportional hazards (PH) model which models the hazard
function as
λ(t) = λ0(t) exp(βx), (2.1)
where λ0 is the baseline hazard, β is the treatment eﬀect, and x the treatment indicator
(Cox 1972). As the name suggests, this model relies on the proportional hazards
assumption, i.e. the assumption that the hazard ratio is constant over time. The Cox
PH model is a common choice to model survival data to estimate the treatment eﬀect
of an experimental therapy compared to standard of care.
2.1.1.1 Stratiﬁed Cox proportional hazards model
To take into consideration that the biomarkers in the study might be prognostic, the
baseline hazards of the biomarker-groups should be allowed to diﬀer. Hence, a stratiﬁed
Cox PH model (Kalbﬂeisch and Prentice 1980) may be a more suitable choice, where
each biomarker-deﬁned stratum is allowed to have an individual baseline hazard. In the
stratiﬁed Cox PH model with a single covariate the stratum-speciﬁc hazard function is
modeled as
λi(t) = λ0i(t) exp(βx), (2.2)
where i = 1, 2, ..., s is the stratum indicator and λ0i(t) is the baseline hazard for
stratum i.
For the simulation studies in Section 3, the Cox PH model and the stratiﬁed Cox PH
model were applied using the R function coxph{survival}.
2.1.1.2 Two-step procedure
Mehrotra et al. (2012) suggested an alternative to the stratiﬁed Cox PH model for
the case of unequal hazard ratios. They developed a two-step approach which ﬁrst
estimates the treatment eﬀects within the strata separately and then combines them
via a weighted average to an estimate for the overall treatment eﬀect:
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1. Estimate treatment eﬀect β̂i for each stratum i individually, using an unstratiﬁed
Cox PH model, separately ﬁtted to each stratum.
2. Combine the treatment eﬀect estimates for the strata to an overall treatment
eﬀect by a weighted mean
β̂ =
s∑
i=1
ωiβ̂i,
with weights ωi (
∑s
i=1 ωi = 1).
These weights can, for example, be deﬁned by the proportion of patients in the strata,
i.e. ωi = gi, where gi is the proportion of total sample size in stratum i. Under the
assumption of homogeneous treatment eﬀects, using these weights for the strata gives
similar results to the stratiﬁed Cox PH model. Allowing to adjust the weighting of the
strata makes this procedure more ﬂexible and can reduce the bias of the estimator in
the case of heterogeneous treatment eﬀects (cf. Mehrotra et al. 2012). Hence, the
usage of this two-step approach is a possibility to use the Cox PH model in situations
when the assumption of homogeneous treatment eﬀects across strata, which is made
by the stratiﬁed Cox PH model, is violated.
Note that the overall treatment eﬀect β can be considered as the average beneﬁt of a
random patient sampled from a mixture distribution with weights ωi.
To calculate a Wald test statistic (the Wald test will be discussed in more detail in
Section 2.1.2.3), one also needs a variance estimate:
Vˆ (βˆ) =
s∑
i=1
ω2i Vˆ (βˆi),
where Vˆ (βˆi) is the variance estimate for βˆi from the Cox PH model ﬁtted to stratum i.
2.1.1.3 Frailty model
Another alternative to the stratiﬁed Cox PH model is the shared frailty model, a
type of random eﬀects model (e.g. see Duchateau and Janssen 2007). Instead of
considering diﬀerent baseline hazards for the strata, this model extends the Cox PH
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model by including an unobservable random variable W which acts multiplicatively on
the common baseline hazard across all strata, λ0. For each stratum i the random
variable W achieves an outcome wi, i.e. this model assumes homogeneity within the
strata but heterogeneity across strata. The stratum-speciﬁc hazard function is modeled
as
λi(t) = wiλ0(t) exp(βx). (2.3)
The most common distribution choices for the frailty variable W are the gamma dis-
tribution and the lognormal distribution. The probability density function for the log-
normal distribution with E(Y ) = exp(γ/2) and V ar(Y ) = exp(2γ)− exp(γ) is
f(y) =
1
y
√
2piγ
exp
(
−(log y)
2
2γ
)
, (2.4)
with γ > 0.
The probability density function for the gamma distribution with E(Y ) = 1 and
V ar(Y ) = θ is
f(y) =
y
1
θ
−1e−
y
θ
Γ
(
1
θ
)
θ
1
θ
. (2.5)
The shape and scale parameters of this gamma distribution are 1
θ
and θ, respectively.
The popularity of the Gamma distribution is mainly due to mathematical and com-
putational convenience, as it is easy to derive closed-form expressions of the survival
and hazard functions. The lognormal frailty model is more computationally intensive.
It requires the solution of numerical integrals, because there exists no closed-form ex-
pression of the marginal likelihood. With increasing computer power, the lognormal
distribution has become a popular alternative due to its close connection to random
eﬀects and mixed eﬀects models (Wienke 2010).
For the simulation studies in Section 3, the shared frailty model was applied using the
R function coxme{coxme}.
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2.1.1.4 Firth correction
Firth (1993) addressed the issue of bias of maximum likelihood estimates caused by
small sample sizes and rare events. To reduce this bias, he suggested using a penalized
likelihood based on a modiﬁed score function. Heinze and Schemper (2001) formulated
the modiﬁed score function, which is oftentimes referred to as Firth correction or Firth
penalty, for Cox regression:
U(β)∗ = U(β) + 0.5 trace
[
I(β)−1 {∂I(β)/∂β}] , (2.6)
where U(·) is the score function and I(·) is the Fisher information matrix. This
modiﬁed score function is related to the penalized log likelihood function logL(β)∗ =
logL(β) + 0.5 log |I(β)|.
For the simulation studies in Section 3, the Cox PH model with Firth correction was
applied using the R function coxphf{coxphf}.
2.1.2 Signiﬁcance tests
There are several tests available to test the signiﬁcance of the estimated treatment
eﬀect, i.e. to test the null hypothesis H0: β = β0 against the alternative hypothesis
H1: β 6= β0. The coxph procedure from the R-package survival, which can be used
for all of the analysis methods discussed above, gives 3 diﬀerent test statistics and
corresponding p-values: the score test, the Wald test, and the likelihood ratio test. In
the following, the focus will be on the former two.
2.1.2.1 Asymptotic stratiﬁed log-rank test
The stratiﬁed log-rank test statistic is given by
Z =
s∑
i=1
Oi − Ei√
s∑
i=1
V (Oi − Ei)
∼ N(0, 1), (2.7)
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where i = 1, ..., s are the strata, and
Oi − Ei =
∑
j
∑
k
(oijk − eijk), (2.8)
where j and k are the treatment groups and failure times, respectively, and oijk and
eijk are the observed and expected events at time k in treatment group j and stratum i.
For the simulation studies in Section 3, the asymptotic log-rank test was applied using
the R function survdiff{survival}.
2.1.2.2 Score test
If no other covariates are included in the model, and the single covariate in the model
is categorical, the score test is identical to the log-rank test (Therneau and Grambsch
2000). Rao's score test (Rao 1948) tests the hypothesis H0 : β = β0 and its test
statistic is given by
Z =
U(β0)√
I(β0)
∼ N(0, 1), (2.9)
where U(β0) is the score function, i.e. the derivative of the log-likelihood function
with respect to β at β0, and I(β0) is the Fisher information.
The stratiﬁed version of the log-rank test is used to test the null hypothesis that there
is no diﬀerence between two populations with respect to the probability of a speciﬁc
event, controlling for a stratiﬁcation variable. The test statistic of the stratiﬁed log-
rank test approximately follows a standard normal distribution (cf. Kleinbaum and
Klein 1996). However, just as for the unstratiﬁed log-rank test, this assumption may
not apply for small sample situations, resulting in loss of power. For small samples,
the exact log-rank test by Mehta et al. (1992) is a suitable alternative, because it
is based on permutation. The downside of this test is that due to the permutation,
the exact log-rank test becomes computationally expensive quite fast as the sample
size increases. Alternatively, the approximate version of the exact log-rank test can be
used, which approximates the exact log-rank test via Monte Carlo resampling (Strasser
and Weber 1999).
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For the simulation studies in Section 3, the exact/approximate log-rank test was applied
using the R function logrank_test{coin}.
2.1.2.3 Wald test
The Wald test and the score test are asymptotically equivalent, however the Wald
test has been referred to as less reliable in ﬁnite samples by several authors, such as
Therneau and Grambsch (2000) and Agresti (2007). The test statistic of the Wald
test is given by
Z =
βˆ − β0√
V ar(βˆ)
. (2.10)
In contrast to the score test, the Wald test statistic not only depends on β0 (cf.
Equation 2.9), but also on the estimate βˆ. Therefore, it can be used when comparing
the performance of Mehrotra's two-step procedure (cf. Section 2.1.1.2) to the regular
stratiﬁed Cox PH model. Note that the score test would give the same test statistic
for both cases, since it only depends on the treatment eﬀect under the null, β0.
2.1.3 Sample size calculation for survival trials
2.1.3.1 Schoenfeld's formula
A well-known formula for sample size calculation for the Cox PH model is the Schoen-
feld formula (Schoenfeld 1983). In his paper, Schoenfeld showed that the sample size
n needed to compare two survival distributions is given by:
n =
(z1−α/2 + z1−β)2
r(1− r)(logHR)2 q , (2.11)
where α and 1 − β are signiﬁcance level and required power of the test, respecti-
vely, z1−α/2 and z1−β are the 1 − α/2 and 1− β percentiles of the standard normal
distribution, respectively, r is the proportion of patients randomized to the standard
treatment arm, HR is the minimal detectable hazard ratio of the experimental and
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standard treatments, and q is the expected probability to experience the event of inte-
rest. An advantage of Schoenfeld's formula is that, beyond the proportional hazards
assumption, it does not rely on a speciﬁc survival distribution.
Note that Schoenfeld's formula neither allows stratiﬁcation nor stratum speciﬁc hazard
ratios.
2.1.3.2 Palta and Amini's formula
A few years later, Palta and Amini (1985) extended Schoenfeld's formula to allow for
stratiﬁcation. They generalized Equation 2.11 for m > 1 strata:
n =
(z1−α + z1−β)2
µ2
, (2.12)
where
µ =
s∑
i=1
gi
∫ ∞
0
logHRi(t) ri(1− ri)vi(t)dt√
s∑
i=1
gi
∫ ∞
0
vi(t)ri(1− ri)dt
, (2.13)
where gi is the proportion of total sample size in stratum i, ri is the proportion of
patients in stratum i randomized to standard of care, and the function vi(t) is the
density function of an observed event. In their paper, vi(t) is given for exponential
survival with hazard rate λji , for treatment j, and stratum i, accrual and follow-up
periods of length a and f , respectively, and uniform patient entry:
vi(t) =

riλ0i exp(−λ0it) + (1− ri)λ1i exp(−λ1it) t ≤ f
ri
a+f−t
a λ0i exp(−λ0it) + (1− ri)a+f−ta λ1i exp(−λ1it) f < t ≤ a+ f
0 t > a+ f,
(2.14)
keeping in mind that for administrative censoring C the probability P(C > t) = a+f−t
a
for f < t ≤ a+ f . This integrates to
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Vi =
∫ a+f
0
vi(t)dt = ri
[
1− 1
aλ0i
(
exp [−λ0if ]− exp [−λ0i(a+ f)]
)]
+ (1− ri)
[
1− 1
aλ1i
(
exp [−λ1if ]− exp [−λ1i(a+ f)]
)]
.
(2.15)
Note that Equation 2.15 is the probability for a patient in stratum i to experience the
event of interest during follow-up: Consider a study with uniform accrual, an accrual
period [0, a], a follow-up time f , and no loss to follow-up. Then we have a uniform
distribution for administrative censoring, C, with density 1
a
1[f,a+f ](t). Assuming expo-
nentially distributed survival times T , the probability q for a patient to experience an
event of interest throughout the study is given by
q = P(T ≤ C) =
∫ ∞
0
P (T ≤ t)1
a
1[f,a+f ](t)dt
=
∫ a+f
f
[1− exp(−λt)] 1
a
dt
= 1− 1
λa
(
exp [−λf ]− exp [−λ(a+ f)]
)
. (2.16)
Coming back to the formula by Palta and Amini (1985), they give a simpliﬁed version
of their formula (Equation 2.13) assuming proportional hazards over time:
µ = logHR
√√√√ s∑
i=1
giri(1− ri)Vi, (2.17)
where HR is the hazard ratio, and Vi is the integral of vi(t) over the study length, i.e.
the probability of not being censored in stratum i (see Equation 2.15).
2.1.3.3 Lachin's formula
Schoenfeld's - and consequently Palta and Amini's - sample size formula is derived
using the score statistic, testing whether the hazard ratio is diﬀerent from 1. Another
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sample size formula, which in contrast is based on the Wald test, was introduced
by Lachin in 1981. It tests the diﬀerence in hazard rates between the standard and
experimental treatment arms for unstratiﬁed, exponentially distributed survival time
data:
n =
z1−α/2
√
Φ(λ)
(
1
r
+ 1
1−r
)
+ z1−β
√
Φ(λ1)
1
1−r + Φ(λ0)
1
r
λ1 − λ0

2
, (2.18)
where r is the proportion of patients randomized to the standard treatment arm, λj
is the hazard rate of treatment arm j (for the unstratiﬁed case), λ = (λ1 + λ0)/2,
and, assuming exponential survival, uniform patient entry, and (only) administrative
censoring
Φ(λ) =
λ2
q
= λ2
[
1− 1
λa
(
exp [−λf ]− exp [−λ(a+ f)]
)]−1
, (2.19)
where a and f are the accrual and follow-up time, respectively. For details on the
probability for a patient to experience an event of interest throughout the study, q, see
Equation 2.16.
2.1.3.4 Lachin and Foulkes' formula
Later on, Lachin extended his sample size formula together with Foulkes, to allow for
nonuniform patient entry, loss to follow-up, noncompliance and stratiﬁcation (Lachin
and Foulkes 1986). Note that Lachin's formula and the extension by Lachin and Foulkes
is based on the assumption of exponential survival, which makes it less ﬂexible than
the other two formulas.
Their extension of the formula for stratiﬁed trials with two strata uses a pooled esti-
mator as test statistic, which is calculated as a weighted average over the strata of the
within-stratum diﬀerences in hazard rates:
λ̂0 − λ̂1 = ν1(λ̂11 − λ̂01) + ν2(λ̂12 − λ̂02) (2.20)
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where λ̂ji is the estimated hazard rate for treatment j in stratum i and νi are weights
that are inversely proportional to the variances of the within-stratum hazard rate dif-
ferences:
νi =
1
σ20,i
(
1
σ20,1
+
1
σ20,2
)−1
(2.21)
where
σ20,i =
ψ
Ni
, (2.22)
where Ni is the total sample size of stratum i, and
ψ = Φ(λi)
(
1
ri
+
1
1− ri
)
, (2.23)
with λi = (λ1i + λ0i)/2 and Φ as deﬁned in Equation 2.19.
With the pooled estimator, the sample size can be calculated as:
n=

zα
√
Ω−1+zβ
√
Ω−2
2∑
i=1
gi
(
Φ(λ1i)
1
1−r+Φ(λ0i)
1
r
)(
Φ(λi)
(
1
r
+ 1
1−r
))−2
λ1 − λ0

2
, (2.24)
where λji is the hazard rate for treatment j ∈ {0, 1} in stratum i, λi = (λ1i + λ0i)/2,
and
Ω =
g1
Φ(λ1)
(
1
r
+ 1
1−r
) + g2
Φ(λ2)
(
1
r
+ 1
1−r
).
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2.2 Data generation for simulation studies
2.2.1 Generating survival time data
For the generation of survival times, the baseline hazards, hazard ratios, proportion of
patients in each stratum, and the randomization probability are predetermined. Survival
is assumed to be exponential and the randomization probability between treatments is
set to 0.5 for all strata. Patients are assigned to biomarker-group i by drawing from
a multinomial distribution according to the prespeciﬁed proportions of the strata, and
are then randomized equally to the treatment arms. For every patient k, three times
were generated:
The survival time for patient k in stratum i obtaining treatment x was generated
according to Bender et al. (2005):
tk = − log(Uk)
h0 exp(βi x)
, (2.25)
where x ∈ {0, 1} is the treatment indicator, Uk ∼ Unif(0, 1) and h0 = λ0 for the Cox
PH model, h0 = λ0i for the stratiﬁed Cox PH model, and h0 = wiλ0 for the shared
frailty model.
Times to administrative censoring, tad, k, were generated by drawing from a uniform
distribution Unif(f, a+ f) with accrual period a and follow-up time f .
A time for random censoring tcens, k for each patient k was generated from an expo-
nential distribution with hazard λcens, calculated by
λcens =
pcens λ˜
1− pcens , (2.26)
where λ˜ =
∑s
i=1 gi(λ1i + λ0i)/2 is an average hazard rate, where λji is the hazard
rate for treatment j in stratum i, and pcens is the expected proportion of random
censoring among patients.
Realized overall survival (os) is then derived as the minimum of these three generated
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times, i.e. osk = min(tk, tad, k, tcens, k). If tk = osk, patient k is assigned status 1
(dead), and 0 (alive) otherwise. All simulation studies were carried out in R.
2.2.2 Generating missing at random data
To generate missing data that is missing at random (MAR), ﬁrst a complete data set is
generated as described above. Then, the probability of missingness for variable y, i.e.
Pr(y = missing|x), can be modeled, e.g. using a logistical model. If the missingness
is modeled to depend on a single other observed variable, the probability is given by
Pr(yk = 1|xk) = exp(c+ βxk)
1 + exp(c+ βxk)
, (2.27)
where y is the variable for which missing data shall be generated, and x is the variable
upon which the missingness depends. Now a binary variable can be generated which
indicates whether y is missing by drawing from a binomial distribution with proba-
bility pk. Whenever this variable is 1, the corresponding data point of y is deleted
(Van Buuren 2012).
If a certain proportion of missing data, pmiss, is targeted, c and β need to be determined
that satisfy f(c, β) = pmiss, where f(c, β) is the mean of the probabilities:
f(c, β) =
1
n
n∑
i=1
1
1 + exp(c+ βxi)
. (2.28)
This can, for example, be done by ﬁxing β at some value, and then solving
f(c, β)− pmiss = 0 (2.29)
for c. Then, using c and the ﬁxed value for β, the probabilities for missingness can be
obtained from Equation 2.27.
Chapter 3
Results
3.1 Development of a concept for a trial with
multiple biomarkers
Some sections of this chapter are part of papers that have already been published.
For Section 3.1 and Section 3.3, the relevant passages have been taken verbatim from
Habermehl et al. (2017), and for Section 3.2 the relevant passages have been taken
verbatim from Beisel et al. (2017).
The optimal choice of the trial design is an important step within the process of develop-
ing a trial. However, there is not a single answer which design is best - it depends on
various factors. One type of multiple-biomarker trials, which were introduced in Section
1.1.3, are the so-called umbrella trials, where enrollment is generally restricted to one
tumor type. The biomarker-deﬁned subtrials of an umbrella trial are usually analyzed
individually, treating each subtrial as an independent trial, due to the heterogeneity
caused by the diﬀerent biomarkers and diﬀerent experimental therapies targeting these
biomarkers. Biomarkers can cause heterogeneity in the study population if they are
either prognostic, predictive, or both.
An example for an umbrella trial is the FOCUS4 trial (Kaplan et al. 2013), which
is aimed at patients with colorectal cancer. One of the biomarkers investigated in
28
3.1. DEVELOPMENT OF A TRIAL CONCEPT 29
the trial is the BRAF-mutation, which is indicative of a poor prognosis in this tumor
type. The excessive signaling caused by this mutation can be targeted by an inhibitor
of the BRAF-protein. However, in colorectal cancer, signaling through the epidermal
growth factor receptor (EGFR) plays a role. Therefore, the treatment investigated in
FOCUS4 is a combination of BRAF-inhibitor and EGFR-inhibitor, with and without a
MEK-inhibitor. For more details see Kaplan et al. (2013).
Since colorectal cancer is one of the most common cancer types, recruitment of patients
should not be an issue. However, completion of accrual may become unfeasible when
this type of design is used for a less prevalent disease. In this case, small sample sizes
within the subtrials have to be expected, as well as many biomarker-negative patients at
the initial screening stage, i.e. patients which test negative for all biomarkers considered
in the trial. The small sample sizes may make it unfeasible to treat the subtrials as
independent and analyze them individually. Moreover, the small sample sizes can lead
to biased treatment eﬀect estimates. This imposes the need to investigate alternative
approaches for the analysis of such a trial, and possibly for the study design itself.
The following sections will discuss several options for multiple-biomarker trials and
give examples for which situations the design option would be an appropriate choice.
Furthermore, the issue of whether or not biomarker-negative patients should be included
in the study will be discussed.
3.1.1 Biomarker-negative patients
Before considering speciﬁc design features, a decision should be made whether to use an
enrichment-type or an all-comers design, i.e. it should be decided if patients that cannot
be matched with one of the relevant biomarkers are excluded from the trial or if they are
included in a separate trial arm. Excluding biomarker-negative patients may seem like
the most cost-eﬀective option at ﬁrst. But it should be taken into consideration that the
initial step of determining a patient's biomarker proﬁle already entails costs. Excluding
these patients after this step means spending resources on valuable information that is
not going to be used afterwards. Especially for trials with lower prevalence biomarkers,
where it is expected to encounter numerous biomarker-negative patients throughout
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the accrual period, it might be worth considering to at least include these patients for
follow-up purposes, if possible. This way, a valuable database of patients for which the
biomarker-proﬁle has already been assessed can be obtained. This database can later
be utilized for retrospective analyses and identiﬁcation of new potential biomarkers.
3.1.2 Design choices
A popular strategy for designing a multiple-biomarker trial, such as an umbrella trial,
is to exclude biomarker-negative patients at the screening stage. This basically leads
to a multiple-biomarker enrichment design (Figure 3.1, Design 1). For less prevalent
biomarkers, this means disregarding many biomarker-negative patients for whom infor-
mation about their biomarker proﬁle was already gathered during the screening process.
Alternatively, a study design could be used that includes the biomarker-negative pa-
tients in the study. There are several possibilities to do so.
A possibility that oﬀers the most information about the biomarkers investigated in
the study is to randomize the biomarker-negative patients between all the experimen-
tal therapies targeting the biomarkers in the study and standard of care (Figure 3.1,
Design 2). This way, these experimental therapies can be investigated in the biomarker-
positive and the biomarker-negative population. Additionally, this design allows drawing
conclusions about prognostic, as well as predictive properties of the biomarkers. Essen-
tially, this design is a biomarker-stratiﬁed design (also called biomarker-by-treatment
interaction design) with more than one biomarker. While this design can supply useful
information about the properties biomarkers, it simultaneously limits the number of
biomarkers that can be investigated in the study, since each added biomarker adds
another treatment arm for the biomarker-negative patients. Furthermore, treating
biomarker-negative patients with an experimental therapy which targets a biomarker
that they do not have can be an issue. Based on prior evidence it needs to be decided
for each of these treatments whether this treatment strategy is ethically tenable.
Another option to include biomarker-negative patients in a multiple-biomarker trial is
a stratiﬁed randomize-all design, where biomarker-negative patients are randomized
between a (diﬀerent) experimental therapy and standard of care (Figure 3.1, Design
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1Figure 3.1: Schematic study designs for a multiple-biomarker trial, simpliﬁed to two
biomarkers, with diﬀerent options for biomarker-negative patients.
3). This way, the resulting study has multiple strata with two treatment arms each.
While the analysis of such a design is fairly straight forward, it is important to take
into consideration the heterogeneity within the study population. On the one hand,
this can be caused by prognostic and predictive biomarkers, and on the other hand
by the diﬀerent treatments with, most likely, diﬀerent treatment eﬀects. For smaller
sample sizes, which is likely to be the case for lower prevalence biomarkers, the analysis
concept for the resulting data could be an evaluation of the overall biomarker-guided
treatment strategy, rather than performing separate analyses for each biomarker. This
will be discussed in more detail in Section 3.2. This evaluation of an overall treatment
strategy should be performed in conjunction with subsequent subgroup analyses to
avoid false conclusions about individual biomarkers. The subgroup analyses could
either be of exploratory nature or preplanned, utilizing multiple comparison strategies.
One option would be a serial chain procedure (Millen and Dmitrienko 2012) where the
primary hypothesis is ﬁrst tested at a predetermined signiﬁcance level, α. If the null
hypothesis is rejected, the unspent α from the main hypothesis can be reallocated to
the remaining secondary hypotheses, since chain procedures are a class of closed testing
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procedures. The α can be split equally or weighted between the remaining hypotheses.
Multiple comparison procedures will be discussed in more detail in Section 3.5. In
practice, the usability of this stratiﬁed randomize-all design depends on availability of
a suitable experimental therapy for the biomarker-negative patients.
The remaining alternative to excluding biomarker-negative patients at the screening
stage is a `multi-biomarker hybrid design' where these patients are kept in the study
and treated with standard of care (Figure 3.1, Design 4). This allows gathering follow-
up data for the biomarker-negative patients as well as potentially using this data for
retrospective identiﬁcation of new biomarkers. Additionally, the prognostic properties
of the biomarkers can be investigated by comparing the standard of care arms. If the
biomarkers in the study are assumed to be non-prognostic, the data for the biomarker-
negative patients can be used in the analysis by pooling the three standard of care
arms. For prognostic biomarkers the inclusion of the biomarker-negative patients in the
analysis becomes more complicated. This will be discussed in more detail in Section
3.3. A practical drawback of this multi-biomarker hybrid design is that biomarker-
negative patients potentially have a larger risk of dropping out of the study if other
studies become available that oﬀer an experimental therapy.
3.2 Stratiﬁed randomize-all design
The categorization of cancer types into subtypes leads to a stratiﬁcation of the study
population into multiple subtrials investigating diﬀerent experimental therapies. In
umbrella trials, these subtrials are usually analyzed individually, treating each subtrial
as an independent trial. While this is feasible for common cancer types, it may be
diﬃcult to recruit enough patients to each subtrial to obtain statistically meaningful
results within a reasonable time frame.
An alternative approach could be a proof of eﬃcacy of the overall treatment strategy
(e.g. a biomarker-guided treatment strategy) as primary hypothesis before looking
at the subtrials individually. However, this approach entails several diﬃculties. The
subpopulations cannot simply be assumed to be homogeneous across all subtrials, espe-
cially if various disease subtypes and diﬀerent treatments are investigated in the trial.
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Obviously, it cannot be assumed that diﬀerent treatments will have similar treatment
eﬀects. Some of the factors deﬁning the subtypes, such as targeted mutations, might
be prognostic or predictive and have an impact on the outcome or the treatment eﬀect,
respectively. For this situation, the assumption that the treatment eﬀect is the same
across all strata does not seem appropriate. However, the Cox PH model, its stratiﬁed
version, and most sample size formulas rely on this assumption and a violation may
result in deviation from the desired level of power.
In the following sections, the performance of diﬀerent methods for sample size calcu-
lation and data analysis under heterogeneous treatment eﬀects will be investigated.
With regard to sample size calculation, the commonly used sample size formula by
Schoenfeld (1983) is compared to a formula by Lachin and Foulkes (1986), and an ex-
tension of Schoenfeld's formula by Palta and Amini (1985). Possibilities for statistical
modeling of heterogeneity are stratiﬁcation by factors, the assumption of a probability
distribution of the inter-patient or inter-strata variation, or the inclusion of covariates
in the regression model. With a focus on the former two options, the widely used (stra-
tiﬁed) Cox PH model (Kalbﬂeisch and Prentice 1980), a two-step analysis approach
by Mehrotra et al. (2012), and the lognormal shared frailty model (Duchateau and
Janssen 2007) will be considered as potential methods for data analysis which attempt
to adjust for inter-strata heterogeneity.
3.2.1 Data modeling and analysis
The study design considered in the following is a stratiﬁed design with s strata. The
strata are denoted by Bi, i ∈ {1, 2, ..., s}, and are deﬁned by biomarkers which are
targeted by one of the stratum-speciﬁc experimental treatments investigated in the
study (see Figure 3.2). Upon entering the study, the patients' biomarker-status is
determined and they are assigned to the strata accordingly. Patients matched with
neither of the biomarkers are assigned to the biomarker-negative stratum. For the case
that a patient is matched with more than one biomarker, there should be predeﬁned
priorities for the biomarkers, such that the patient can be distinctly allocated to one
of the biomarker-deﬁned strata. These priorities could, for example, be deﬁned by
biomarker prevalence or expected treatment outcomes.
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The proportion of patients in stratum Bi is denoted by gi ∈ [0, 1]. Within each stratum
i, patients are randomized between the stratum-speciﬁc experimental therapy (Expi)
and standard of care (Std), with probabilities 1− ri and ri, respectively. Patient entry
is assumed to be uniform throughout the accrual time a. Patients are then monitored
for the event of interest. Patients that are still in the study after follow-up time f are
subject to administrative censoring. It is assumed that additional random censoring
can occur. The hazards of death at time t for patients in stratum i receiving treatment
j are denoted by λji(t), where j = 1 for experimental treatment or j = 0 for standard
of care.
As mentioned in Section 2.1.1, a common choice for modeling data and estimating a
corresponding treatment eﬀect is the Cox PH model, or, for a stratiﬁed study popula-
tion, the stratiﬁed Cox PH model. An alternative to the stratiﬁed Cox PH model is the
shared frailty model, which was introduced in Section 2.1.1.3. An advantage of this
model is that it is able to treat heterogeneity between strata without requiring speciﬁc
assumptions about stratum speciﬁc prognostic eﬀects.
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1Figure 3.2: Schematic study design.
Mehrotra et al. (2012) suggested another alternative to the stratiﬁed Cox PH model
for the case of unequal hazard ratios. They developed a two-step approach which ﬁrst
estimates the treatment eﬀects within the strata separately and then combines them via
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a weighted average to an estimate for the overall treatment eﬀect (see Section 2.1.1.2).
Allowing to adjust the weighting of the strata makes this procedure more ﬂexible and
can reduce the bias of the estimator in the case of heterogeneous treatment eﬀects (cf.
Mehrotra et al. 2012). Hence, the usage of this two-step approach is a possibility to
use the Cox PH model in situations when the assumption of homogeneous treatment
eﬀects across strata, which is made by the stratiﬁed Cox PH model, is violated. Note
that the overall treatment eﬀect β can be considered as the average beneﬁt of a random
patient sampled from a mixture distribution with weights ωi.
Two commonly used tests for the treatment eﬀect in Cox regression are the score test
and the Wald test. Since Mehrotra et al. (2012) use the Wald test in their two-step
approach, both tests are considered in the subsequent simulation study.
More details on the methods discussed in this section can be found in Section 2.1.1.
3.2.2 Sample size calculation
An advantage of the well-known Schoenfeld formula, which was introduced in Section
2.1.3.1, is that, beyond the proportional hazards assumption, it does not rely on a
speciﬁc survival distribution. But Schoenfeld's formula neither allows stratiﬁcation nor
stratum speciﬁc hazard ratios. To be able to examine the performance of Schoenfeld's
formula in a scenario with heterogeneous treatment eﬀects, an average hazard ratio
is calculated that can be used in the formula:
HR =
− log
( s∑
i=1
(1− ri)gi exp
[
− λ0i
(a
2
+ f
)
HRi
])
λ0
(
a
2
+ f
) , (3.1)
where i ∈ {1, ..., s} are the strata, λ0i is the baseline hazard for stratum i, HRi is the
hazard ratio for stratum i, gi is the proportion of patients in stratum i, and ri is the
randomization probability to the standard treatment in stratum i. For λ0 see Equation
3.4.
The ﬁrst step in the derivation of Equation 3.1 is ﬁnding the survival function of the
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patient population across all strata. An average survival function S˜(t|x) can then be
found by integrating over the strata given the treatment option:
S˜(t|x) =
s∑
i=1
ri
1−x(1− ri)x gi exp
[− λ0i t exp(logHRi · x)], (3.2)
where x ∈ {0, 1} is the treatment indicator.
Next, the observed survival function is considered, which contains an average baseline
hazard λ0 and an average hazard ratio HR:
S(t|x) = exp [− λ0 t exp(logHR · x)]. (3.3)
Now, HR can be found by equating the two survival functions (Equations 3.2 and 3.3),
i.e. S˜(t|x) != S(t|x), at t = a
2
+ f , where a and f are accrual and follow-up time,
respectively, i.e. t is the average time a patient is under observation.
In a ﬁrst step, it is necessary to solve Equation 3.3 for λ0 (for x = 0), which yields
λ0 =
− log
( s∑
i=1
rigi exp
[
− λ0i
(a
2
+ f
)])
a
2
+ f
. (3.4)
Equation 3.4 can then be used to solve Equation 3.3 for HR (for x = 1), which yields
Equation 3.1.
Palta and Amini (1985) extended Schoenfeld's formula to allow for stratiﬁcation, tes-
ting the null hypothesis log(HRi) = 0 ∀i, where HRi is the stratum-speciﬁc hazard
ratio (see Equation 2.17). The formula by Palta and Amini does require an assump-
tion about the distribution of survival times, but it is not restricted to the exponential
distribution. To consider other survival distributions, one simply needs to adjust Vi
accordingly (see Equations 2.14 and 2.15).
In their paper, Palta and Amini give a simpliﬁed version of their formula by assuming
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equal hazard ratios across strata. However, using their general formula (see Equation
2.17), and assuming unequal but constant hazard ratios over time, one can obtain a
sample size formula that allows for unequal hazard ratios across strata:
µ =
s∑
i=1
gi logHRi ri(1− ri)Vi√
s∑
i=1
giri(1− ri)Vi
, (3.5)
where HRi is the hazard ratio for stratum i, and Vi is the integral of vi(t) over the
study length, i.e. the probability of not being censored in stratum i (see Equation
2.15).
The extension of Lachin's formula by Lachin and Foulkes (1986), allowing for strati-
ﬁcation (Equation 2.24), which was given for two strata, was generalized for a case
with s strata:
n=
zα
√
Ω−1+zβ
√
Ω−2
s∑
i=1
gi
(
Φ(λ1i)
1
1−r+Φ(λ0i)
1
r
)(
Φ(λi)
(
1
r
+ 1
1−r
))−2
λ1 − λ0

2
,
where λji is the hazard rate for treatment j ∈ {0, 1} in stratum i, λi = (λ1i + λ0i)/2,
Ω =
(
s∑
i=1
gi
Φ(λi)
(
1
r
+ 1
1−r
)),
and
λ1 − λ0 =
s∑
i=1
νi(λ1i − λ0i).
More details on the sample size formulas discussed in this section can be found in
Section 2.1.3.
Unfortunately, there is currently no closed sample size formula available for a shared
frailty model of the kind discussed in Section 2.1.1.3. Therefore, the required sample
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size was calculated empirically as follows: The ﬁrst step for an empirical sample size
calculation is to choose the required power of the test (ρr), and to pick a starting
value for the sample size, e.g. from a sample size formula which is expected to provide
a reasonable initial estimate. Then, a suﬃcient number of data sets is simulated, e.g.
10, 000 data sets, under a speciﬁc alternative hypothesis, according to the planned
study design. Subsequently, these data sets are analyzed by the chosen data analysis
method, e.g. the lognormal shared frailty model. The actual power (ρa) is then
obtained from the percentage of rejected null hypotheses. If the actual power is
within the required accuracy range of the required power, i.e. if ρa = ρr ± 0.01, the
calculation is completed and no further iteration steps are needed. If the actual power
is outside this range, the sample size needs to be adjusted. This adjustment should be
a predetermined rule, e.g. nnew = nold(1 − (ρa − ρr)). The sample size is iteratively
adjusted until the actual power reaches the required power with the desired accuracy,
which was chosen here as 0.01.
3.2.3 Simulation study: Heterogeneous treatment eﬀects
To compare the performance of the sample size formulas and the analysis methods
for the case of heterogeneous treatment eﬀects a simulation study with three strata
is carried out. The following sections explain the study design, parameter setup and
data generation before presenting and discussing the results.
3.2.3.1 Study design
A scenario is considered with two biomarkers, each targeted by a corresponding ex-
perimental therapy, which is to be included in the study. Furthermore, patients that
cannot be matched with either biomarker should also be included in the study to test
another, more broadly aimed experimental therapy. This leads to a study design with
three strata, denoted by Bi, i ∈ {0, 1, 2}, where B1 and B2 are each comprised of
patients matched with biomarker 1 or 2, respectively. All other patients are allocated
to B0, the biomarker-negative patients. Patients in strata B1, B2, and B0 are rando-
mized between the corresponding stratum speciﬁc experimental therapy (Exp1, Exp2,
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and Exp0, respectively) and standard of care (Std).
3.2.3.2 Data generation
The data were generated as described in Section 2.2.1. For the baseline hazards,
initially a common baseline hazard was chosen (0.05) and then the baseline hazards for
B1 and B2 were multiplied by factors 0.8 and 1.2, respectively, to simulate stratiﬁcation.
For the remaining simulation parameters see Table 3.1. Note that a rough correction
for loss to follow-up due to random censoring was made for all sample size formulas by
dividing the calculated sample size by 1− pcens, where pcens is the expected proportion
lost to follow-up. For this simulation, pcens was set to 0.05.
Table 3.1: Parameters for the simulation study using a design with three biomarker-
groups, denoted by Bi, i ∈ {0, 1, 2}.
Fixed simulation parameters
Accrual time (months), a 24
Follow-up time (months), f 36
Proportion random censoring, pcens 0.05
Treatment allocation ratio 1 : 1
Hazard ratio B1, exp(β1) 0.8, 0.7, 0.6, 0.5, 0.4, 0.3
Hazard ratio B2, exp(β2) 0.8, 0.7, 0.6, 0.5, 0.4
Number of simulations 10,000
Parameters for biomarker-groups (B0,B1,B2)
Proportion of patients, gi (0.5, 0.25, 0.25)
Baseline hazards, λ0i (0.05, 0.04, 0.6)
If one wishes to simulate a stratum speciﬁc random eﬀect in the patient data, as is
assumed by the lognormal shared frailty model, the stratiﬁcation factors for the baseline
hazard, mentioned in the beginning of this section, can be replaced by numbers drawn
from a lognormal distribution for each stratum. The choice of mean and variance of
the lognormal distribution determines the intensity of the random eﬀect, e.g. using
a lognormal distribution with mean 0 and variance 0.15 on the log scale results in a
relatively minor random eﬀect. The data used in the next section is simulated without
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a random eﬀect present. Results for random eﬀects data can be found in the sensitivity
analysis in Section 3.2.3.4. The simulation study was carried out in R (Version 3.2.2).
3.2.3.3 Results of the simulation study
In this section, the formulas for sample size calculation by Schoenfeld, Palta and Amini,
and Lachin and Foulkes are compared. Afterwards, the diﬀerent analysis methods are
evaluated with respect to the power to detect a signiﬁcant overall treatment eﬀect,
given speciﬁc hazard ratio scenarios.
For each parameter constellation of the simulation study, the required sample size
for a power of 0.8 is determined with Schoenfeld's, Palta and Amini's and Lachin
and Foulkes' sample size formula. For each calculated sample size, 10,000 data sets
are simulated and then analyzed using the stratiﬁed Cox PH model, Mehrotra's two-
step approach, and the shared frailty model. The empirical power for each method is
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Figure 3.3: Comparison of sample size formulas for diﬀerent hazard ratio scenarios:
Sample sizes calculated from formulas by Schoenfeld, Palta and Amini, and Lachin
and Foulkes.
assessed as percentage of rejected null hypotheses. The sample size formulas as well as
the analysis methods, will be compared with respect to their compliance to the power
used at the planning stage.
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A comparison of the sample sizes calculated with the formulas by Schoenfeld, Palta
and Amini, and Lachin and Foulkes for diﬀerent hazard ratio scenarios can be seen in
Figure 3.3. The formula by Lachin and Foulkes yields the smallest sample size in all
cases. The sample size calculated by Palta and Amini's formula mostly lies between
the ones calculated by the other two formulas, except for the scenarios with the most
extreme diﬀerences in hazard ratios. For those scenarios, the sample size by Schoenfeld
is slightly smaller. The numerical results can be found in the Appendix.
The results of the empirical sample size calculation (see Section 3.2.2) are not shown
in Figure 3.3, because Palta and Amini's formula provided an adequate sample size
for the lognormal shared frailty model to reach the required power (see Table 3.2).
The empirically calculated sample size only diﬀered in one case, but not by much (3
Table 3.2: Numerical results for the empirical sample size calculation for the lognor-
mal shared frailty model.
Input Power Sample size Iterations
HR Shared Empirical Palta Lachin Iteration
B0, B1, B2 Frailty estimate Amini Foulkes steps
0.8 0.8 0.8 0.805 763 763 627 1
0.8 0.8 0.7 0.798 574 574 465 1
0.8 0.8 0.6 0.796 437 437 357 1
0.8 0.8 0.5 0.800 336 336 280 1
0.8 0.8 0.4 0.803 259 259 224 1
0.8 0.8 0.3 0.802 197 200 182 2
0.8 0.7 0.7 0.800 461 461 378 1
0.8 0.7 0.6 0.797 360 360 295 1
0.8 0.7 0.5 0.792 282 282 235 1
0.8 0.7 0.4 0.796 222 222 191 1
0.8 0.7 0.3 0.801 174 174 157 1
0.8 0.6 0.6 0.807 297 297 246 1
0.8 0.6 0.5 0.798 238 238 199 1
0.8 0.6 0.4 0.799 190 190 163 1
0.8 0.6 0.3 0.806 152 152 135 1
0.8 0.5 0.5 0.805 200 200 168 1
0.8 0.5 0.4 0.801 163 163 140 1
0.8 0.5 0.3 0.803 131 131 117 1
0.8 0.4 0.4 0.797 138 138 120 1
0.8 0.4 0.3 0.799 113 113 101 1
patients less). Hence, it was decided that the (computationally expensive) empirical
calculation of the sample size for the shared frailty model is not necessary. Note that
this conclusion may not be valid for other scenarios, e.g. for more diverse baseline
hazards.
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Subsequently, the methods for sample size calculation were compared with respect to
compliance to the desired power level for each of the data analysis methods. Figure 3.4
shows the power for all three sample size calculation methods using the exact log-rank
test as reference analysis method which does not depend on asymptotic assumptions.
Equivalent comparisons were also made for the stratiﬁed Cox PH model, the two-step
approach, and the lognormal shared frailty model. Using these analysis methods yields
similar results (see Figures 3.5-3.7).
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Figure 3.4: Power of the exact log-rank test to detect a true treatment eﬀect for
the diﬀerent sample size formulas and diﬀerent hazard ratios.
The sample size formula by Schoenfeld appears to overestimate the required sample
size when the hazard ratios are similar and then begins a downward trend as the
hazard ratios become more heterogeneous (see Figure 3.4). One has to keep in mind
though, that this formula does not take the stratiﬁcation into consideration and an
averaged hazard ratio has to be used in the formula (see Equation 3.1). Therefore,
this behavior was not surprising. Note that even though hazard ratios in the ﬁrst
scenario are homogeneous (HR1 = HR2 = HR0 = 0.8), the baseline hazards are still
heterogeneous due to stratiﬁcation, which causes the non-compliance to the desired
power level.
For the case of a stratiﬁed population, the sample size formula by Lachin and Foulkes
uses a pooled estimator of the within-stratum diﬀerences in hazard rates. For this
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pooled estimator, they deﬁne optimal weights for each within-stratum diﬀerence (see
Equations 2.20 - 2.23). However, the formula for these weights requires knowledge
of the stratum-speciﬁc sample sizes. To be able to calculate these weights, in a ﬁrst
step the sample size was calculated empirically (analogous to the empirical sample size
calculation for the shared frailty model in Section 3.2.3.2) before using the formula
given by Lachin and Foulkes in the second step. This made the usage of this formula
computationally more expensive than the other two. Additionally, one might question
why one would use the formula at all if the required sample size was already calculated
empirically. The resulting sample size from Lachin and Foulkes' method is too small
to reach the desired power of 0.8. The power curve has a downward tendency as the
hazard ratios of B1 and B2 get smaller, i.e. Lachin and Foulkes' formula does not seem
to handle heterogeneous treatment eﬀects well.
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Figure 3.5: Power of the two-step approach to detect a true treatment eﬀect for
diﬀerent hazard ratios.
Two alternate attempts, both avoiding empirical calculation, were made to reduce
computation time and potentially improve the resulting power. The ﬁrst attempt to
replace the empirical calculation in the ﬁrst step was to use the original formula by
Lachin (1981) that does not account for stratiﬁcation (see Equation 2.18). For the
hazard rates, weighted means of the stratum speciﬁc hazard rates were used, using the
expected sample proportion per stratum as weights. As before, the resulting sample size
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was then used to calculate the weights for the pooled estimator of the within stratum
diﬀerences. This did not change the sample size calculated with Lachin and Foulkes'
formula in the second step, even though the sample sizes used for the calculation of
the pooled estimator of the within stratum diﬀerences were quite diﬀerent: The former
(empirical) sample size from step 1 was always larger than the ﬁnal sample size in step
2, while the latter (from Equation 2.18) was always smaller. Hence, the formula for the
weights seems to be rather robust regarding the stratum speciﬁc sample size. While
this did not improve the sample size with respect to power, this shows that empirical
calculation is not necessary, because it suﬃces to use a very rough estimate of the
stratum speciﬁc sample size.
Another simulation was run where the weights used by Lachin and Foulkes were repla-
ced with sample size proportions, i.e. the pooled estimator of the overall diﬀerence in
hazard rates is a weighted average of the stratum speciﬁc hazard diﬀerences, weighted
by the expected sample proportions of the strata. For similar and moderately hete-
rogeneous treatment eﬀects this sample size yields a lower power than the previous
one. But, surprisingly, the resulting power increases as the treatment eﬀects diverge,
improving the power by up to 0.08 compared to using the original weights.
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Figure 3.6: Power of the lognormal shared frailty model to detect a true treatment
eﬀect for the diﬀerent sample size formulas and diﬀerent hazard ratios.
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Figure 3.7: Power of the stratiﬁed Cox PH model to detect a true treatment eﬀect
for the diﬀerent sample size formulas and diﬀerent hazard ratios.
Nevertheless, it is still more than 0.02 short of reaching the desired power of 0.8.
Hence, Lachin and Foulkes is an unreliable method for sample size calculation in the
case of heterogeneous treatment eﬀects.
The formula by Palta and Amini, allowing for unequal hazard ratios, yields the most
reliable sample size: The actual power matches the expected power the closest. For
similar hazard ratios it neither over- nor underestimates the sample size. As the hazard
ratios become more heterogeneous, the power curve takes on a slight upwards trend (for
the exact log-rank test). This is a considerable improvement over the other sample
size formulas, which exceed or undercut the desired power level by up to 0.1. In
conclusion, Palta and Amini's sample size formula performs best for most scenarios
and was used to compare the diﬀerent analysis methods in the following sections. If
one is only interested in a rough number for the required sample size, the slightly easier
to compute method by Schoenfeld is also acceptable in most cases.
Prior to the comparison of the analysis methods, it was veriﬁed that all methods control
the type I error rate. For a sample size of 10,000 subjects and 10,000 simulations, the
type I error rates ranged between 0.486 and 0.494.
The power to detect a signiﬁcant treatment eﬀect when using the sample size calculated
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from Palta and Amini's formula is compared for the stratiﬁed Cox PH model, the
shared frailty model, and the two-step approach by Mehrotra et al. (see Figure 3.8).
Additional to these three methods, the stratiﬁed asymptotic log-rank test and the
exact log-rank test are included as well, to reveal potential failure of asymptotics.
The asymptotic properties are also investigated as part of the sensitivity analysis in
Section 3.2.3.4. Note that the approximate version of the exact log-rank test was used
(for details see Section 2.1.2.2). The diﬀerent analysis methods perform similarly for
large sample sizes and minor heterogeneity of hazard ratios. As the sample size gets
smaller and the hazard ratios become more heterogeneous, the power curves of the
methods increasingly diverge. As expected, the curves diﬀer the most for the most
extreme scenario, with a minimum of 0.748 (stratiﬁed Cox) and a maximum of 0.829
(approximate log-rank). For the complete numerical results see Table 3.3.
The stratiﬁed Cox regression and the asymptotic log-rank test perform the worst. In
the most extreme scenarios, the power is about 0.1 below the desired level of 0.8. Note
that since there are no other covariates included in the model, the score-statistic of
the stratiﬁed Cox regression would yield the same curve as the asymptotic stratiﬁed
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Figure 3.8: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Palta and Amini's sample size formula
under diﬀerent hazard ratios.
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log-rank test. The diﬀerence between the two curves is caused by usage of the Wald-
statistic for the stratiﬁed Cox regression. Since Mehrotra et al. (2012) use the Wald
test in their two-step approach, the Wald test was also used for the stratiﬁed Cox PH
model for a fair comparison.
The shared frailty model, the two-step approach, and the approximate log-rank test
perform similarly for small to moderate diﬀerences in hazard ratios. For the most
extreme scenarios, the shared frailty model yields a slightly lower power than the other
two, but does not drop considerably below the desired power.
Mehrotra et al. (2012) suggested two diﬀerent weighting options for the second step
of their two-step approach: sample size weights, which use the sample proportions
of the strata as weights, and minimum risk weights, which are intended to minimize
the mean squared error when estimating β. Both weighting options were tested, but
Table 3.3: Numerical results for the power comparison of the stratiﬁed Cox PH mo-
del, Mehrotra's two-step approach, the lognormal shared frailty model, and stratiﬁed
exact and asymptotic log-rank test to detect a true treatment eﬀect when using
Palta and Amini's sample size formula under diﬀerent hazard ratios.
Input Power
HR Sample Strat. Cox Two-step Frailty Frailty Exact Asympt.
B0, B1, B2 Size Wald Wald lognorm Gamma log-rank log-rank
0.8 0.8 0.8 763 0.802 0.803 0.805 0.804 0.802 0.802
0.8 0.8 0.7 574 0.796 0.794 0.796 0.795 0.785 0.796
0.8 0.8 0.6 437 0.794 0.796 0.796 0.795 0.788 0.795
0.8 0.8 0.5 336 0.790 0.802 0.798 0.797 0.795 0.792
0.8 0.8 0.4 259 0.777 0.808 0.803 0.805 0.806 0.778
0.8 0.8 0.3 200 0.764 0.827 0.810 0.816 0.825 0.766
0.8 0.7 0.7 461 0.796 0.803 0.798 0.797 0.799 0.798
0.8 0.7 0.6 360 0.792 0.801 0.798 0.797 0.795 0.793
0.8 0.7 0.5 282 0.776 0.794 0.790 0.790 0.791 0.778
0.8 0.7 0.4 222 0.771 0.802 0.796 0.799 0.802 0.773
0.8 0.7 0.3 174 0.756 0.813 0.800 0.805 0.814 0.758
0.8 0.6 0.6 297 0.795 0.812 0.804 0.805 0.812 0.795
0.8 0.6 0.5 238 0.783 0.804 0.795 0.795 0.803 0.785
0.8 0.6 0.4 190 0.773 0.806 0.800 0.802 0.805 0.775
0.8 0.6 0.3 152 0.758 0.819 0.804 0.809 0.821 0.761
0.8 0.5 0.5 200 0.782 0.817 0.804 0.805 0.820 0.784
0.8 0.5 0.4 163 0.768 0.813 0.800 0.802 0.816 0.771
0.8 0.5 0.3 131 0.755 0.815 0.801 0.806 0.820 0.759
0.8 0.4 0.4 138 0.758 0.817 0.796 0.803 0.824 0.761
0.8 0.4 0.3 113 0.744 0.819 0.798 0.804 0.827 0.748
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the resulting weights did not diﬀer by much. Therefore, the simpler weights, i.e. the
sample proportions, were used for the results presented here.
Overall, the shared frailty model, the two-step analysis, and the approximate log-rank
test do not suﬀer loss of power for any of the scenarios and are hence the preferable
choice over the asymptotic log-rank test and the stratiﬁed Cox PH model when dealing
with heterogeneous treatment eﬀects.
A plot where the roles of the hazard ratios of B1 and B2 are interchanged shows similar
results and is shown in the sensitivity analysis in Section 3.2.3.4.
The results for the sample size formulas other than the formula by Palta and Amini
are shown in Figures 3.9 - 3.11. While Schoenfeld's sample size formula performs well
for all analysis methods for small to moderate diﬀerences in hazard ratios, the power
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Figure 3.9: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Schoenfeld's sample size formula under
diﬀerent hazard ratios.
declines for all methods as the diﬀerence between the hazard ratios increases. For the
most extreme hazard ratio scenarios, all methods yield a power below 0.8.
With Lachin and Foulkes' sample size formula, all analysis methods have less than
0.8 power to detect a true treatment eﬀect for all hazard ratio scenarios and for both
3.2. STRATIFIED RANDOMIZE-ALL DESIGN 49
weighting options for the sample size formulas (Figures 3.10 and 3.11).
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Figure 3.10: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Lachin and Foulkes' sample size formula
under diﬀerent hazard ratios.
0.8 0.7 0.6 0.5 0.4 0.3 0.7 0.6 0.5 0.4 0.3 0.6 0.5 0.4 0.3 0.5 0.4 0.3 0.4 0.3HR B2
0.
65
0.
70
0.
75
0.
80
0.
85
0.
90
Po
w
er
HR B1 = 0.8 HR B1 = 0.7 HR B1 = 0.6 HR B1 = 0.5 HR B1 = 0.4Stratified CoxTwo−step approach
Shared frailty
Exact log−rank
Asymptotic log−rank
1
Figure 3.11: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Lachin and Foulkes' sample size formula
(with sample proportions as weights) under diﬀerent hazard ratios.
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3.2.3.4 Sensitivity analysis
Sensitivity analyses were performed to investigate the robustness of the results under
diﬀerent parameter settings and violations of assumptions.
Comparing the asymptotic and the exact log-rank test for the scenarios with the largest
diﬀerences in hazard ratios, and taking into consideration the calculated sample sizes,
an obvious question is whether the reason for the poorer performance of the log-rank
test and the stratiﬁed Cox PH model is that the assumptions regarding asymptotic
properties are not met. For the most extreme scenarios, the calculated sample size
is below 300, which, with prevalences of 0.5, 0.25, and 0.25 for B0, B1, and B2
respectively, results in stratum sizes of less than 75 patients for B1 and B2. Hence,
asymptotic assumptions are problematic in these cases. Another small simulation study
was carried out with equal hazard ratios across strata but smaller sample sizes. The
results in Table 3.4 show that there is indeed some loss of power, but for an overall
sample size of 115 patients (which is very close to the 113 patients in the most extreme
case considered), the loss of power is minor. E.g., the stratiﬁed Cox PH model has
a power of 0.77 as opposed to a power of 0.744 with heterogeneous hazard ratios
(see Table 3.3). For control of the type-I-error rate, the exact log-rank test should be
considered instead if the strata sizes are expected to be small, i.e. in the double digits,
and there is too little data available for reliable approximations. The shared frailty
Table 3.4: Check of asymptotic properties: Numerical results for the power compa-
rison of the stratiﬁed Cox PH model, Mehrotra's two-step approach, the lognormal
shared frailty model, and stratiﬁed exact and asymptotic log-rank test to detect
a true treatment eﬀect when using Palta and Amini's sample size formula under
homogeneity of hazard ratios but under small sample sizes.
Input Power
HR Sample Strat. Cox Two-step Frailty Exact Asympt.
B0, B1, B2 Size Wald Wald Lognorm log-rank log-rank
0.70 0.70 0.70 306 0.801 0.806 0.809 0.804 0.802
0.65 0.65 0.65 213 0.792 0.796 0.800 0.794 0.794
0.60 0.60 0.60 154 0.787 0.793 0.797 0.791 0.790
0.55 0.55 0.55 115 0.779 0.788 0.796 0.789 0.784
0.50 0.50 0.50 87 0.770 0.777 0.794 0.786 0.776
0.45 0.45 0.45 67 0.756 0.745 0.784 0.772 0.762
0.40 0.40 0.40 53 0.759 0.683 0.789 0.778 0.769
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model also appears to be an appropriate choice and additionally oﬀers the possibility
to include covariates in the model, which is an advantage over the exact log-rank test.
In Figure 3.12, the role of the hazard ratios for B1 and B2 was interchanged, i.e. within
each of the plot windows, the hazard ratio for B2 is ﬁxed and the hazard ratio for B1
varies, rather than the other way around (as in Figure 3.8). The results shown in the
plot are similar to Figure 3.8. The minor diﬀerences that can be seen could be caused
by the diﬀerent baseline hazards of the two strata.
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Figure 3.12: Role of hazard ratios of B1 and B2 exchanged: Power of the stratiﬁed
Cox PH model, Mehrotra's two-step approach, the lognormal shared frailty model,
and stratiﬁed exact and asymptotic log-rank test to detect a true treatment eﬀect
when using Schoenfeld's sample size formula under diﬀerent hazard ratios.
It was also investigated whether larger diﬀerences in baseline hazards, i.e. stronger
stratiﬁcation, have an impact on the results. Stratiﬁcation factors 1, 0.5, 1.5 were
used, leading to baseline hazards 0.05, 0.025, 0.075 for B0, B1, and B2, respectively.
Figure 3.13 shows that there is some impact, but especially for the more extreme
hazard ratio scenarios the two-step procedure and the approximate log-rank test still
have a power close to 0.8.
As discussed in section 3.2.3.2, it is possible to simulate a stratum speciﬁc random
eﬀect in the data, as is assumed by the shared frailty model. The results for a minor, a
moderate, and a stronger random eﬀect (with lognorm(0, 0.15), lognorm(0, 0.3), and
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lognorm(0, 0.5), respectively) can be seen in Figures 3.14, 3.15, and 3.16, respectively.
Note the diﬀerent scaling of the y-axes compared to the previous sections.
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Figure 3.13: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Palta and Amini's sample size formula
under diﬀerent scenarios for stronger stratiﬁcation (stratiﬁcation factors 1, 0.5, 1.5
leading to baseline hazards 0.05, 0.025, 0.075 for B0, B1 and B2, respectively).
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Figure 3.14: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Palta and Amini's sample size formula
under diﬀerent hazard ratio scenarios and data with minor random eﬀect (lognorm(0,
0.15)).
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While the minor random eﬀect does not have much of an impact compared to Figure
3.8, the analysis methods do suﬀer some power loss in the presence of a moderate
random eﬀect. The largest power loss happens for the strong random eﬀect. It can
also be observed that the shared frailty model loses less power than the other methods,
while the exact log-rank test does not appear to handle the random eﬀect very well.
Finally, it was investigated how the analysis methods perform under a misspeciﬁed
censoring distribution, under dependent censoring and under misspeciﬁcation of the
survival distribution.
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Figure 3.15: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank
test to detect a true treatment eﬀect when using Palta and Amini's sample size
formula under diﬀerent hazard ratio scenarios and data with moderate random eﬀect
(lognorm(0, 0.3)).
Figure 3.17 shows the results for Weibull distributed censoring when exponential cen-
soring is assumed and Figure 3.18 shows the results for dependent censoring when
independent censoring assumed. In both cases, there is only a minor impact on the
results compared to Figure 3.8. Figure 3.19, on the other hand, shows that the mo-
dels are sensitive to a misspeciﬁed survival distribution. The data were simulated with
Weibull distributed survival times with a shape parameter of 0.8 while the methods
assume exponential survival.
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Figure 3.16: Power of the stratiﬁed Cox PH model, Mehrotra's two-step approach,
the lognormal shared frailty model, and stratiﬁed exact and asymptotic log-rank test
to detect a true treatment eﬀect when using Palta and Amini's sample size formula
under diﬀerent hazard ratio scenarios and data with strong random eﬀect (lognorm(0,
0.5)).
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Figure 3.17: Sensitivity to misspeciﬁed censoring distribution: Weibull distributed
censoring with shape 0.8. Power of the stratiﬁed Cox PH model, Mehrotra's two-step
approach, the lognormal shared frailty model, and stratiﬁed exact and asymptotic
log-rank test to detect a true treatment eﬀect when using Lachin and Foulkes' sample
size formula.
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Figure 3.18: Sensitivity to non-independent censoring. Power of the stratiﬁed Cox
PH model, Mehrotra's two-step approach, the lognormal shared frailty model, and
stratiﬁed exact and asymptotic log-rank test to detect a true treatment eﬀect when
using Lachin and Foulkes' sample size formula.
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Figure 3.19: Sensitivity to misspeciﬁed survival distribution: Weibull distributed
survival with shape 0.8. Power of the stratiﬁed Cox PH model, Mehrotra's two-step
approach, the lognormal shared frailty model, and stratiﬁed exact and asymptotic
log-rank test to detect a true treatment eﬀect when using Lachin and Foulkes' sample
size formula.
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3.2.4 Data example
The approach of investigating several biomarker-deﬁned groups with corresponding
stratum-speciﬁc experimental treatments within a single clinical trial has only just
emerged in recent years. Therefore, most trials of this kind are either still in the
planning or recruitment stage, making it diﬃcult to obtain data for a study design
as it is considered here. For illustration purposes, data were taken from three studies
carried out by the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
and subsets of the data were combined to be used as example data set. For stratum
B1, patients from the 06-04 study (Tassara et al. 2014) with mutated Nucleophosmin-
1 (NPM1) were chosen (n=40). Stratum B2 is comprised of patients from the 07-04
study (Schlenk et al. 2016) with internal tandem duplication mutations of FMS-like
tyrosine kinase 3 (FLT3-ITD) (n=139). The data from the study HD98B (Schlenk
et al. 2004) were used for stratum B0, excluding patients with mutated NPM1 and
FLT3-ITD (n=144). This resulted in a data set with 323 patients. The survival curves
for the three strata can be seen in Figure 3.20.
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B0
(HD98B study)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 75
Standard, n = 69
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B1
(06−04 Study, NPM1 mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 18
Standard, n = 22
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B2
(07−04 Study, FLT3−ITD mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 73
Standard, n = 66
1
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B0
(HD98B study)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 75
Standard, n = 69
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B1
(06−04 Study, NPM1 mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 18
Standard, n = 22
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B2
(07−04 Study, FLT3−ITD mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 73
Standard, n = 66
1
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B0
(HD98B study)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 75
Standard, n = 69
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B1
(06−04 Study, NPM1 mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 18
Standard, n = 22
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Kaplan−Meier Plot for Stratum B2
(07−04 Study, FLT3−ITD mutation)
Time (months)
S
ur
v
iv
a
l p
ro
ba
bi
lit
y
0 12 24 36 48 60 72
Experimental, n = 73
Standard, n = 66
1
Figure 3.20: Kaplan-Meier plots for event-free survival for the data from the German-
Austrian Acute Myeloid Leukemia Study Group (AMLSG). The x-axes were cut at 6
years.
Just like the simulated data, the data set was then analyzed using the asymptotic
and exact log-rank test, the stratiﬁed Cox PH model, the two-step approach, and the
shared frailty model. The resulting hazard ratio estimates for event-free survival were
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0.81 for the stratiﬁed Cox PH model, 0.82 for the two-step approach, and 0.83 for the
lognormal shared frailty model (Table 3.5). The hazard ratios for the individual strata
were also estimated with 0.74, 0.68, and 0.96 for B0, B1, and B2, respectively. Due to
the small sample sizes, especially in B1, one might consider using an unconventional α
of 0.1. Then, rejection of the null hypothesis in this example depends on the analysis
method used. While the null hypothesis would be rejected using the stratiﬁed Cox
PH model, the two-step approach, and the asymptotic log-rank test, it cannot be
rejected using the lognormal shared frailty model and the exact log-rank test. Note
that the performance of the shared frailty model could be inﬂuenced by more complex
underlying baseline hazards than the constant ones in the simulation study.
The performed overall analysis can be understood as assessing the beneﬁt of using
targeted therapies in the overall patient population. Such an overall analysis should
be performed in conjunction with subsequent subgroup analyses to avoid drawing false
conclusions, as it could have been the case for B2 in this example. But especially in
small sample situations, an evaluation of the overall targeted treatment strategy can
be a useful tool to guide further analysis and procedure.
Table 3.5: Hazard ratios with corresponding p-values for the data from the German-
Austrian Acute Myeloid Leukemia Study Group (AMLSG) estimated with the strati-
ﬁed Cox PH model, the two-step approach, and the shared frailty model. Additionally,
p-values are given for the stratiﬁed exact and asymptotic log-rank test.
Analysis Method HR 90% C.I. p-value
Stratiﬁed Cox 0.81 (0.67, 0.99) 0.08
Lognormal shared frailty 0.83 (0.68, 1.01) 0.11
Overall Two-step approach 0.82 (0.67, 0.99) 0.09
Exact log-rank 0.13
Asymptotic log-rank 0.08
Cox B0 0.74 (0.55, 0.98) 0.08
Individual Cox B1 0.68 (0.38, 1.20) 0.26
Cox B2 0.96 (0.71, 1.31) 0.83
From the results of this study, it can be concluded that the assumption of homogene-
ous treatment eﬀects is not appropriate in this context. Hence, the heterogeneity of
treatment eﬀects supports using the sample size formula by Palta and Amini instead
of the formula by Lachin and Foulkes, since the latter does not facilitate the option to
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use stratum-speciﬁc treatment eﬀects within the formula. Furthermore, the two-step
analysis seems like a reasonable ﬁrst step in a multi-stage analysis. Looking at stratum
2 with a hazard ratio of 0.96, one could also consider using an adaptive design for
future studies to be able to stop strata that perform poorly early in the study.
3.3 Multiple biomarker hybrid design
When a design with multiple biomarkers, such as the multiple biomarker hybrid design,
is used for a less prevalent disease, it may be diﬃcult to recruit enough patients to
each subtrial to obtain statistically meaningful results within a reasonable time frame.
In this case, small sample sizes within the subtrials have to be expected, as well as
many biomarker-negative patients at the initial screening stage, i.e. patients which test
negative for all relevant biomarkers. The small sample sizes may make it unfeasible to
analyze the subtrials individually. Moreover, the small sample sizes can lead to biased
treatment eﬀect estimates. This imposes the need to investigate alternative approaches
for the analysis of such a trial, and possibly for the study design itself. Measures should
be taken to reduce the potential bias of the treatment eﬀect estimates. Additionally,
with an expected large group of biomarker-negative patients, it seems reasonable to
explore options to include them in such a trial and potential beneﬁts to the trial through
their inclusion, such as collection of additional data, improving power, or reducing bias.
For the following sections, Design 4 from Figure 3.1 will be considered. The biomarker-
groups are denoted by Bi, i = {0, 1, 2}, where B0 stands for biomarker-negative. Upon
entering the study, the patients' biomarker-proﬁle is determined and they are assigned
to the biomarker-groups accordingly. The proportion of patients in biomarker-group i is
denoted by gi. With a total sample size of n patients, this results in a total number of
ni = gin patients in group i. Within B1 and B2, patients are randomized between the
biomarker-speciﬁc experimental therapy (Exp1 and Exp2, respectively) and standard of
care (Std), with probabilities 1−ri and ri, respectively. Patients in B0 are treated with
standard of care only. The baseline hazard for patients in biomarker-group i is denoted
by λ0i . The hazards of death at time t for biomarker-positive patients in biomarker-
group i receiving treatment j are denoted by λji(t), where j = 1 for experimental
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treatment or j = 0 for standard of care.
3.3.1 Data modeling and analysis
A prognostic biomarker can be modeled by allowing diﬀerent baseline hazards for the
biomarker-groups (stratiﬁed Cox PH model). If a biomarker is predictive on the other
hand, it causes the treatment eﬀects for the biomarker-groups to be diﬀerent, which
cannot be modeled using the stratiﬁed Cox PH model, since it assumes homogeneous
treatment eﬀects. The inclusion of a single treatment arm for biomarker-negative
patients in the regression model for the multi-biomarker hybrid design (Figure 3.1,
Design 4) adds the diﬃculty that data analysis methods for a stratiﬁed analysis, such
as the stratiﬁed Cox PH model, the shared frailty model, or the two-step approach by
Mehrotra et al. (2012), as used in Section 3.2 for the stratiﬁed randomize-all design,
are not applicable in this situation.
There are two possibilities to include the data from the biomarker-negative patients
in the analysis. For non-prognostic biomarkers the three standard of care arms could
simply be pooled. For prognostic biomarkers, however, this approach is not appropriate.
Since it is quite common for biomarkers to be prognostic, it was investigated to include
the biomarker status in the Cox PH model as a factor variable (with dummy variables
b1 and b2) to account for the prognostic eﬀect, as an alternative to using a stratiﬁed
Cox PH model.
To evaluate the beneﬁt of this strategy and of including biomarker-negative patients
the following approaches were compared:
Approach 1: Separate models for both biomarkers, using data only from B1
patients or B2 patients, respectively:
λ1 = λ01 exp(β1x1) (sample size: n1, all patients in B1)
λ2 = λ02 exp(β2x2) (sample size: n2, all patients in B2)
The parameters β1 and β2 represent the treatment eﬀects for Exp1 and Exp2, re-
spectively. This is equivalent to using an enrichment design with two biomarkers
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with separate analyses for the biomarkers.
Approach 2: A model performing a combined analysis, using data from B1 pa-
tients and B2 patients, but excluding biomarker-negative patients (B0):
λ = λ01 exp(γ2b2 + β1x1 + β2x2) (sample size: n1 + n2, all patients in B1 and B2)
The parameters β1 and β2 represent the treatment eﬀects for Exp1 and Exp2,
respectively, and γ2 is the prognostic eﬀect of B2 (with dummy variable b2)
with B1 as reference. This is equivalent to using an enrichment design with two
biomarkers with a combined analysis for the biomarkers.
Approach 3: A model performing a combined analysis, using the entire data set
(B1, B2, and B0)
λ = λ0 exp(γ1b1 + γ2b2 + β1x1 + β2x2) (sample size: n, all patients)
The parameters β1 and β2 represent the treatment eﬀects for Exp1 and Exp2,
respectively, and γ1 and γ2 are the prognostic eﬀects of B1 and B2 (with dummy
variables b1 and b2), respectively, with B0 as reference. This uses all data available
from the multi-biomarker hybrid design.
Note that these three approaches use diﬀerent sample sizes due to the exclusion of
biomarker-groups in Approaches 1 and 2.
For lower prevalence biomarkers, n1 and n2 have to be expected to be rather small
compared to n. While estimates of maximum-likelihood methods, such as Cox regres-
sion, are asymptotically unbiased, this is not necessarily the case for ﬁnite samples (cf.
Cordeiro and McCullagh 1991). Hence, especially for small samples, the estimates of
the Cox regression can be biased. Langner et al. (2003) investigated the relationship
of bias to sample size for logistic and Cox regression. In their simulation study they
found that the bias from maximum likelihood methods depends on sample size, but
also on baseline hazard and treatment hazard ratio. They found a strong bias for
extreme baseline risks and extreme treatment hazards, and also for small numbers of
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events in the control group.
The bias of estimators due to small sample sizes and rare events can be reduced by
using a penalized likelihood based on a modiﬁed score function proposed by Firth
(1993), the so-called Firth correction or Firth penalty (see Section 2.1.1.4). The bias
and root mean squared error (RMSE) of estimators when using the Firth penalty in
situations with a small number of events was investigated by Lin et al. (2013). They
reported that for a small number of events per variable, Firth's approach had less
absolute value of relative bias and a smaller mean squared error (MSE) compared to
the Cox PH model.
3.3.2 Simulation study: Small sample size bias
A simulation study was conducted to compare the performance of the three approaches
discussed in Section 3.3.1 with respect to bias, standard deviation and RMSE of the
diﬀerent parameter estimates, and to investigate whether there is a beneﬁt of including
biomarker-negative patients in the study. Moreover, it was examined to use the Firth
correction to reduce the small sample size bias of the parameter estimates.
3.3.2.1 Study design and data generation
The data were generated as described in Section 2.2.1. The hazard ratios of B1 and
B2, exp(β1) and exp(β2), were varied between 0.8 and 0.4. Note that, due to the
single treatment arm, no hazard ratio can be speciﬁed for B0. For B0, the baseline
hazard λ0 was chosen to be 0.05 and then the baseline hazards for B1 and B2, λ01
and λ02 , were determined by multiplying 0.05 by factors 0.5 and 2, respectively, i.e.,
γ1 = log(0.5) and γ2 = log(2). This was done to simulate a biomarker indicative of
a favorable and a poor prognosis, respectively. Survival and random censoring were
assumed to be exponential and the allocation ratio between treatments for B1 and B2
was set to 1:1. Time will be measured in months. Accrual time a was chosen to be 24
months and follow-up time f 36 months. For the remaining simulation parameters see
Table 3.6. For this simulation study, the censoring proportion pcens was set to 0.05.
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The resulting mean overall censoring proportions over 10,000 simulation runs can be
found in Table 3.7.
Table 3.6: Parameters for the simulation study using a design with three biomarker-
groups. Note that due to the single treatment arm there is no hazard ratio for
B0.
Fixed simulation parameters
Accrual time (months), a 24
Follow-up time (months), f 36
Proportion random censoring, pcens 0.05
Treatment allocation ratio 1 : 1
Hazard ratio B1, exp(β1) 0.8, 0.7, 0.6, 0.5, 0.4
Hazard ratio B2, exp(β2) 0.8, 0.7, 0.6, 0.5, 0.4
exp(γ1) 0.5
exp(γ2) 2
Sample size, n 100, 150, 250, 1,000
Parameters for biomarker-groups (B0,B1,B2)
Proportion of patients, gi (0.5, 0.25, 0.25)
Baseline hazards, λ0i (0.05, 0.025, 0.1)
Diﬀerent sample sizes were considered in the simulation study: smaller sample sizes
with 100 and 150 patients in the study, a moderate sample size with 250 patients, and
a large sample size with 1,000 patients.
The three approaches discussed in section 3 were compared with respect to bias,
standard deviation and RMSE of the estimates βˆ1, βˆ2, γˆ1 and γˆ2 out of S = 10, 000
simulations. The bias and standard deviation of the estimates were calculated as
bias(βˆ) =
1
S
S∑
l=1
βˆl − β and s(βˆ) =
√√√√ 1
S − 1
S∑
l=1
(βˆl − ¯ˆβ)2.
The MSE was then calculated as MSE(βˆ) = bias(βˆ)2 + s2(βˆ) and the RMSE as
RMSE(βˆ) =
√
MSE(βˆ). As a result of the consideration of extreme scenarios, the
algorithm did not converge for some simulation runs due to lack of events in one group.
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These runs were excluded from the analyses (between 0 and 1% of the runs, depending
on the hazard ratios of B1 and B2).
To simulate a non-constant baseline hazard for the sensitivity analysis, data were simu-
lated where the hazard function is given by a Weibull distribution with shape parameters
0.4 and 5. A shape parameter of 1 corresponds to the exponential distribution. For
better comparability, λ0 was adjusted such that the same number of events is reached
at 60 months for all shape parameters, i.e. λ0 = 0.05 · 60/60shape. Additionally, the
simulations were run without censoring to ensure equal numbers of events.
Table 3.7: Mean number of events over 10,000 simulations for the individual treat-
ment arms and overall censoring proportion (both administrative and random) for
n = 100, 150, 250, and 1,000.
n = 100
HR of B1 Events B1 Exp Events B1 Std cens. prop. HR of B2 Events B2 Exp Events B2 Std cens. prop.
0.8 7.3 8.3 0.17 0.8 11.7 12.0 0.17
0.7 6.7 8.3 0.18 0.7 11.5 12.0 0.17
0.6 6.0 8.3 0.19 0.6 11.2 12.0 0.18
0.5 5.3 8.3 0.19 0.5 10.8 12.0 0.18
0.4 4.5 8.3 0.20 0.4 10.1 12.0 0.19
n = 150
HR of B1 Events B1 Exp Events B1 Std cens. prop. HR of B2 Events B2 Exp Events B2 Std cens. prop.
0.8 10.9 12.4 0.17 0.8 17.6 18.0 0.17
0.7 10.0 12.4 0.18 0.7 17.3 18.1 0.17
0.6 9.1 12.4 0.19 0.6 16.9 18.1 0.18
0.5 8.0 12.4 0.19 0.5 16.2 18.1 0.18
0.4 6.7 12.4 0.20 0.4 15.1 18.1 0.19
n = 250
HR of B1 Events B1 Exp Events B1 Std cens. prop. HR of B2 Events B2 Exp Events B2 Std cens. prop.
0.8 18.1 20.6 0.17 0.8 29.4 30.0 0.17
0.7 16.7 20.6 0.18 0.7 28.9 30.1 0.17
0.6 15.0 20.6 0.19 0.6 28.2 30.1 0.18
0.5 13.2 20.6 0.19 0.5 27.1 30.1 0.18
0.4 11.1 20.6 0.20 0.4 25.3 30.1 0.19
n = 1, 000
HR of B1 Events B1 Exp Events B1 Std cens. prop. HR of B2 Events B2 Exp Events B2 Std cens. prop.
0.8 72.5 82.3 0.17 0.8 118.1 120.4 0.17
0.7 66.7 82.3 0.18 0.7 116.1 120.4 0.17
0.6 60.3 82.3 0.19 0.6 113.1 120.5 0.18
0.5 52.9 82.4 0.19 0.5 108.6 120.6 0.18
0.4 44.7 82.4 0.20 0.4 101.6 120.7 0.19
3.3.2.2 Comparison of analysis approaches
The three approaches discussed in Section 3.3.1 were compared with respect to bias,
standard deviation and RMSE of the diﬀerent parameter estimates out of 10,000 simu-
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lations. The bias correction by Firth (1993) was applied in an additional analysis and
the bias, standard deviation, and RMSE were again compared for the three approaches.
For β1, the treatment eﬀect for the biomarker indicative of a favorable prognosis (B1),
the bias and standard deviation of the estimate βˆ1 for diﬀerent sample sizes are shown
in Figure 3.21. The Figures showing the RMSE of βˆ1 (and also of the other estimates)
can be found in the Appendix, since there were only minor visible diﬀerences between
standard deviation and RMSE. For all approaches and sample sizes, it can be observed
that bias, standard deviation, and RMSE increase in absolute terms as the hazard ratio
for B1, exp(β1), gets smaller, i.e. as the treatment eﬀect gets larger. Without Firth
correction, Approach 1 yields a slightly smaller bias than Approach 2 and 3, which
perform similarly. The diﬀerences between the approaches get smaller as the sample
size increases. For standard deviation and RMSE all three approaches perform similarly.
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Figure 3.21: Bias and standard deviation of the estimate of log hazard ratio β1, the
treatment eﬀect estimate for the biomarker indicative of a favorable prognosis (B1),
using a Cox PH model without and with Firth correction for sample sizes 100, 150,
250, and 1,000.
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The Firth correction was applied to all three approaches. It is able to reduce the bias
for all three approaches but appears to over-correct the bias for Approach 1, and for
n = 100 also for Approach 2 and 3. The Firth correction oﬀers a slight reduction in
standard deviation and RMSE for all three approaches, which all perform similarly.
For β2, the treatment eﬀect for the biomarker indicative of a poor prognosis (B2), the
bias and standard deviation of the estimate βˆ2 for diﬀerent sample sizes are shown in
Figure 3.22. For all approaches and sample sizes, it can be observed that the bias, as
well as standard deviation and RMSE, increases in absolute terms as the hazard ratio
for the treatment eﬀect of biomarker 2, exp(β2), gets smaller.
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Figure 3.22: Bias and standard deviation of the estimate of log hazard ratio β2,
the treatment eﬀect estimate for the biomarker indicative of a poor prognosis (B2),
using a Cox PH model without and with Firth correction for sample sizes 100, 150,
250, and 1,000.
Comparing the three approaches, it can be seen that for the small to moderate sample
sizes, the bias of βˆ2 is approximately similar for Approach 1 and Approach 2, while
Approach 3 yields a smaller bias. This diﬀerence gets larger as the treatment eﬀect
increases. With increasing sample size, the diﬀerences in bias of βˆ2 between the three
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approaches get smaller. For n = 1, 000 there is no longer a visible diﬀerence. Approach
1 yields the largest standard deviation and RMSE, and Approach 3 the smallest. Again,
these diﬀerences get smaller with increasing sample size.
The Firth correction was applied to all three approaches. The results are also shown
in Figure 3.22. Just as before, for all approaches and sample sizes, the bias, standard
deviation, and RMSE increase in absolute terms as the hazard ratio for biomarker 2,
exp(β2), gets smaller.
For n = 100 and n = 150, a diﬀerence in bias between Approaches 1 and 2 can now
be observed. For the larger hazard ratios, Approach 2 yields a slightly smaller bias, but
as the hazard ratio decreases, the diﬀerences get smaller and for the smaller hazard
ratios, Approach 1 yields the smaller bias. For standard deviation and RMSE, there is
a similar situation for the estimates without Firth correction: Approach 1 yields the
largest and Approach 3 the smallest result, but the diﬀerences between the approaches
are now smaller and again get smaller with increasing sample size. Note that the true
value of β1 does not aﬀect the bias and standard error for βˆ2 and vice versa.
A comparison of bias, standard deviation, and RMSE of γˆ1 and γˆ2 for Approach 3
is shown in Figure A.3 in the Appendix. The estimates are almost constant for each
sample size and do not change with increasing bias of the treatment eﬀect estimates.
Overall, the bias, standard deviation, and RMSE of γˆ1 and γˆ2 get smaller with increasing
sample size. Note that bias and standard deviation of γˆ1 and γˆ2 are not aﬀected by
the values of β1 and β2. This allows the conclusion that, while bias and error for γˆ1
and γˆ2 do depend on the overall sample size, they do not depend on the number of
events in the treatment arms.
Figures 3.23 and 3.24 show the behavior of the bias of βˆ1, βˆ2, γˆ1, and γˆ2 for diﬀerent
baseline hazards. For both Figures, the baseline hazards for B2 correspond to multi-
plying λ00 = 0.05 with exp(γ2), where γ2 = log(2), γ2 = log(7/4), γ2 = log(3/2), and
γ2 = log(5/4), respectively. The baseline hazards for B1 correspond to multiplying λ00
with exp(γ1), where γ1 = log(
1
2
), γ1 = log(4/7), γ1 = log(2/3), and γ1 = log(4/5),
respectively.
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Figure 3.23: Comparison of bias of the estimates of log hazard ratio β1 and log
hazard ratio β2 for diﬀerent baseline hazards for n = 100, using a Cox PH model
without and with Firth correction for diﬀerent baseline hazards.
Figure 3.23 shows that there is not much diﬀerence for the diﬀerent baseline hazards
looking at the bias of βˆ1 for the three approaches without Firth correction. For the
model with Firth correction, the upwards bias that can be observed in the ﬁrst plot
for λ01 = 0.025 gets smaller as the baseline hazard increases, i.e. as λ01 approaches
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Figure 3.24: Comparison of bias and standard deviation of the estimates of γ1 and
γ2 for diﬀerent baseline hazards, using a Cox PH model without and with Firth
correction for Approach 3 and for diﬀerent baseline hazards.
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λ0. For the standard deviation of βˆ1, there is not much of a diﬀerence between the
plots for the diﬀerent baseline hazards, but overall the standard deviation decreases as
the baseline hazard increases and it is smaller for the models with Firth correction (see
Figure A.4 in the Appendix).
For βˆ2 there are also only slight diﬀerences between the plot for bias and standard
deviation of βˆ2 for the diﬀerent baseline hazards. But for both models, with and
without Firth correction, Approach 1 improves in bias as λ02 decreases, i.e., approaches
λ0. The plots for the standard deviation of βˆ2 look similar for all baseline hazards.
Figure 3.24 shows that the diﬀerence of bias and standard deviation between γˆ1 and
γˆ2 gets smaller as the diﬀerence between the baseline hazards gets smaller.
3.3.2.3 Sensitivity analysis
Further simulations were run to investigate the robustness of the estimators against
violations of model assumptions and change of parameters. Besides diﬀerent baseline
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Figure 3.25: Diﬀerent patient proportions: Bias and standard deviation of the es-
timate of log hazard ratio β1, the treatment eﬀect estimate for B1, using a Cox
PH model without and with Firth correction when the patient proportions in the
biomarker-groups B0, B1, and B2 are 0.6, 0.3, and 0.1, respectively.
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hazards for the biomarkers, the bias and standard deviation were also investigated for
diﬀerent biomarker prevalences. Figures 3.25 and 3.26 show the bias and standard
deviation of βˆ1 and βˆ2 for patient proportions 0.6, 0.3, and 0.1 in biomarker-groups
B0, B1, and B2, respectively.
The diﬀerent prevalences do not seem to have much of an impact on bias and standard
deviation of βˆ1. Both are a bit smaller, which would be expected, given the slightly
larger group size. For βˆ2, the results diﬀer for n = 100 and n = 150. But given the
small numbers of patients in B2 (10 and 15, respectively), the upwards bias and larger
standard deviation that can be seen in those cases is most likely caused by the very
small sample size. So it seems that the small prevalence, rather than the diﬀerences
in prevalence, is the cause for the change in bias and standard deviation.
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Figure 3.26: Diﬀerent patient proportions: Bias and standard deviation of the es-
timate of log hazard ratio β2, the treatment eﬀect estimate for B2, using a Cox
PH model without and with Firth correction when the patient proportions in the
biomarker-groups B0, B1, and B2 are 0.6, 0.3, and 0.1, respectively.
For the non-constant (Weibull distributed) hazard function, shape parameters of the
Weibull distribution were chosen to be 0.4, 1 and 5 (cf. Section 3.3.2.1). For the
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corresponding shape of the resulting survival distribution see Figure 3.27. For better
comparability, λ0 was adjusted such that the same number of events is reached at 60
months for all shape parameters, i.e. λ0 = 0.05 ·60/60shape. Shape parameters smaller
than 1 result in survival curves that are steeper at ﬁrst and then ﬂatter towards the end
of the trial, whereas shape parameters greater than 1 result in survival curves which
are ﬂatter at ﬁrst and get steeper towards the end.
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Figure 3.27: Kaplan-Meier plots showing survival distributions for diﬀerent shape
parameters of the Weibull distribution. The red curve shows survival of patients
receiving experimental therapy and black stands for standard of care.
For both, βˆ1 and βˆ2, not much of a diﬀerence can be seen compared to the simulation
results in Figures 3.21 and 3.22. The results are shown in Figures 3.28 and 3.29.
The slight diﬀerences disappear when these simulations are also run without censoring.
Hence, it can be concluded that the diﬀerences seen between Figures 3.21 and 3.28,
and 3.22 and 3.29, respectively, were caused by the diﬀerent numbers of events, rather
than the time-dependent baseline-hazard. With censoring, and therefore with diﬀerent
numbers of events, there are diﬀerences in bias and standard deviation.
Additionally, it was veriﬁed that all three approaches for β1 and β2 without and with
Firth correction for the diﬀerent biomarker prevalences and for the diﬀerent Weibull
shape parameters roughly control the type one error rate. The tables with the numerical
results can be found in Tables A.5 and A.6 in the Appendix.
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(a) Weibull shape parameter: 0.4
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(b) Weibull shape parameter: 1.
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(c) Weibull shape parameter: 5.
Figure 3.28: Bias with and without censoring of the estimate of log hazard ratio β1
for Weibull distributed hazard function using Cox PH model withou and with Firth
corre tion for sample sizes 100 and 150. Results for sample sizes 250 and 1,000 not
shown.
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(a) Weibull shape parameter: 0.4
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(b) Weibull shape parameter: 1.
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(c) Weibull shape parameter: 5.
Figure 3.29: Bias with and without censoring of the estimate of log hazard ratio β2
for Weibull distributed hazard function using Cox PH model withou and with Firth
corre tion for sample sizes 100 and 150. Results for sample sizes 250 and 1,000 not
shown.
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3.4 Flexible study designs
The ﬁeld of biomarker research is rapidly and constantly developing. With a typical trial
duration of up to several years, it is desirable to be able to react to the emergence of
new potential biomarkers and corresponding experimental therapies during the course
of the study, without having to conduct a new, separate clinical trial. Having the
ﬂexibility of incorporating a new biomarker and corresponding treatment in an ongoing
clinical trial could make their investigation more time- and cost-eﬃcient.
However, adding a new biomarker-group to an ongoing trial needs careful considera-
tion and planning to ensure feasibility and statistical soundness. Note that so far,
the biomarker-groups were treated as mutually exclusive. While this is a convenient
simpliﬁcation, it is not necessarily realistic. Often times, patients have more than
one biomarker. This will be taken into consideration in the following sections, where
several possibilities for the modiﬁcation of the study design by adding a new biomar-
ker will be presented and statistical considerations and issues will be discussed. To
distinguish between biomarkers and biomarker-deﬁned groups, in the following the bi-
omarkers themselves will be denoted as Bi. The biomarker-groups will be denoted as
Gi, deﬁned by biomarker Bi. The diﬀerence between Bi and Gi is that patients are
distinctly allocated to one of the biomarker-groups Gi, but patients within group Gi
may also have other biomarkers, additional to Bi.
3.4.1 Inclusion of a new biomarker-group
In the following, a study design with two biomarker-groups is considered, denoted by
Gi, i ∈ {0, 1}, where G1 is comprised of patients matched with B1 (see Figure 3.30a).
Upon entering the study, the patients' biomarker-proﬁle is determined and they are
assigned to the biomarker-groups accordingly. All patients that cannot be matched
with B1 are allocated to G0, the biomarker-negative patients. While patients in G1 are
randomized between an experimental therapy, targeting their biomarker, and standard
of care, patients in G0 are treated with standard of care only.
Beyond this initial study design, it is assumed that there is another biomarker, B2
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(see Figure 3.30b). This biomarker is not included at the beginning of the study, but
throughout the study, external information becomes available that patients with B2
could potentially beneﬁt from a new experimental treatment Exp2. It is aimed to be
able to react quickly to such developments in the ﬁeld of targeted therapies without
going through the lengthy process of planning a new, separate trial for patients with
B2. Additionally, there could be concern that the coexistence of the ongoing and the
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1(a) Initial study design
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Figure 3.30: Adding a new biomarker to an ongoing clinical trial
potential new study may impair recruitment rates. Instead, the study shall be planned
such that the study protocol allows adding a biomarker-group G2 with experimental
therapy Exp2 to the ongoing trial at some point throughout the trial, denoted as tb,
where 0 ≤ tb ≤ a (see Figure 3.30c). For this situation, the protocol should also
include guidelines for an algorithm that prioritizes the biomarkers, such that patients
with both biomarkers are distinctly allocated to either G1 or G2. The following sections
will discuss potential design options, and practical and statistical considerations and
challenges.
3.4.2 Extension of the study design
One important initial question is whether or not it is possible to retrospectively de-
termine the biomarker status of the patients included in the study up to time tb with
respect to B2. If it is possible to retrospectively determine the biomarker status with
respect to B2, it is possible to distinguish between patients with B1 and B2 in G1 and
patients with B1 without B2 in G1, i.e. patients within the already existing biomarker-
group can be subdivided into B1+B2 and B1−B2. With this information available, it
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could be considered excluding the patients with B1+B2 from the ﬁnal analysis. This
exclusion could, for example, be based on known interactions between the two biomar-
kers regarding the treatment, i.e. if B2 is known to have a positive or negative eﬀect
on the response to the given treatment Exp1. Alternatively, an interaction term could
be included in the ﬁnal model to accommodate for and estimate this eﬀect.
One option to exclude patients from the analysis could be with the goal of not having
a change in patient population within the biomarker-groups at time tb. If B2 was
assigned a higher priority in the allocation algorithm than B1, this would change the
population in group G1 from B1±B2 before tb to B1−B2 after tb, due to patients with
B1+B2 being assigned to group G2 instead. Then, in this option, all patients with B2
already assigned to G1 would be excluded from the analysis, maintaining consistency
in patient population before and after time tb with respect to B2.
Additional to the retrospective determination of B2, it is important to assess the re-
liability of the external information used. If there is strong evidence, e.g. a large
conﬁrmatory study has just revealed that patients with B1 and B2 do not beneﬁt
from treatment Exp1, exclusion of patients who ﬁt this proﬁle and have already been
randomized would be reasonable. Additionally, investigators should consider stopping
ongoing treatment for these patients. If, on the other hand, there is only weak evi-
dence, e.g. the information is merely a conjecture from an early phase study, the
patients should be kept in the study and treatment should be continued. After the
main analysis, an exploratory subgroup analysis should be performed comparing B1+B2
and B1−B2 patients to see if the collected data support the conjecture.
In the following, options for study design and analysis will be discussed, depending
on the reliability of the external evidence and the suspected interaction of the new
biomarker with the other biomarker or experimental therapy.
If there is strong evidence that B2 has a negative eﬀect on the response of patients
with B1+B2 to the experimental therapy Exp1, it could be considered to exclude all
patients with B1+B2 already assigned to group G1 from the analysis and additionally
to stop ongoing treatment of these patients (see Fig. 3.31). The patients whose
treatment was stopped could possibly be given the new experimental therapy Exp2 oﬀ-
protocol. Due to the negative eﬀect of B2 on response, no new patients with B1+B2
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should be assigned to group G1 after tb. This can be achieved by giving a higher
priority to B2 than to B1 in the allocation algorithm.
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Figure 3.31: Potential approach if there is strong evidence that B2 has a negative
eﬀect on the response of patients with B1+B2 to the experimental therapy Exp1
If the evidence of a negative eﬀect of B2 on the response is weaker, it is advisable to
keep all patients in the analysis and rather aim for strengthening the evidence with the
data resulting from the study through an exploratory subgroup analysis, comparing the
treatment eﬀect in subpopulation B1+B2 against the treatment eﬀect in B1−B2 (see
Figure 3.32). A challenge here is the change in patient population at tb, given that B2
is assigned a higher priority in the allocation algorithm. It should be considered if and
how this change can be taken into consideration. If the suspicion is correct that B2
has a negative eﬀect on the response, there would be two diﬀerent treatment eﬀects
for the experimental therapy, the treatment eﬀect after tb being larger than before.
Additionally, the two subpopulations could also diﬀer with respect to prognostic eﬀects
of the biomarkers.
If there is no evidence that B2 has an eﬀect on the response of patients with
B1+B2 to the experimental therapy Exp1, there is no necessity of excluding patients
from the analysis, since there is no expected diﬀerence in treatment eﬀects between
patients with B1+B2 and patients with B1−B2 (see Figure 3.32). However, if B2 is
assigned a higher priority in the allocation algorithm, the population does change at
tb, since patients with B1+B2 are no longer assigned to group G1, but rather to group
G2. In that case, it should be considered accounting for this in the analysis. While
the treatment eﬀect is not expected to be diﬀerent between the two subpopulations,
there can still be diﬀerences, e.g. due to prognostic factors. After performing the
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Figure 3.32: Potential approach if there is only weak or no evidence that B2 has a
(negative) eﬀect on the response of patients with B1+B2 to the experimental therapy
Exp1
main analysis, exploratory subgroup analyses can be performed, comparing B1+B2 and
B1−B2.
If there is evidence that B2 has a positive eﬀect on the response of patients with
B1+B2 to the experimental therapy Exp1, patients should not be excluded. If patients
with B1+B2 are expected to have a better response to Exp1 than to Exp2, it should
be considered assigning a higher priority to B1 than to B2 in the allocation algorithm.
Otherwise, it should be the other way around. Again, a subsequent exploratory sub-
group analysis can be performed to compare B1+B2 and B1−B2 to see if the collected
data support the existence of a positive eﬀect of B2.
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Biomarker
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G1 (B1 ±B2)
B1 −B2
B1 +B2
R
G1 (B1 ±B2)
B1 −B2
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Figure 3.33: Potential approach if there is evidence that B2 has a positive eﬀect on
the response of patients with B1+B2 to the experimental therapy Exp1
When a new biomarker-group is added to an ongoing trial, several issues need to
be addressed. First of all, the study protocol should state up until which point of the
study a new biomarker-group with corresponding treatment can still be added, e.g.
until accrual is halfway completed. This already leads to the next issue. Since accrual
for this group begins later than for the other groups, it needs to be addressed how
this is compensated for. Assigning the highest allocation priority to B2 could help to
somewhat speed up accrual compared to the other groups. But depending on how long
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after initial begin of accrual G2 is added, this will probably not be enough. Additionally,
the accrual phase could be extended to ensure suﬃcient accrual to G2, but this will
automatically prolong the overall study duration.
Finally, the group of biomarker-negative patients should also be addressed. In this
group there is also a change in population, since patients with (only) B2 are no longer
considered 'biomarker-negative' after adding G2 to the study. This population change
should be considered in the analysis.
Patients
Biomarker
assessment
G1 (B1 ±B2)
B1 −B2
B1 +B2
R
G1 (B1 ±B2)
B1 −B2
B1 +B2
R
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G0 (±B2)
B
− −B2
B
− +B2
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B1 +B2
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G1 (B1 ±B2)
B1 −B2
B1 +B2
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G2 R
G0 (±B2)
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− −B2
B
− +B2
Exp1
Std
Exp1
Std
Exp2
Std
Std
1Figure 3.34: Considerations for biomarker-negative patients.
Additional to practical aspects of the design modiﬁcations, it is important to look at the
options from a statistical point of view and address potential issues and challenges. If it
is considered to exclude some of the patients from the main ﬁnal analysis, it should be
discussed whether it is acceptable to do so from a statistical point of view. Additionally,
the overall sample size needs to be adjusted since there is a new biomarker-group added
which was not included in the initial sample size calculation. Furthermore, it might
be necessary to adjust the sample size of the other biomarker-groups if some of the
patients in these groups are excluded from the analysis.
There can be many reasons why one might consider to exclude patients from a study
or an analysis, but in the following only the exclusion of patients after adding a new
biomarker-group will be discussed. Among other situations, Fergusson et al. (2002)
consider the case when ineligible patients are mistakenly included in a study who do not
meet inclusion criteria. This is not exactly equivalent to the situation considered here,
since the patients to be excluded do meet the inclusion criteria for their biomarker-
group in the beginning, but that may no longer be true after modiﬁcation of the study.
In their paper, Fergusson et al. (2002) discuss that investigators could avoid bias if
patients who were mistakenly included are removed from both treatment arms and the
decision to remove the patients is blinded to treatment and outcome, and independent
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from any events that occurred after randomization. Furthermore, they argue that,
if these patients are expected to have a reduced or no response to treatment, their
inclusion in the analysis could be a source of random error, reduced power of the study,
and a less precise estimate of the treatment eﬀect. This reasoning could also be applied
in the situation considered here, especially if external evidence suggests that B2 has
a negative eﬀect on the response to treatment with Exp1. Additionally, exclusion of
patients from the analysis would only depend on external information (e.g. potential
interaction with the new biomarker) and information obtained before randomization
(assessment of biomarker status).
In a situation where the new biomarker cannot be determined retrospectively,
it is not possible to exclude patients from the analysis or account for the eﬀect by
including an interaction term. In this case it should be considered to perform an analysis
that factors in the heterogeneity within the biomarker-groups caused by B2. If the new
biomarker cannot be determined retrospectively for only part of the population (e.g.
due to insuﬃcient amounts of stored specimens for these patients), data imputation
methods could be considered. This will be discussed in more detail in Section 3.4.5.
If the biomarker status cannot be determined retrospectively for any of the patients, it
could be considered to treat the change in patient population as changes in inclusion
criteria for the aﬀected biomarker-groups. Lösch and Neuhäuser (2008) discuss the
statistical analysis of a trial when an amendment has changed the inclusion criteria and
suggest using Fisher's combination test after performing separate statistical tests for
the patients recruited before and after the amendment. In their simulation study, they
compare the suggested combination test to simple pooling of data with respect to po-
wer. Following some simpler scenarios, they consider a case where the treatment eﬀect
is diﬀerent for the two phases and compare the power of the tests for diﬀerent changes
in variance. But they only consider an inﬂation of variance due to broadening of the
inclusion criteria, while in the case considered here, deﬂation of the variance is more
likely, since the inclusion criteria are basically narrowed by no longer assigning patients
with B1+B2 to group G1. Hence, the behavior for variance deﬂation would additionally
have to be investigated. There is a subsequent publication by Leuchs and Neuhäuser
(2013) who suggest a modiﬁed Bauer and Köhne's test after an amendment has chan-
ged the inclusion criteria. They compare the performance - with respect to power - of
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their suggested test to the tests by Liptak, Fisher, Bauer and Köhne, and Edgington.
However, they ﬁnd in their simulation study that their method is not advisable to use
in situations with changes in both, treatment eﬀect and variance. In these situations,
they ﬁnd that Fisher's test and Liptak's Z-score approach perform best. Note that
both papers compare the tests with respect to power, focusing on hypothesis testing.
For estimation of treatment eﬀects, they refer the reader to a publication addressing
estimation in ﬂexible two stage designs by Brannath et al. (2006).
In the following, the focus will be on situations where B2 can be fully or partially
determined retrospectively.
3.4.3 Approaches for data analysis after adding a new
biomarker-group
A study design was considered where the study initially includes one biomarker (B1)
that is investigated, with group G1 and the group of biomarker-negative patients, G0.
At time tb, a new, second biomarker, B2, and a corresponding group G2 are added to
the study (cf. Figure 3.30). It is assumed that there is evidence that B2 has a negative
eﬀect on the response of patients with B1+B2 in G1 to the experimental therapy
Exp1. Within G1 and G2, patients are randomized between the biomarker-speciﬁc
experimental therapy (Exp1 and Exp2, respectively) and standard of care (Std), with
probabilities 1−ri and ri, respectively. Patients in G0 are treated with standard of care
only. The baseline hazard for patients in biomarker-group i is denoted by λ0i . Several
new parameters have to be considered:
• Eﬀect τ of B2 on Exp1: Factor by which hazard ratio for B2-patients treated
with Exp1 diﬀers from hazard ratio for B1-patients treated with Exp1, e.g. if
eﬀect= 1.5 and HR= 0.5 for B1, then HRB2,Exp1 = 1.5 ∗ 0.5 = 0.75.
• Overlap l: Proportion of the entire patient population which has both biomar-
kers (expected number of n·l patients), e.g. if both biomarkers have a prevalence
of 25% and an overlap of B1 and B2 within the entire population of l =12.5%,
50% of patients within G1 (or G2) have both biomarkers.
• Time tb: Time at which G2 is added to the study.
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Additionally, the priority for the treatment allocation algorithm needs to be chosen,
i.e. which biomarker-group patients are assigned to if they have both biomarkers.
Diﬀerent models are compared to evaluate whether excluding patients from the analysis
or including an interaction term for the eﬀect of B2 on the treatment eﬀect of Exp1 is
the better strategy with respect to bias and standard deviation of the treatment eﬀect
estimates. Additionally, a combined model, analogous to Approach 3 in Section 3.3,
is compared to ﬁtting models for the individual biomarker-groups.
Model 1: Exclude patients with B2
λ(t) = λ0 exp(β1x1)
Expected sample size: n1 − tba n · l (G1 excluding patients with B2)
Model 2: Include interaction term for patients with B2
λ(t) = λ0 exp(β1x1 + β1,21{B2}x1,2)
Expected sample size: n1 (G1 including patients with B2)
Model 3: Combined model (as discussed in Section 3.3)
λ(t) = λ0 exp(γ1b1 + γ2b2 + β1x1 + β2x2 + β1,21{B2}x1,2)
Expected sample size: n (all patients)
The parameters β1 and β2 are representing the treatment eﬀects for Exp1 and Exp2,
respectively and γ1 and γ2 are the prognostic eﬀects of B1 and B2, respectively, with
B0 as reference. The biomarker status is included as a factor variable (with dummy va-
riables b1 and b2). Note that usage of all three models requires that B2 is determinable
retrospectively for all patients recruited before time tb.
3.4.4 Simulation study: Comparison of models
A simulation study was performed to compare bias and standard deviation for all three
models to determine if exclusion of patients or including an interaction term is the
better option and if using a combined model for all biomarkers can provide additional
beneﬁt.
82 CHAPTER 3. RESULTS
3.4.4.1 Study design and data generation
The data were generated as described in Section 2.2.1 with parameters according to
Table 3.8. The time tb at which G2 is added to the study was chosen to be 12
months, i.e. after half of the accrual time has passed. To take into account the
overlap of the biomarkers within the population, an overlap l between the biomarkers
was simulated. This overlap was set to be 12.5% out of the entire population. This
ﬁxed overlap between the biomarkers can be simulated by drawing from a multinomial
distribution. But rather than having three possible outcomes (B1, B2, or B0), there is
a fourth possible outcome, which means that a patient has both biomarkers, B1 and
B2. If the expected proportions of the biomarkers B1 and B2 in the population are p1
Table 3.8: Parameters for the simulation study using a design with three biomarker-
groups, denoted by Gi, i ∈ {0, 1, 2}.
Fixed simulation parameters
Accrual time (months), a 24
Follow-up time (months), f 36
Time tb (months) 12
Proportion random censoring, pcens 0.05
Treatment allocation ratio 1 : 1
Prevalence p of biomarkers B1 and B2 0.25
Hazard ratio G1, exp(β1) 0.8, 0.7, 0.6, 0.5, 0.4
Hazard ratio G2, exp(β2) 0.8
Sample size, n 1,000
Number of simulations 10,000
Overlap l of biomarkers 0.125
Eﬀect τ 1.5
Parameters for biomarker-groups (G0,G1,G2)
Baseline hazards, λ0i (0.05, 0.025, 0.1)
and p2, respectively, then the sampling proportions for B0, B1, B2, and B1∩ B2 are
1 − (p1 + p2 − l), p1 − l, p2 − l, and l, respectively. The resulting proportions gi in
the groups Gi then depend on which biomarker was chosen as priority in the allocation
algorithm and at which time tb G2 was added to the study.
As mentioned before, it is also taken into consideration that a biomarker could have an
eﬀect on the treatment eﬀect of the experimental therapy targeting another biomarker.
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For data generation, it was assumed that B2 has an eﬀect τ on the treatment outcome
of patients (that also have B1) treated with Exp1, while B1 has no eﬀect on treatment
with Exp2. This eﬀect was chosen to be τ = 1.5, which means that patients with
B1 and B2 treated with Exp1 have a hazard ratio that diﬀers by a factor 1.5 from the
hazard ratio for patients with only B1 treated with Exp1. A large sample size case with
1,000 patients was considered to avoid small sample size bias (as observed in Section
3.3). Bias and standard deviation of the estimates were calculated as described in
Section 3.3.2.1.
3.4.4.2 Comparison of models
The three models discussed in Section 3.4.3 were compared with respect to bias and
standard deviation of the estimates βˆ1, βˆ2, and βˆ1,2 out of 10,000 simulations. The
simulation results in Figure 3.35 show that the three models do not diﬀer by much
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Figure 3.35: Bias and standard deviation of βˆ1, βˆ2, and βˆ1,2, using models 1, 2, and
3 with ﬁxed sample size 1,000. Note that for βˆ2, Model 1 was used with data from
G2.
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when it comes to bias of βˆ1 and βˆ1,2. Model 3, i.e. the combined model, yields
a slightly smaller standard deviation for βˆ1 compared to models 1 and 2. For βˆ1,2,
not much of a diﬀerence can be seen for the standard deviation. Note that Model
1 cannot be included in the comparison for βˆ1,2. It does not provide an estimate for
β1,2, since it does not include an interaction term. If Model 1 is used for G2, i.e.
λ(t) = λ0 exp(β2x2), bias and standard deviation of βˆ2 are larger than for Model 3.
Note that Model 2 was not applied and compared for β2, since there is no biomarker-
treatment interaction that can be estimated. Additionally, for this simulation B1 was
given priority, i.e. patients with both biomarkers are allocated to G1. Thus, there are
no patients with B1 in G2 and Model 1 and Model 2 would yield similar results. Overall,
Model 3 appears to be slightly advantageous over the other two models. It yields a
smaller bias and standard deviation for βˆ2 and facilitates estimating β1, β2, and β1,2
simultaneously in one model.
3.4.5 What if B2 is not determinable retrospectively?
In clinical trials missing data is a common issue. There are a multitude of reasons
why there may be certain data points missing for a certain patient. When it comes
to determining the biomarker status of a patient, common reasons are insuﬃcient
amounts of collected specimens, or technical diﬃculties of the screening procedure.
As previously mentioned, usage of all three models discussed int he previous section
requires that B2 is retrospectively determinable for all patients recruited before time
tb.
If B2 is not retrospectively determinable for any of the patients, it will not be possible to
incorporate this in the model. However, if B2 is only missing for part of the population,
data imputation methods can be applied to be able to use data for patients with missing
B2 status in the analysis.
In the context of missing data, Rubin (1976) distinguished between missing at random
(MAR) and missing completely at random (MCAR). If the data are MCAR, the mis-
singness depends on neither the missing values nor the observed values. In the weaker
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case, MAR, the missingness does not depend on the missing values but may depend
on the observed values. If neither is the case, the data are referred to as missing not
at random (MNAR) (Van Buuren 2012). Hereafter, missing data will be assumed to
be MCAR or MAR.
3.4.5.1 Data imputation
A common approach to handling missing data is to simply delete all cases with missing
data and only include the complete cases (CC) in the analysis. While CC analysis still
produces unbiased estimates for data that is MCAR, Van Buuren (2012) argues that
if the data is not MCAR, this approach may produce severely biased estimates. In
the case of missing B2 status, it is not unlikely that the data are MAR rather than
MCAR, i.e. that the missingness depends on one or more of the observed variables.
The missingness could for example depend on the time at which a patient entered
the study: The probability of missing B2 status could be higher the earlier a patient
entered the study, e.g. due to decrease of amount or quality of stored specimens over
time.
Instead of CC analysis, Van Buuren (2012) recommends using regression imputation,
where a regression model is ﬁt using the complete cases to predict the missing values
with the resulting equation. One of the advantages of (single) regression imputation
over CC analysis pointed out by Van Buuren is that, additional to producing unbiased
estimates under MCAR, regression imputation produces unbiased regression weights
under MAR, given that the regression model contains the factors inﬂuencing the mis-
singness. The variance, however, is underestimated since the estimates do not include
an error term and therefore do not provide information about the uncertainty of the
imputed values. The extent of underestimation depends on the explained variance and
the proportion of missing values in the data (Van Buuren 2012).
Creating several data sets with imputed values including a random component is re-
ferred to as multiple imputation and is utilized to account for the uncertainty in the
imputed data. There are several diﬀerent methods to do so. Van Buuren (2012) uses
multiple imputation by chained equations, which uses a series of conditional distribu-
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tions. For each variable, regression models are ﬁtted successively, using the already
imputed values for the following regressions. This is done iteratively until the model
converges. Each of the resulting complete data sets from the multiple imputation is
analyzed separately and afterwards the overall estimate is obtained by averaging the
estimates from the individual data sets (Van Buuren 2012). The standard error for
this pooled estimate can be obtained from a formula suggested by Rubin (1987):
s( ˆ¯β) =
√√√√ 1
M
M∑
k=1
s2k +
(
1 +
1
M
)(
1
M − 1
) M∑
k=1
(βˆk − ˆ¯β)2, (3.6)
where k = 1, 2, ...,M is the kth imputation, βˆk is the estimate from the k
th imputed
data set, and ˆ¯β is the pooled estimate out of the M imputations.
In the past, there have been some discussions about the number of imputations to
use, M . For quite a while, a common recommendation was to use low numbers, such
as M = 5 or M = 10 imputations (Van Buuren 2012). In 2008, Bodner recommen-
ded to use approximately the percentage of missing data as number of imputations.
This rule of thumb was later also recommended by White et al. (2011). Regarding
subsequent analysis with a Cox PH model, White and Royston (2009) recommend
using the Nelson-Aalen estimate of the cumulative hazard function as predictor in the
imputation model rather than simply using time. Furthermore, White et al. (2011)
caution their readers that although multiple imputation gives asymptotically unbiased
estimates under MCAR/MAR and a correctly speciﬁed model, departures from the
MAR assumption and model misspeciﬁcation may lead to substantial bias.
3.4.5.2 Multiple imputation with interactions
As mentioned in the previous section, the unbiasedness of estimates obtained from
multiple imputation depends on the regression model containing all the factors inﬂu-
encing the missingness. White et al. (2011) recommend that the imputation model
should include all variables that will later be used in the analysis model, as well as the
outcome variable, to avoid bias. Additionally, they state that caution is required when
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it is intended to include non-linear or interaction terms in the analysis model. Their
advice is to include these terms in the imputation model in the correct functional form.
There are several suggestions for imputation with non-linear terms or interaction terms.
Seaman et al. (2012) compared diﬀerent approaches in several simulation studies:
passive imputation (PI), predictive mean matching (PMM), and `just another variable'
(JAV). PI only imputes the main eﬀects and then uses these imputed values to calculate
the interaction term. PMM on the other hand calculates a predicted value and then
draws from a set of actually observed values which are close to the prediction. PMM
may be problematic in small sample size cases, because of the limited number of
observed values to sample from (White et al. 2011). For JAV the interaction term is
treated as `just another variable' in the imputation model, ignoring its relationship to
the main eﬀects. Another option, which is referred to as a `simple congenial approach'
by White et al. (2011), can be used if one of the variables in the interaction term is
categorical and completely observed. In that case, it is also possible to split the data
into several data sets, one for each level of the categorical variable, and recombine the
data after imputation. This method is also referred to as stratify-approach.
Each of these methods has its advantages and disadvantages, which have been in-
vestigated and discussed by several authors, such as Von Hippel (2009), White et al.
(2011), and Seaman et al. (2012). Von Hippel (2009) applied several methods to a
real data example and found that, while PI may yield plausible data but biased esti-
mates, JAV may yield implausible data but unbiased estimates. The biased estimates
resulting from the PI approach can be caused by using a linear model for the imputa-
tion, which is not suitable for non-linear terms. Hence the estimate for the non-linear
term would be biased towards zero (White et al. 2011). Seaman et al. (2012) per-
formed a series of simulation studies and concluded that JAV is the best of a set of
imperfect methods (Seaman et al. 2012) when it is applied for linear regression with
quadratic or interaction terms, but they do not recommend it for logistic regression
and caution that JAV may yield biased estimates under MAR. White et al. (2011)
point out that the proof of unbiasedness of JAV relies on the MCAR assumption and
refer to a simulation study that shows bias for JAV under an extreme MAR mechanism.
They also conclude from their simulation studies that it is diﬃcult to recommend one
single method, since all methods have their pitfalls. Note that simulation studies in
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this section use linear or logistic regression as analysis model. They do not investigate
the behavior when the analysis model is a Cox PH model.
3.4.6 Simulation study: Missing biomarker status
A simulation study was conducted to compare the performance of the diﬀerent appro-
aches for handling missing data imputation with respect to bias and standard deviation
of the diﬀerent parameter estimates resulting from the combined model (Model 3 from
Section 3.4.3). Data was generated according to Section 3.4.4.1, except that the ha-
zard ratios for B1 and B2, exp(β1) and exp(β2), were ﬁxed at 0.7 to ensure suﬃcient
numbers of events in both groups to minimize bias due to small numbers of events.
Missing data was either generated as MCAR or MAR and missing data proportions of
0.1, 0.2, ..., 0.8 were considered. MCAR data can be generated rather straight forward
by using random sampling to delete a given proportion of data points. Generating MAR
data is a bit more complex. One or more variables should be determined on which the
missingness depends. For this simulation study, the entry time of a patient was chosen.
Then MAR data can be generated according to Section 2.2.2. For the data imputation
the R functions mice and with from the package mice were used. Time as a predictor
was replaced by the Nelson-Aalen estimator (Aalen 1978) as suggested by White and
Royston (2009).
The bias of the estimates of β1, β2, and β1,2 when using PI, the JAV-approach or the
stratify-approach was compared to the bias resulting from CC analysis and from the
analysis of the full data set. Three imputation methods to predict the missing values
were used and compared for the three imputation approaches: logistic regression (LR),
polytomous logistic regression (PLR), and predictive mean matching (PMM). Unless
otherwise indicated, missing data are MCAR. The bias of the estimates of γ1 and γ2 is
not shown in the following ﬁgures. Since they are linear terms, there was no notable
bias for any of the approaches.
Note that strictly speaking, x1, x2 and x1,2 in Model 3 (see Section 3.4.3) are all
interaction terms. They are created by multiplying biomarker status and treatment
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variable. If biomarker status and treatment are coded as dummy variables, x1 is
obtained by multiplying dummy variables for B1 and Exp1, x2 is obtained by multiplying
B2 and Exp2, and ﬁnally x1,2 is obtained by multiplying B2 and Exp1. Usually, all main
eﬀects that are part of the interaction are also included in the model. Note that this
would not be meaningful in this situation, since there is no general treatment eﬀect
that can be estimated. Hence, this may be somewhat of an unconventional model
speciﬁcation, which requires additional care when specifying the imputation and the
analysis method.
For the ﬁrst simulation PI was used, i.e. interactions were not included in the imputa-
tion model. In this case, the interactions are created by multiplication of the imputed
main eﬀects (as described in Section 3.4.5.2). The results in the ﬁrst row of Figure
3.36 show that the bias of the estimate of β1,2 linearly increases in absolute terms
for all three imputation methods as the proportion of missing data increases. While
there is some bias for the estimate of β1 when using PMM, which linearly increases
for increasing proportions of missing data (see middle plot of Figure 3.36c), there is
substantial bias for both, LR and PLR (middle plots of Figures 3.36a and 3.36b). This
is similar for the estimate of β2. While there is no visible bias for βˆ2 when using PMM,
there is a constant, substantial bias for all proportions of missing data when using LR
or PLR.
Subsequently, two imputation approaches for handling interactions terms were imple-
mented and tested: the stratify-approach and the JAV-approach. When the stratify-
approach is used, the bias of βˆ1,2 is drastically reduced for all three methods. While
there is only a small amount of bias for larger proportions of missing data when using
LR and PLR, there is some bias for PMM which increases in absolute terms with in-
creasing proportions of missing data (see ﬁrst row of Figure 3.37). Note the diﬀerent
scaling of the y-axis for βˆ1,2 compared to Figure 3.36. However, while PMM yields
approximately unbiased estimates for β1 and β2, there is still a substantial bias for the
estimates of β1 and β2 when using LR or PLR, and the bias is more or less constant
over all proportions of missing data (see second and third row of Figures 3.37a and
3.37b).
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(a) Logistic regression
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Figure 3.36: Bias for imputation methods logistic regression, polytomous logistic
regression, and predictive mean matching for βˆ1,2, βˆ1, and βˆ2 when imputation model
does not include interactions (naive imputation). B1 is the prioritized biomarker in
the allocation algorithm, data is MCAR, and m=10 imputations.
Using the JAV-approach results in considerable improvements for all three methods
and all estimates compared to PI. There is now only a small bias left for βˆ1,2 and βˆ2
when using LR for larger proportions of missing data (see Figure 3.38). There is hardly
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any visible bias for βˆ1 for either method. PLR appears to perform slightly better than
regular LR for larger proportions of missing data. For PMM, there is no notable bias
for any of the three estimates. Note the diﬀerent scaling of the y-axes for βˆ1 and βˆ2
compared to the previous two ﬁgures.
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(b) Polytomous logistic regression
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Figure 3.37: Stratify: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 when data
is stratiﬁed by treatment before imputation. B1 is the prioritized biomarker in the
allocation algorithm, data is MCAR, and m=10 imputations.
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Regarding standard deviation, a small improvement can bee seen for βˆ1 for all three
methods compared to CC analysis (see Figure 3.39). For βˆ1,2 and βˆ2, only minor
diﬀerences can be seen between imputation and CC analysis, and it varies which of the
two yields a slightly smaller standard deviation.
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.38: JAV: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 treating inte-
ractions as JAV in imputation model. B1 is the prioritized biomarker in the allocation
algorithm, data is MCAR, and m=10 imputations.
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Up to this point, only 10 imputations were used for the simulations. For Figure 3.40,
the recommendation of Bodner (2008) and White et al. (2011) was followed to use
the percentage of missing data as number of imputations. However, this only results
in minor visible improvements compared to Figure 3.38.
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.39: JAV: Standard deviation for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2
treating interactions as JAV in imputation model. B1 is the prioritized biomarker in
the allocation algorithm, data is MCAR, and m=10 imputations.
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(a) Logistic regression
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.40: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 treating interactions
as JAV in imputation model when the number of imputations equal to percentage
of missing data. B1 is the prioritized biomarker in the allocation algorithm and data
is MCAR.
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.41: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 treating interactions
as JAV in imputation model when data is MAR. B1 is the prioritized biomarker in
the allocation algorithm and m=10 imputations.
Additional to data that is MCAR, a case with data that is MAR was considered, where
the missingness of B2 depends on entry time such that the probability of missingness
is higher, the earlier a patient entered the study (cf. Section 3.4.6). Again, not much
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of a diﬀerence can be observed between the results for data that is MAR (Figure 3.41)
and for data that is MCAR (Figure 3.40). Note that this may be diﬀerent for other or
more extreme scenarios of data that is MAR.
3.4.6.1 Sensitivity analysis
Additional to the scenario with data that is MAR, it was also investigated whether
the results are sensitive to a change of parameters, focusing on the newly introduced
parameters in Section 3.4.3: The time at which G2 is added, tb, the priority of the
biomarkers, and the factor by which the hazard ratio for B2-patients treated with Exp1
diﬀers from the hazard ratio for B1-patients treated with Exp1, i.e. the eﬀect τ , and
the priority of the biomarkers, i.e. to which biomarker-group patients are assigned to
if they have both biomarkers.
For a scenario with tb = 6 months, Figure 3.42 shows that for all imputation methods
the bias of the estimates is reduced compared to Figure 3.38, for which tb = 12
months. This could be expected, since altering tb has an eﬀect on the group sizes.
Choosing tb to be smaller means that G2 is added earlier and there is more time to
accrue patients to this group. Simultaneously, the number of patients in G1 which
were accrued before tb gets smaller, causing the number of patients with potentially
missing biomarker status for B2 to be smaller. Hence, with more complete cases in the
study data, the bias of the eﬀect estimates obtained from the data imputation would
be expected to be smaller.
For a scenario where B2 is chosen as priority rather than B1, Figure 3.43 shows that
there is a larger bias for βˆ1,2 and βˆ1 for all methods compared to Figure 3.38. Again,
this could be expected, since giving priority to B2 would lead to a smaller number of
patients in G1 and especially to a smaller number of patients with both biomarkers in
G1, since patients with both biomarkers are allocated to G2 after tb.
Finally, when the eﬀect τ is set to 2 instead of 1.5, there are barely any noticeable
diﬀerences compared to Figure 3.38. For τ = 0.75, the bias of βˆ2 again shows no
visible diﬀerences. The bias of βˆ1,2 and βˆ1 behaves mostly similar for PLR and PMM
and is reduced for LR for larger proportions of missing data. The results are shown in
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Figures A.5 and A.6 in the Appendix.
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.42: tb=6: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 treating
interactions as JAV in imputation model when G2 is added to the study after 6
months. B1 is the prioritized biomarker in the allocation algorithm, data is MCAR,
and m=10 imputations.
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure 3.43: Priority=B2, JAV: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2
treating interactions as JAV in imputation model. B2 is the prioritized biomarker in
the allocation algorithm, data is MCAR, and m=10 imputations.
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3.5 Choice of strategy for subgroup analyses
When analyzing survival data, there is often more than one hypothesis that is of
interest. During the planning stage of a clinical trial, it is important to formulate all
relevant hypotheses. Subsequently, it should be determined which one is the primary
hypothesis and which hypotheses are secondary. For multiple biomarker trials, there
are many potential hypotheses that could be investigated. In the following, the focus
will be on hypotheses regarding eﬀectiveness of treatment. Besides testing within each
biomarker-group individually, an overall biomarker-guided treatment strategy could be
evaluated, as previously discussed for the stratiﬁed randomize-all design in Section
3.2. Alternatively, a group of subgroups could be tested (e.g. all biomarker-positive
patients), which could for example be used if not all biomarker-groups are randomized,
as discussed for the multiple-biomarker hybrid design in Section 3.3. If it is preferred to
test the biomarker-groups individually, but small sample sizes are expected, a hypothesis
could be chosen which tests if a treatment beneﬁt can be detected in at least one of the
biomarker-groups. For designs like the stratiﬁed randomize-all design (see Figure 3.1,
Design 3) or the multiple-biomarker hybrid design (see Figure 3.1, Design 4) and for a
case with two biomarker-positive groups and one biomarker-negative group, hypotheses
of interest could be, but are not limited to:
• H1: Overall strategy: Experimental therapy vs. standard,
i.e. β = 0 vs. β 6= 0
• H2 - H4: Individual hypotheses:
H2: Experimental therapy vs. standard within biomarker-group 1,
i.e. β1 = 0 vs. β1 6= 0
H3: Experimental therapy vs. standard within biomarker-group 2,
i.e. β2 = 0 vs. β2 6= 0
H4 (if applicable): Experimental therapy vs. standard within biomarker-
negative group, i.e. β0 = 0 vs. β0 6= 0
• H5: Group of subgroups: E.g. experimental therapy vs. standard for biomarker-
positive groups only, i.e. β+ = 0 vs. β+ 6= 0
• H6: At least one: H2 or H3 or H4
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where β is the overall treatment eﬀect, βi is the treatment eﬀect for biomarker-group
i, and β+ is the overall treatment eﬀect for the biomarker-positive groups.
As main focus or primary hypothesis, one could either choose proof of con-
cept/treatment strategy (H1), or the individual biomarkers (H2 -H6). Decision criteria
to choose a primary hypothesis could be the prevalence of the biomarkers, or the ex-
tent of similarities between the biomarkers. To maintain an overall α-level, one option
to test these hypotheses is a multiple comparison procedure that adjusts for multi-
ple testing. If the sample size calculation is only based on the primary hypothesis
H1, the other hypotheses may be under-powered, especially those hypotheses which
only include a fraction of the patients included in the study. In this case, a classical
method like Bonferroni, where each of m hypotheses is tested at α/m level, would
be very restrictive. Instead, a procedure which allows reallocation of the unspent α
could be considered. A potential approach is a so-called chain procedure (Millen and
Dmitrienko 2012). Chain procedures are a class of closed testing procedures, which are
based on the closure principle, meaning that a hypothesis is only rejected if and only
if all intersection hypotheses that contain this hypothesis can be rejected. The advan-
H1
w1
H2
w2
H3
w3
H4
w4
g1,3 g1,4
g1,2
g2,3
g3,2
g3,4
g4,3
g2,4
g4,2
1
Figure 3.44: Cyclical chain procedure for testing four hypotheses incorporating logical
relationships for an example where H1 is the main hypothesis of interest. If w1 = 1
is chosen, H2-H4 are only tested if H1 is rejected. If w1 < 1 is chosen, then H2-
H4 can still be tested at the remaining α. (Adapted from Millen and Dmitrienko
(2012)).
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tage of a closed testing procedure is that, after a hypothesis is rejected, the unspent
α can be carried over to the remaining hypotheses. For a chain procedure, initially
all hypotheses are assigned weights wc, such that in the beginning, hypothesis Hc is
allocated a fraction of the overall α, αc = wcα. Additionally, transition parameters
gc,d are determined which, after testing Hc, are used to reallocate the unspent αc from
hypothesis c to hypothesis d, i.e. αd is updated such that αdnew = αd + gc,dαc.
Millen and Dmitrienko (2012) describe diﬀerent kinds of chain procedures. One type
are serial chain procedures, which test a family of ordered hypotheses, i.e. the order in
which the hypotheses are tested is prespeciﬁed. Unlike serial chain procedures, cyclical
chain procedures do not assume an ordering of the hypotheses; the hypothesis tested
ﬁrst is the one with the most signiﬁcant weighted p-value. If desired, a serial and a
cyclical chain procedure can be combined to incorporate a logical relationship, e.g. to
test the primary hypothesis ﬁrst (see Fig. 3.44). If the weight of the primary hypothesis
is chosen to be one, i.e. if the secondary hypotheses are only tested if the primary
hypothesis can be rejected, this combination of cyclical and serial chain procedure can
also be classiﬁed as a type of gatekeeping procedure. Here, the primary hypothesis
would be the `gatekeeper', which needs to be rejected in order to test the remaining
hypotheses.
The following sections will suggest several testing strategies for testing multiple hypot-
heses. These strategies are based on the approaches of Millen and Dmitrienko (2012)
and Bretz et al. (2009, 2011) for multiple comparison and closed testing procedures.
Note that the hypothesis weights and α transition weights in the following sections
were chosen to be equal among hypotheses of the same hierarchy (e.g. among all
secondary hypotheses). These weights can be adjusted as needed. The ﬁgures shown
for the diﬀerent strategies were created using the gMCP package for R (Rohmeyer and
Klinglmueller 2015), which was developed based on Bretz et al. (2011).
3.5.1 Options for main focus Proof of concept
If proof of concept or proof of treatment strategy is the main point of interest, H1
could be chosen to be the primary hypothesis. A few of the many possible testing
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strategies are brieﬂy presented in this section. A conservative approach would be the
Bonferroni method, where α is split equally between the secondary hypotheses. Taking
advantage of the closure principle, the unspent α can be reallocated to the secondary
hypotheses if the primary hypothesis is rejected. The ﬁrst option that is suggested
below is a combination of serial and cyclical chain procedure. It is a sensible strategy
if all secondary hypotheses are of similar interest and importance to the investigators.
If, on the other hand, the investigators would prefer the secondary hypotheses to be
tested in a speciﬁc order, a serial chain procedure could be used, where the hypotheses
are tested in a prespeciﬁed order and the unspent α is split between the remaining
hypotheses. The way both these options are shown in Figures 3.45 and 3.46, with
w1 = 1, these testing strategies can also be categorized as two-stage gatekeeping
procedures, as mentioned in the previous section. If, additionally, the hypotheses can
be classiﬁed as secondary, tertiary, and quaternary, a multi-stage serial gatekeeping
procedure can be considered instead, where the unspent α from a hypothesis is only
reallocated to the hypothesis that is next in line in the prespeciﬁed order.
Option 1: Mixed chain procedure
Step 1: Test H1 (overall strategy) at level α.
H1
1
H3
0
H4
0
H2
0
1
3
1
3
1
3
1
2
1
2
1
2
1
2
1
2
1
2
1Figure 3.45: Mixed chain procedure for multiple testing when the main hypothesis
is the overall treatment strategy.
Step 2: If H1 is rejected, pass α on to H2 - H4 using the prespeciﬁed transition
3.5. CHOICE OF STRATEGY FOR SUBGROUP ANALYSES 103
parameters. In case of a rejection of Hc (where c = 2, 3, 4), αc can be
split equally between the remaining hypotheses to be tested (see Figure
3.45).
If H1 cannot be rejected, subgroup analyses could be performed on an exploratory
basis.
Option 2: Serial chain procedure
Step 1: Deﬁne order for H2 - H4 (individual biomarkers), e.g. based on prevalence
or expected outcome. Let H∗2 , H
∗
3 , H
∗
4 denote H2 - H4 ordered by this
hierarchy.
Step 2: Test H1 (overall strategy) at level α.
Step 3: If H1 is rejected, pass α on to H
∗
2 - H
∗
4 (individual biomarkers). In case
of a rejection of H∗c (where c = 2, 3, 4), αc can be split equally between
the remaining hypotheses to be tested (see Figure 3.46).
If a hypothesis in the sequence cannot be rejected, the remaining subgroup analyses
could be performed on an exploratory basis.
Figure 3.46: Serial chain procedure for multiple testing when the main hypothesis is
the overall treatment strategy.
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Option 3: Multi-stage serial gatekeeping procedure
Step 1: Deﬁne order for H2 - H4 (individual biomarkers), e.g. based on prevalence
or expected outcome. Let H∗2 , H
∗
3 , H
∗
4 denote H2 - H4 ordered by this
hierarchy.
Step 2: Test H1 (overall strategy) at level α.
Step 3: If H1 is rejected, pass α on to H
∗
2 (highest ranked individual biomarker,
according to prespeciﬁed order).
Step 4: Test H∗2 at level α. If H
∗
2 cannot be rejected, stop. If H
∗
2 is rejected, pass
α on to next hypothesis in the sequence. Proceed the same way for H∗3
and H∗4 .
If a hypothesis in the sequence cannot be rejected, the remaining subgroup analyses
could be performed on an exploratory basis.
H1
1
H∗2
0
H∗3
0
H∗4
0
1 1 1
1
Figure 3.47: Multi-stage serial gatekeeping procedure for multiple testing when the
main hypothesis is the overall treatment strategy.
If the individual biomarker-groups are expected to be small and testing the individual
hypotheses seems unpromising, either H5 (group of subgroups) or H6 (at-least-one)
could be tested instead.
Option 4: Group of subgroups
Step 1: Test H1 (overall strategy) at level α.
Step 2: If H1 is rejected, pass α on to H5 (group of subgroups). If H1 cannot be
rejected, subgroup analyses could be performed on an exploratory basis.
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H1
1
H5
0
1
1
Figure 3.48: Testing strategy with hypothesis for group of subgroups instead of
separate hypotheses for individual biomarkers.
Option 5: At least one
Step 1: Test H1 (overall strategy) at level α.
Step 2: If H1 is rejected, pass α on to H6 (at least one). If H1 cannot be rejected,
subgroup analyses could be performed on an exploratory basis.
H1
1
H6
0
1
1
Figure 3.49: Testing strategy with at-least-one hypothesis instead of separate
hypotheses for individual biomarkers.
Option Overview
Table 3.9: Overview of testing strategies, when the main focus of the analysis is a
proof of concept.
Focus: Overall treatment strategy
Strategy Mixed chain
procedure
Serial chain
procedure
Serial
gatekeeping
Group of
subgroups
At least
one
Step 1 Test H1 at level α
Step 2 Split remaining
α equally
among H2 - H4
Deﬁne order for H2
- H4 and split
remaining α equally
among remaining
hypotheses
Deﬁne order for
H2 - H4 and
pass remaining α
down sequentially
Test H5 at
remaining α
Test H6 at
remaining α
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3.5.2 Options for main focus Individual biomarkers
If investigators believe that they will have suﬃciently large biomarker-groups, but would
also like to evaluate the overall treatment strategy, they could choose the individual
biomarkers (H2 - H4) as main hypotheses and the treatment strategy as secondary
hypothesis. Similar to the previous section, a mixed chain procedure could be applied
where the primary hypotheses are tested ﬁrst and the unspent α is split between
the remaining hypotheses to be tested. Or, if the hypotheses are to be tested in a
prespeciﬁed order, a serial chain procedure or a multi-stage serial gatekeeping procedure
could be chosen instead. Again, if w1 = 1, as shown in Figures 3.50 and 3.51, both
chain procedures can also be categorized as two-stage gatekeeping procedures. Finally,
instead of testing H2 - H4, H5 or H6 could be chosen as primary hypotheses.
If some of the hypotheses cannot be tested, remaining analyses of interest could be
performed on an exploratory basis.
Option 1: Mixed chain procedure
Step 1: Test H2 - H4 (individual biomarkers). In case of a rejection of Hc (where
c = 2, 3, 4), its proportion of α can be split equally between the remaining
hypotheses to be tested (including H1; see Fig. 3.45).
H2
1
3
H3
1
3
H4
1
3
H1
0
1
3
1
3
1
3
1
3
1
3
1
3
1
3
1
3
1
3
1Figure 3.50: Mixed chain procedure for multiple testing when the main hypothesis
are the individual biomarkers.
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Step 2: Test H1 (overall strategy) at the level resulting from Step 1, i.e. if one
hypothesis was rejected, test at 1
9
α, if two were rejected, test at 1
3
α, and
if all preceding hypotheses were rejected, test at full α.
Option 2: Serial chain procedure
Step 1: Deﬁne order for H2 - H4 (individual biomarkers), e.g. based on prevalence
or expected outcome. Let H∗2 , H
∗
3 , H
∗
4 denote H2 - H4 ordered by this
hierarchy.
Step 2: Test H∗2 at level α. If H
∗
2 cannot be rejected, stop. If H
∗
2 is rejected, pass
α on to next hypothesis in the sequence. Proceed the same way for H∗3
and H∗4 .
Step 3: Test H1 (overall strategy) at the level resulting from Step 1, i.e. if one
hypothesis was rejected, test at 1
9
α, if two were rejected, test at 1
3
α, and
if all preceding hypotheses were rejected, test at full α.
Figure 3.51: Serial chain procedure for multiple testing when the main hypothesis
are the individual biomarkers.
108 CHAPTER 3. RESULTS
Option 3: Multi-stage serial gatekeeping procedure
Step 1: Deﬁne order for H2 - H4 (individual biomarkers), e.g. based on prevalence
or expected outcome. Let H∗2 , H
∗
3 , H
∗
4 denote H2 - H4 ordered by this
hierarchy.
Step 2: Test H∗2 at level α. If H
∗
2 cannot be rejected, stop. If H
∗
2 is rejected, pass
α on to next hypothesis in the sequence. Proceed the same way for H∗3
and H∗4 .
Step 3: If H∗2 , H
∗
3 , H
∗
4 were all rejected, test H1 (overall strategy) at level α.
H∗2
1
H∗3
0
H∗4
0
H1
0
1 1 1
1
Figure 3.52: Multi-stage serial gatekeeping procedure for multiple testing when the
main hypothesis are the individual biomarkers.
Option 4: Group of subgroups
Step 1: Test H5 (group of subgroups) at level α.
Step 2: If H5 is rejected, pass α on to H1 (overall strategy).
H5
1
H1
0
1
1
Figure 3.53: Testing strategy with hypothesis for group of subgroups instead of
separate hypotheses for individual biomarkers when the main hypothesis are the
individual biomarkers.
Option 5: At least one
Step 1: Test H6 (at least one) at level α.
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Step 2: If H6 is rejected, pass α on to H1 (overall strategy) .
H6
1
H1
0
1
1
Figure 3.54: Testing strategy with at-least-one hypothesis instead of separate
hypotheses for individual biomarkers when the main hypothesis are the individual
biomarkers.
Option Overview
Table 3.10: Overview of testing strategies when the main focus of the analysis is on
the individual biomarkers.
Focus: Individual biomarkers
Strategy Mixed chain
procedure
Serial chain
procedure
Multi-stage serial
gatekeeping
Group of
subgroup
At least
one
Step 1 Test
H2 - H4
Test H2 - H4 se-
quentially, split α
equally among re-
maining hypotheses
Test H2 - H4 se-
quentially, allocate
unspent α to next
hypothesis
Test H5 at
level α
Test H6 at
level α
Step 2 Test H1 at
remaining α
Test H1 at
remaining α
Test H1 at
remaining α
Test H1 at
remaining α
(H2 - H4 ex-
ploratory?)
Test H1 at
remaining α
(H2 - H4 ex-
ploratory?)
The are many strategies to choose from for testing multiple hypotheses. The options
suggested here are just a selection and were chosen in consideration of the study
designs discussed in this thesis. The strategies in Section 3.5.1 can be utilized for the
stratiﬁed randomize-all design as discussed in Section 3.2, while Section 3.5.2 could
be useful for the multi-biomarker hybrid design as discussed in Section 3.3. Especially
for designs that evaluate an overall treatment strategy, secondary hypotheses that test
the individual biomarkers should be included, to avoid false conclusions. For further
reading on multiple comparison procedures refer to e.g. Dmitrienko et al. (2009).
Chapter 4
Discussion
Planning and analyzing a multiple biomarker trial is a challenging task comprising
various factors which have to be considered. It is an area of ongoing research and only
a limited number of multiple biomarker trials have already been completed and their
results published. Learning from these completed trials is an important part of the
planning process, which can help to avoid issues and pitfalls that these trials may have
encountered. Some of the issues which were reported by completed trials, such as low
prevalence of the biomarkers and not being able to react to the latest developments
regarding biomarkers and treatments, have been addressed in this thesis. Sample
size calculation and data analysis methods for testing an overall treatment strategy
were investigated for situations where biomarker prevalences make it unfeasible to test
within the individual biomarker-groups. The results will be discussed in Section 4.1.
Additionally, the issue of a large number of biomarker-negative patients was addressed,
which is a side eﬀect in trials that investigate lower prevalence biomarkers. Diﬀerent
analysis approaches for a trial that includes biomarker-negative patients were compared
and it was examined whether inclusion of biomarker-negative patients in the analysis
can improve bias and standard deviation of the treatment eﬀect estimates. Section 4.2
will discuss the results in more detail. Finally, a ﬂexible study design was considered
that allows a new biomarker-group with corresponding experimental treatment to be
added to the study after accrual has already begun. Diﬀerent aspects of study design
modiﬁcation were discussed and diﬀerent models for analysis of such a study were
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compared. Furthermore, the issue of missing biomarker data was addressed. If the
initial biomarker screening did not include the new biomarker before it was added
to the study, the biomarker status regarding this biomarker has to be determined
retrospectively for patients that were included in the study before adding the new
biomarker. This may lead to missing biomarker data for some or all of the patients.
For cases where data is only partially missing, diﬀerent methods for missing data
imputation for models with interaction terms were investigated and compared. The
results for the diﬀerent analysis models and the missing data will be discussed in Section
4.3.
4.1 Sample size calculation and evaluation of
overall treatment strategy
Section 4.1 is largely part of a paper that has already been published. The relevant
passages have been taken verbatim from Beisel et al. (2017).
With regard to sample size calculation, the Schoenfeld method is acceptable to use
in situations with only minor heterogeneity of treatment eﬀects. But for more hete-
rogeneous cases, which was the focus of Section 3.2, the formula by Palta and Amini
provides the most adequate sample size, in the sense that it delivers the level of po-
wer which was aimed for at the planning stage. This is true not just for the case of
equal hazard ratios, but also for minorly to moderately heterogeneous hazard ratios.
If the hazard ratios are extremely heterogeneous, the adherence to the level of power
depends on the analysis method used. It seems that in this case, the formula by Palta
and Amini cannot compensate for the loss of power of the stratiﬁed Cox PH model in
spite of taking into consideration the heterogeneous hazard ratios.
However, comparing the asymptotic and the exact log-rank test for these particular
scenarios, and taking into consideration the calculated sample sizes, an obvious que-
stion is whether the reason for the poorer performance of the log-rank test and the
stratiﬁed Cox PH model is that the assumptions regarding asymptotic properties are
not met. For the most extreme scenarios, the calculated sample size is below 300,
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which, with prevalences of 0.5, 0.25, and 0.25 for G0, G1, and G2 respectively, results
in stratum sizes of less than 75 patients for G1 and G2. Hence, asymptotic assumpti-
ons are problematic in these cases. A simulation study with equal hazard ratios across
strata but smaller sample sizes in Section 3.2.3.4 showed that there is indeed some loss
of power, but for an overall sample size of 115 patients (which is very close to the 113
patients in the most extreme case considered), the loss of power is minor (see Table
3.4). For control of the type-I-error rate, the exact log-rank test should be considered
instead if the strata sizes are expected to be small, i.e. in the double digits, and there
is too little data available for reliable approximations. The shared frailty model also
appears to be an appropriate choice and additionally oﬀers the possibility to include
covariates in the model, which is an advantage over the exact log-rank test.
Note that the shared frailty model performs superior to the stratiﬁed Cox PH model
for strata with diﬀerent treatment eﬀects, even if there is no stratum-speciﬁc random
eﬀect present in the data, which is assumed by the shared frailty model. So, even
though it is meant to model heterogeneity in baseline hazards, not hazard ratios, it
may be that it can handle heterogeneity better in general. Note that if one tries to
estimate a stratum eﬀect that is not there, the less degrees of freedom are spent on
this attempt, the better. Hence the shared frailty model would perform better in this
case than the stratiﬁed model (with the simple non-stratiﬁed model being the best).
Additionally, since the shared frailty model assumes a certain functional shape causing
heterogeneity in treatment eﬀects between strata, it is likely to perform better in terms
of power than a method making lesser assumptions, like the stratiﬁed Cox PH model,
which allows more general forms of baseline hazards than the constant baseline hazards
that are considered here.
Another observation worth mentioning is that the formula by Palta and Amini provides
a reasonable sample size for the lognormal shared frailty model in the case of minor
random eﬀects. For stronger random eﬀects, the shared frailty model does suﬀer some
loss of power, but less than the other methods (see Figures in Section 3.2.3.4). In
those cases, it may be that the shared frailty model is not able to compensate for both,
heterogeneity of baseline hazards and heterogeneity of treatment eﬀects. If a strong
random eﬀect is expected, an empirical calculation of the required sample size should
be considered instead (see Section 3.2.2).
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With regard to the diﬀerent analysis methods compared, the exact log-rank test,
Mehrotra's two-step approach, and the shared frailty model yield at least the level
of power which was aimed for, regardless of the heterogeneity of the treatment eﬀects.
The exact log-rank test is only of use if one is not interested in including additional
covariates in the model. The two-step approach, as well as the shared frailty model,
does facilitate this option.
Note that using an overall analysis method as suggested should be understood as
assessing the beneﬁt of a certain treatment strategy for the overall population and
should be performed in conjecture with subsequent subgroup analyses to conﬁrm the
ﬁndings and to avoid false conclusions about treatments and subpopulations.
In consideration of the results in Section 3.2, the asymptotic log-rank test and the
stratiﬁed Cox PH model should not be used in case of small sample sizes and hetero-
geneous treatment eﬀects. In this case, the exact log-rank test, Mehrotra's two-step
approach, or the shared frailty model appear to be suitable alternatives. For all models,
these results should be used with caution if one wishes to model a greater magnitude of
stratiﬁcation or include a strong random eﬀect in addition to heterogeneous treatment
eﬀects. With respect to sample size calculation for a situation with stratiﬁcation and
heterogeneous treatment eﬀects, it is suggested to use the not widely recognized ex-
tension of Schoenfeld's formula by Palta and Amini rather than the formula by Lachin
and Foulkes.
4.2 Inclusion of biomarker-negative patients and
small sample size bias
Section 4.2 is largely part of a paper that has already been published. The relevant
passages have been taken verbatim from Habermehl et al. (2017).
While there already exists some literature on biomarker designs, the inclusion of
biomarker-negative patients is rarely addressed. Therefore, the focus of Section 3.3 was
a study design including biomarker-negative patients and possible analysis approaches
for the resulting data.
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If it is contemplated to include biomarker-negative patients in a trial, the pros and cons
should be carefully considered. The added expense of inclusion of biomarker-negative
patients should be weighed against potential gains in eﬃciency for treatment eﬀect
estimation. If it is possible, it might be a better option to recruit a larger number
of biomarker-positive patients instead of spending resources on following biomarker-
negative patients. If there is strong interest in gaining information about prognostic
eﬀects, then it would be necessary to study biomarker-positive and -negative patients
under standard therapy. But, depending on availability, this might also be done retro-
spectively by subdividing a patient cohort from an already existing study using stored
specimens. For each trial it should be considered individually which goals are most
important and then resources can be allocated accordingly.
For the situation when biomarker-negative patients are to be included in the study,
the results of the simulation study in Section 3.3 show that for smaller sample sizes,
and especially for biomarkers indicative of a poor prognosis, using a combined model
and including the biomarker-negative patients in the analysis can reduce bias and
standard deviation of the estimates of the regression coeﬃcients compared to excluding
biomarker-negative patients from the analysis and to performing separate analyses for
the biomarkers, assuming proportional hazards. For larger sample sizes (n = 1, 000)
no noticeable reduction in bias and standard deviation can be observed. This leads to
the conclusion that the observed beneﬁt with respect to bias reduction could be due
to the reduction of the small sample size bias of the Cox PH model. The diﬀerent
results for biomarkers with diﬀerent prognoses are likely due to the smaller number
of events in the biomarker-group indicative of a favorable prognosis, which seems to
cause additional bias.
The increase of bias and standard deviation in absolute terms as the treatment eﬀect
gets larger shows that the bias not only depends on the sample size but also on the
number of events. Hence, other factors inﬂuencing the bias of the treatment eﬀect
estimates appear to be baseline hazard and hazard ratio, which agrees with the results
reported by Langner et al. (2003). The greatest beneﬁt with respect to reduction of
bias was observed for large treatment eﬀects and for the biomarker indicative of a poor
prognosis relative to the biomarker-negative population. These results indicate that,
for small sample situations such as low prevalence biomarkers, using a Cox PH model
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with the biomarker status as factor variable and one variable for each biomarker-speciﬁc
treatment can help reduce bias and standard deviation of the estimates. Additionally,
this modeling approach facilitates the opportunity to estimate the treatment eﬀects
and prognostic eﬀects for all biomarkers in one model.
The simulation study also demonstrates the beneﬁt of the Firth correction in small to
moderate sample size situations with respect to reduction of bias and also standard de-
viation, which increases as the treatment eﬀect for the biomarker-group increases. This
was observed for both biomarkers. The upwards bias that can be seen for βˆ1 for small
sample sizes when the Firth correction is used could be caused by the small number of
events, a behavior which Elgmati et al. (2015) described for logistic regression.
As with all simulation studies, there are some limitations because of model assumptions.
The model assumptions, such as constant baseline hazards and proportional hazards,
were fulﬁlled by the simulated data set but that is not necessarily the case for real
data sets. The simulation results in Section 3.3.2.3 suggest that, while using diﬀerent
biomarker prevalence and time-dependent baseline hazards did not have much of an
impact on bias and standard deviation, one needs to be careful in the case of very
small numbers of events. Furthermore, the assumption of proportional hazards is a
key assumption of the Cox PH model. Therefore, it should always be checked if this
assumption is reasonable before applying the model. For mid to late phase trials, it
can be assumed that there is some knowledge available prior to the study that can
give guidance on whether proportional hazards are a reasonable assumption. If non-
proportional hazards are expected, the model(s) suggested in Section 3.3 may not
be an appropriate choice. A simulation study on the extent of bias of the hazard
ratio caused by non-proportional hazards, as well as censoring rate, type of censoring,
and sample size can be found in Persson and Khamis (2005). Depending on the
individual situation, alternatives or extensions to the Cox PH model that can handle
non-proportional hazards should be considered. Some literature on Cox regression
under non-proportional hazards can, e.g. be found in Schemper (1992). Alternative
models to the Cox PH model are, e.g. additive hazards models or accelerated failure
time models, which are, in the context of causal inference, suggested by Aalen et al.
(2015).
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Overall, based on the results of the simulation study, it can be concluded that the small
sample size bias of the Cox PH model should not be neglected. Additionally, attention
should be paid to the expected number of events, which also appears to inﬂuence
the bias. In the analysis of a multiple-biomarker trial with low prevalence biomarkers
and hence small sample sizes, a bias correction should be applied, such as the well-
known Firth correction. Moreover, the results of the simulation study demonstrate
that for biomarkers indicative of a poor prognosis, the inclusion of biomarker-negative
patients in the analysis can help to further reduce bias of the eﬀect estimates and can
additionally lead to small improvements of the standard deviation of the estimates.
4.3 Adding a new biomarker-group: Interaction
eﬀects and missing data
When it is intended to add a new biomarker-group to an ongoing clinical trial, many
factors need to be considered. The study protocol should facilitate this option from
the beginning and explicitly state the conditions under which a new biomarker-group
can be added throughout the trial. This should include the time point up to which it is
possible to add the new biomarker-group to the study, as well as guidelines regarding
allocation to the biomarker-groups for new patients with both biomarkers after the new
group is added, e.g. by assigning priorities to the biomarkers. Additionally, it should
be discussed how to adjust the ﬁnal analysis for the belatedly added group and how to
address the potential overlap of biomarkers within the groups. While simply excluding
the patients with both biomarkers would be an acceptable option, with respect to bias of
the treatment eﬀect estimates, the overlap of the biomarkers and a potential interaction
between therapy and additional biomarker could be accounted for by including an
interaction term in the model. Both approaches can help avoiding biased treatment
eﬀect estimates but the interaction term oﬀers the additional beneﬁt of quantifying
the interaction eﬀect. Similar to Section 3.3, a combined model, which estimates the
treatment eﬀect estimates for both biomarkers and additionally the interaction term
could be applied.
If the biomarker status with respect to the newly added biomarker cannot be determined
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retrospectively for all patients which were included prior to adding the new biomarker-
group, multiple imputation can be utilized. However, data imputation for models
that include interaction terms can be diﬃcult and the simulation study in Section
3.4.6 shows that it is rather sensitive to model misspeciﬁcation, such as omission of
interaction terms from the imputation model.
When the interaction terms are imputed passively, i.e. calculated from the imputed
main eﬀects, the interaction terms are omitted from the imputation model. This results
in moderately to severely biased estimates for all considered imputation methods, which
were predictive mean matching, logistic regression, and polytomous logistic regression.
When the stratify-approach is used instead of PI, the bias of βˆ1,2 is reduced, but both
logistic regression methods still yield biased estimates for β1 and β2. This may be due
to the speciﬁc model considered here, which only contains one of the main eﬀects.
Since the two biomarker-groups receive a diﬀerent experimental treatment, a main
eﬀect for treatment would not be meaningful in this context. Another aspect making
this a special case is that one of the three data sets into which the data is split for the
stratify-approach (one for each treatment group) does not contain any missing data.
This is due to the fact that Exp2 is added to the study at the same time when G2 is
added. Starting at this point, B2 is determined for all patients upon entering the study,
so the biomarker status for B2 can only be missing for patients treated with Exp1 or
with standard of care who entered the study prior to adding G2. It is possible that these
circumstances lead to the biased estimates for the stratify-approach. Hence, while the
stratify-approach may work well in general, it does not seem to be an appropriate
choice for the situation considered here.
The JAV-approach on the other hand is able to eliminate most of the bias of βˆ1,2,
βˆ1 and βˆ2 for all three imputation methods, even for the MAR scenario considered
here. Thus, for this particular situation, the JAV-approach seems to be the most
appropriate choice. Using the percentage of missing data as number of imputations,
as suggested by Bodner (2008), only resulted in minimal improvements in bias. This
may not always be in proportion to the added computation time. PMM and PLR
perform quite well even for larger proportions of missing data. With regard to standard
deviation, PLR performs slightly better than PMM. The observed diﬀerences between
the two logistic regression based methods, LR and PLR, could be due to diﬀerences in
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implementation of these methods in the used R package mice. While the imputation
function for LR uses the function glm (generalized linear models) to ﬁt a regression
model, the function for PLR uses multinom (multinomial log-linear models). These
two functions use diﬀerent methods for model ﬁtting. While glm uses iteratively
reweighted least squares to ﬁt the model, multinom ﬁts a single-hidden-layer neural
network via the function nnet, which is a machine learning technique for generalization
of linear regression functions.
As usual, the conclusions drawn from the simulation study may not necessarily apply
to other situations and diﬀerent models. The results may also diﬀer for more complex
scenarios of data that is MAR or for violations of model assumptions. For the diﬀerent
parameter settings considered in the sensitivity analysis, no unexpected behavior could
be observed.
Overall, an overlap in patient population and interaction of biomarker and treatment
could be accounted for by including an interaction term in the model. Furthermore, if
the biomarker status regarding the new biomarker is missing for some of the patients,
using the interaction terms as variables in the imputation model appears to be the best
way to avoid biased estimates for the situation considered here. PI should not be used
for imputation of interaction terms. The simulation study suggests that, compared
to PI and the stratify-approach, using the JAV-approach together with PLR yields the
least biased estimates along with the smallest standard deviation.
4.4 Overall conclusion and outlook
This thesis aimed to address several issues which can arise when planning and analyzing
a multiple biomarker trial, leading to several main conclusions that can be drawn from
the results. The ﬁrst issue which was addressed in this thesis was low prevalence of the
biomarkers. It was aimed to investigate the evaluation of the biomarker-guided treat-
ment strategy for situations with lower prevalence biomarkers. For a study which tests
an overall biomarker-guided treatment strategy, the sample size calculation method
by Palta and Amini appears to be the most appropriate choice when heterogeneous
treatment eﬀects are expected. The results from the simulation study suggest that the
4.4. OVERALL CONCLUSION AND OUTLOOK 119
subsequent data analysis could be performed using the two-step approach suggested by
Mehrotra or a shared frailty model. If no other covariates are included in the model, an
exact log-rank test could also be used. The asymptotic log-rank test and the stratiﬁed
Cox PH model suﬀered loss of power in the simulation study and therefore should not
be used for heterogeneous treatment eﬀects. To test the individual biomarker-groups
as secondary hypotheses after testing the overall treatment strategy, some strategies
for multiple testing were suggested.
The second issue that was addressed was a large expected number of biomarker-
negative patients at the screening stage. It was aimed to investigate whether inclusion
of biomarker-negative patients in the trial and the analysis provides additional beneﬁt,
such as improvement of power or reduction of bias. For a situation where an overall
biomarker-guided treatment strategy is not desirable, a combined analysis model using
the data from the entire study, including biomarker-negative patients, was investigated.
This combined model estimates the treatment eﬀects for both individual biomarkers.
Application of the Firth correction appeared to be a good method for reduction of
small sample size bias, which is likely to occur for low prevalence biomarkers. The
inclusion of biomarker-negative patients in the model can provide a small additional
beneﬁt with respect to reduction of bias and standard deviation.
The third issue considered were the rapid developments in the ﬁeld of biomarker re-
search. It was aimed to be able to react to these continuous developments by in-
vestigating options to add new biomarkers and corresponding therapies to an ongoing
study. Diﬀerent models for data analysis were compared for a situation with a belatedly
added biomarker, an overlap of biomarkers within the population, and an eﬀect of the
new biomarker on the response to the experimental treatment of the already existing
biomarker-group. Adding an interaction term to the combined analysis model can help
avoiding biased treatment eﬀect estimates when there is overlap of the biomarkers
within the patient population, and when patients with both biomarkers respond diﬀe-
rently to the experimental therapy than patients with only one of the biomarkers. If
there is missing data regarding the biomarker status of the belatedly added biomarker,
data imputation can be utilized. However, the correct model speciﬁcation is crucial
to avoid biased estimates when interaction terms are part of the model for the ﬁnal
analysis. These interaction terms should already be included in the imputation mo-
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del rather than imputing them passively. The simulation study suggests that for the
considered scenario, the JAV-approach with PLR is the best option to avoid obtaining
biased estimates after data imputation, and to reduce standard deviation compared to
CC analysis.
Points of future research based on the results of this thesis could be a comparison of
the performance of the suggested multiple comparison strategies when they are used
for the stratiﬁed randomize-all design. Furthermore, the Firth correction could be
applied to the models investigated in Section 3.4 when smaller sample sizes are used.
For all models considered, the behavior when covariates are added to the model could
be investigated, as well as diﬀerent parameter settings. For the ﬂexible study design,
methods for sample size recalculation after adding the new biomarker group could be
investigated.
Due to the heterogeneity of biomarkers and treatments and the rapid developments
in this ﬁeld, the planning phase of a multiple-biomarker trial is a complex process and
each trial has to be adjusted to the individual situation. This thesis can give guidance
in some of the aspects that need to be considered, but of course there are many more
aspects that need to be addressed. The study designs which were discussed could, for
example, be extended to include and interim analysis strategy to facilitate sample size
recalculation, early stopping, or stopping for futility.
Chapter 5
Summary
Planning and analyzing a multiple biomarker trial is a challenging task comprising va-
rious factors which have to be considered. It is an area of ongoing research and only
a limited number of multiple biomarker trials have already been completed and their
results published. Learning from these completed trials is an important part of the
planning process, which can help to avoid issues and pitfalls that these trials may have
encountered. Some of the issues which were reported by completed trials, such as low
prevalence of the biomarkers and not being able to react to the latest developments
regarding biomarkers and treatments, are addressed in this thesis.
Sample size calculation and data analysis methods for testing an overall treatment
strategy are investigated for situations where biomarker prevalences make it unfeasi-
ble to test within the individual biomarker-groups. Additionally, the issue of a large
number of biomarker-negative patients is addressed, which is a side eﬀect in trials
that investigate lower prevalence biomarkers. Diﬀerent analysis approaches for a trial
that includes biomarker-negative patients are compared and it is examined whether
inclusion of biomarker-negative patients in the analysis can improve bias and standard
deviation of the treatment eﬀect estimates. Finally, a ﬂexible study design is conside-
red that allows a new biomarker-group with corresponding experimental treatment to
be included in the study after accrual has already begun. Diﬀerent aspects of study
design modiﬁcation are discussed and diﬀerent models for analysis of such a study
are compared. Furthermore, the issue of missing biomarker data is addressed. If the
initial biomarker screening did not include the new biomarker before it was added to
the study, the biomarker status regarding this biomarker has to be determined retro-
spectively for patients that are included in the study before adding the new biomarker.
This may lead to missing data for some or all of the patients. For cases where data is
only partially missing, diﬀerent methods for missing data imputation for models with
interaction terms are investigated and compared.
The ﬁrst issue of three issues which are addressed in this thesis is low prevalence of the
biomarkers. For a study which tests an overall biomarker-guided treatment strategy,
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the sample size calculation method by Palta and Amini appears to be the most ap-
propriate choice when heterogeneous treatment eﬀects are expected. The results from
the simulation study suggest that the subsequent data analysis could be performed
using the two-step approach suggested by Mehrotra or a shared frailty model. If no
other covariates are included in the model, an exact log-rank test could also be used.
The asymptotic log-rank test and the stratiﬁed Cox PH model suﬀers loss of power
in the simulation study and therefore should not be used for heterogeneous treatment
eﬀects. To test the individual biomarker-groups as secondary hypotheses after testing
the overall treatment strategy, some strategies for multiple testing are suggested.
The second issue that is addressed is a large expected number of biomarker-negative
patients at the screening stage. For a situation where an overall biomarker-guided
treatment strategy is not desirable, a combined analysis model using the data from
the entire study, including biomarker-negative patients, is investigated. This combined
model estimates the treatment eﬀects for the individual biomarkers. Application of the
Firth correction appeared to be a good method for reduction of small sample size bias,
which is likely to occur for low prevalence biomarkers. The inclusion of biomarker-
negative patients in the model can provide a small additional beneﬁt with respect to
reduction of bias and standard deviation.
The third issue considered is the constant discovery of new biomarkers and correspon-
ding biomarker-guided experimental therapies. It is desirable for a clinical trial to be
able to react to these continuous developments by investigating options to add new
biomarkers and corresponding therapies to an ongoing study. Diﬀerent models for data
analysis are compared for a situation with a belatedly added biomarker, an overlap of
biomarkers within the population, and an eﬀect of the new biomarker on the response
to the experimental treatment of an already existing biomarker-group. Adding an in-
teraction term to the combined analysis model can help avoiding biased treatment
eﬀect estimates when there is overlap of the biomarkers within the patient popula-
tion, and when patients with both biomarkers respond diﬀerently to the experimental
therapy than patients with only one of the biomarkers. If there is missing data regar-
ding the biomarker status of the belatedly added biomarker, data imputation can be
utilized. However, the correct model speciﬁcation is crucial to avoid biased estimates
when interaction terms are part of the model for the ﬁnal analysis. These interaction
terms should already be included in the imputation model rather than imputing them
passively. The simulation study suggests that for the considered scenario, the `just-
another-variable'-approach with polytomous logistic regression is the best option to
avoid obtaining biased estimates after data imputation.
Due to the heterogeneity of biomarkers and treatments and the rapid developments
in this ﬁeld, the planning phase of a multiple-biomarker trial is a complex process and
each trial has to be adjusted to the individual situation. This thesis can give guidance
in some of the aspects that need to be considered, but of course there are many more
aspects that need to be addressed.
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Appendix
A.1. Supplementary ﬁgures
Figures for Section 3.3
A simulation study was conducted to compare the performance of the three approaches
discussed in Section 3.3.1 with respect to bias, standard deviation and RMSE of the
diﬀerent parameter estimates. It was investigated whether there is a beneﬁt of including
biomarker-negative patients in the study. Additionally it was investigated, whether
application of the Firth correction can further reduce the bias.
Figures A.1 and A.2 show the RMSE of βˆ1 and βˆ2 respectively. Figure A.3 shows bias,
standard deviation, and RMSE of γˆ1 and γˆ2. Figure A.4 shows the behavior of the
standard deviation of βˆ1 and βˆ2 for diﬀerent baseline hazards.
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Figure A.1: The RMSE of log hazard ratio β1, the treatment eﬀect estimate for the
biomarker indicative of a favorable prognosis (B1), without and with Firth correction
for sample sizes 100, 150, 250, and 1,000.
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Figure A.2: The RMSE of log hazard ratio β2 without and with Firth correction for
sample sizes 100, 150, 250, and 1,000.
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Figure A.3: Bias and standard deviation of the estimates of γ1 and γ2, the prognostic
eﬀects for biomarkers 1 and 2, respectively, using a Cox model without and with Firth
correction for Approach 3 and sample sizes 100, 150, 250, and 1,000.
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Figure A.4: Comparison of standard deviation for diﬀerent baseline hazards for n =
100: Standard deviation of the estimates of log hazard ratio β1 and log hazard
ratio β2, using a Cox model without and with Firth correction given baseline hazards
λ01 : 0.025, 0.02865, 0.034, 0.04 and λ02 : 0.1, 0.0875, 0.075, 0.0625, respectively.
The baseline hazards for B1 correspond to multiplying λ00 with exp(γ1), where
γ1 = log(
1
2), γ1 = log(4/7), γ1 = log(2/3), and γ1 = log(4/5), respectively. The
baseline hazards for B2 correspond to multiplying λ00 = 0.05 with exp(γ2), where
γ2 = log(2), γ2 = log(7/4), γ2 = log(3/2), and γ2 = log(5/4), respectively.
For all Figures, bias, standard deviation, and RMSE were calculated from 10,000 Si-
mulations runs. Fixed parameters: exp(β2) = 0.8, λ00 = 0.05, γ1 = log(0.5) and
γ2 = log(2). The patient proportions in biomarker groups B0, B1, and B2 are 0.5,
0.25, and 0.25, respectively, and treatment allocation ratio between treatments for B1,
and B2 is 1:1.
Figures for Section 3.4
The bias of the estimates of β1, β2, and β1,2 when using PI, the JAV-approach or the
stratify-approach was compared to the bias resulting from CC analysis and from the
analysis of the full data set. Three imputation methods to predict the missing values
were used and compared for the three imputation approaches: logistic regression (LR),
polytomous logistic regression (PLR), and predictive mean matching (PMM). Unless
otherwise indicated, missing data are MCAR.
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It was investigated whether the results of the simulation study are sensitive to a change
of parameters, e.g. for a diﬀerent eﬀect τ , i.e. the factor by which the hazard ratio
for B2-patients treated with Exp1 diﬀers from the hazard ratio for B1-patients treated
with Exp1. Figures A.5 and A.6 show the results for τ = 0.75 and τ = 2, respectively.
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(a) Logistic regression
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure A.5: Eﬀect τ=0.75: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2
treating interactions as JAV in imputation model. B1 is the prioritized biomarker in
the allocation algorithm, data is MCAR, and m=10 imputations.
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(a) Logistic regression
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(b) Polytomous logistic regression
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(c) Predictive mean matching
Figure A.6: Eﬀect τ = 2: Bias for LR, PLR, and PMM for βˆ1,2, βˆ1, and βˆ2 treating
interactions as JAV in imputation model. B1 is the prioritized biomarker in the
allocation algorithm, data is MCAR, and m=10 imputations.
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A.2. Supplementary tables
Tables for Section 3.2
The formulas for sample size calculation by Schoenfeld, Palta and Amini, and Lachin
and Foulkes were compared (Table A.1). For each hazard ratio constellation of the
simulation study, the required sample size for a power of 0.8 is determined with each
of the sample size formulas.
Afterwards, the diﬀerent analysis methods were evaluated with respect to the power
to detect a signiﬁcant overall treatment eﬀect, given speciﬁc hazard ratio scenarios.
The numerical results for the sample size obtained from the formulas by Schoenfeld
and Lachin and Foulkes are shown in Tables A.2-A.4.
For all following tables, the hazard ratios of B1 and B2 are varied between 0.8 and 0.4,
and 0.8 and 0.3, respectively; the hazard ratio for B0 is held constant at 0.8. 10,000
simulations.
Table A.1: Comparison of sample sizes calculated from formulas by Schoenfeld, Palta
and Amini, and Lachin and Foulkes for diﬀerent scenarios.
HR Sample size
B0, B1, B2 Schoenfeld Palta Amini Lachin Foulkes
0.8 0.8 0.8 831 763 686
0.8 0.8 0.7 652 574 540
0.8 0.8 0.6 495 437 417
0.8 0.8 0.5 365 336 316
0.8 0.8 0.4 263 259 236
0.8 0.8 0.3 185 200 172
0.8 0.7 0.7 492 461 404
0.8 0.7 0.6 390 360 325
0.8 0.7 0.5 300 282 256
0.8 0.7 0.4 224 222 197
0.8 0.7 0.3 163 174 149
0.8 0.6 0.6 305 297 249
0.8 0.6 0.5 243 238 204
0.8 0.6 0.4 188 190 163
0.8 0.6 0.3 141 152 127
0.8 0.5 0.5 195 200 160
0.8 0.5 0.4 156 163 132
0.8 0.5 0.3 121 131 106
0.8 0.4 0.4 128 138 105
0.8 0.4 0.3 102 113 87
135
Table A.2: Numerical results for the power comparison of the stratiﬁed Cox model,
Mehrotra's two-step approach, the lognormal shared frailty model, and stratiﬁed
exact and asymptotic log-rank test to detect a true treatment eﬀect when using
Schoenfeld's sample size formula under diﬀerent scenarios.
Input Power
HR Sample Strat.Cox Twostep Frailty Exact Asympt.
B0, B1, B2 Size Wald Wald lognorm log-rank log-rank
0.8 0.8 0.8 831 0.833 0.833 0.832 0.828 0.833
0.8 0.8 0.7 652 0.841 0.839 0.841 0.831 0.842
0.8 0.8 0.6 495 0.842 0.843 0.842 0.834 0.842
0.8 0.8 0.5 365 0.818 0.830 0.826 0.826 0.819
0.8 0.8 0.4 263 0.781 0.812 0.808 0.809 0.783
0.8 0.8 0.3 185 0.722 0.789 0.773 0.787 0.725
0.8 0.7 0.7 492 0.817 0.823 0.822 0.822 0.817
0.8 0.7 0.6 390 0.824 0.830 0.829 0.828 0.825
0.8 0.7 0.5 300 0.815 0.834 0.827 0.828 0.816
0.8 0.7 0.4 224 0.774 0.807 0.798 0.806 0.776
0.8 0.7 0.3 163 0.725 0.791 0.774 0.790 0.727
0.8 0.6 0.6 305 0.809 0.824 0.817 0.823 0.811
0.8 0.6 0.5 243 0.795 0.816 0.810 0.814 0.796
0.8 0.6 0.4 188 0.767 0.804 0.798 0.804 0.769
0.8 0.6 0.3 141 0.730 0.795 0.778 0.796 0.735
0.8 0.5 0.5 195 0.770 0.805 0.792 0.809 0.772
0.8 0.5 0.4 156 0.750 0.795 0.780 0.796 0.753
0.8 0.5 0.3 121 0.713 0.778 0.765 0.785 0.717
0.8 0.4 0.4 128 0.723 0.787 0.762 0.790 0.727
0.8 0.4 0.3 102 0.689 0.764 0.747 0.773 0.695
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Table A.3: Numerical results for the power comparison of the stratiﬁed Cox model,
Mehrotra's two-step approach, the lognormal shared frailty model, and stratiﬁed
exact and asymptotic log-rank test to detect a true treatment eﬀect when using
Lachin and Foulkes' sample size formula under diﬀerent scenarios.
Input Power
HR Sample Strat.Cox Twostep Frailty Exact Asympt.
B0, B1, B2 Size Wald Wald lognorm log-rank log-rank
0.8 0.8 0.8 686 0.760 0.761 0.762 0.759 0.761
0.8 0.8 0.7 540 0.768 0.767 0.769 0.760 0.769
0.8 0.8 0.6 417 0.775 0.777 0.778 0.767 0.776
0.8 0.8 0.5 316 0.761 0.774 0.773 0.767 0.763
0.8 0.8 0.4 236 0.734 0.767 0.759 0.764 0.736
0.8 0.8 0.3 172 0.680 0.751 0.733 0.751 0.683
0.8 0.7 0.7 404 0.735 0.744 0.741 0.740 0.737
0.8 0.7 0.6 325 0.751 0.760 0.756 0.754 0.752
0.8 0.7 0.5 256 0.742 0.759 0.754 0.754 0.744
0.8 0.7 0.4 197 0.726 0.762 0.757 0.763 0.728
0.8 0.7 0.3 149 0.681 0.748 0.731 0.748 0.684
0.8 0.6 0.6 249 0.717 0.735 0.729 0.733 0.719
0.8 0.6 0.5 204 0.712 0.739 0.733 0.739 0.714
0.8 0.6 0.4 163 0.700 0.741 0.734 0.744 0.703
0.8 0.6 0.3 127 0.675 0.741 0.727 0.740 0.678
0.8 0.5 0.5 160 0.677 0.717 0.707 0.720 0.680
0.8 0.5 0.4 132 0.670 0.726 0.713 0.725 0.674
0.8 0.5 0.3 106 0.649 0.725 0.710 0.731 0.655
0.8 0.4 0.4 105 0.629 0.698 0.679 0.700 0.635
0.8 0.4 0.3 87 0.627 0.695 0.691 0.714 0.634
137
Table A.4: Numerical results for the power comparison of the stratiﬁed Cox model,
Mehrotra's two-step approach, the lognormal shared frailty model, and stratiﬁed
exact and asymptotic log-rank test to detect a true treatment eﬀect when using
Lachin and Foulkes' sample size formula (with sample proportion weights) under
diﬀerent scenarios.
Input Power
HR Sample Strat.Cox Twostep Frailty Exact Asympt.
B0, B1, B2 Size Wald Wald lognorm log-rank log-rank
0.8 0.8 0.8 632 0.721 0.719 0.720 0.714 0.722
0.8 0.8 0.7 469 0.711 0.712 0.713 0.703 0.712
0.8 0.8 0.6 360 0.715 0.718 0.716 0.706 0.716
0.8 0.8 0.5 282 0.701 0.717 0.715 0.710 0.703
0.8 0.8 0.4 226 0.705 0.739 0.733 0.740 0.707
0.8 0.8 0.3 184 0.722 0.786 0.770 0.788 0.724
0.8 0.7 0.7 381 0.716 0.724 0.724 0.725 0.718
0.8 0.7 0.6 298 0.712 0.720 0.719 0.711 0.713
0.8 0.7 0.5 238 0.706 0.723 0.723 0.720 0.708
0.8 0.7 0.4 193 0.711 0.746 0.739 0.745 0.713
0.8 0.7 0.3 159 0.714 0.779 0.762 0.780 0.718
0.8 0.6 0.6 249 0.717 0.735 0.729 0.733 0.719
0.8 0.6 0.5 201 0.707 0.735 0.730 0.733 0.710
0.8 0.6 0.4 165 0.705 0.748 0.739 0.745 0.708
0.8 0.6 0.3 137 0.707 0.772 0.756 0.771 0.710
0.8 0.5 0.5 171 0.706 0.743 0.733 0.746 0.709
0.8 0.5 0.4 142 0.708 0.760 0.746 0.761 0.712
0.8 0.5 0.3 119 0.703 0.772 0.757 0.779 0.708
0.8 0.4 0.4 122 0.699 0.765 0.740 0.768 0.703
0.8 0.4 0.3 103 0.695 0.769 0.752 0.782 0.701
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Tables for Section 3.3
Simulations were run to investigate the robustness of the estimators for the approaches
in Section 3.3 against violations of model assumptions and change of parameters. The
bias and standard deviation were investigated for diﬀerent biomarker prevalences and
for a non-constant (Weibull distributed) hazard function, with Weibull shape parame-
ters 0.4, 1 and 5. For better comparability, λ0 was adjusted such that the same number
of events is reached at 60 months for all shape parameters, i.e. λ0 = 0.05 · 60/60shape.
Tables A.5 and A.6 show the type I error rates for these scenarios for all three appro-
aches for β1 and β2 without and with Firth correction.
Table A.5: Type I error for the diﬀerent approaches and diﬀerent scenarios. Simula-
tions: 10,000. Sample size: 10,000.
Approach 1 Approach 2 Approach 3 Mean no. Scenario
β1 β2 β1 β2 β1 β2 events
0.050 0.048 0.050 0.048 0.050 0.048 8371
0.048 0.049 0.048 0.048 0.048 0.048 8176 diﬀerent biomarker prevalences
0.052 0.050 0.052 0.051 0.052 0.050 9189 Weibull shape 0.4 (no censoring)
0.050 0.048 0.050 0.048 0.050 0.048 9189 Weibull shape 1 (no censoring)
0.052 0.049 0.051 0.049 0.052 0.049 9189 Weibull shape 5 (no censoring)
0.052 0.050 0.052 0.051 0.052 0.050 7848 Weibull shape 0.4 (with censoring)
0.052 0.049 0.051 0.049 0.052 0.049 6053 Weibull shape 5 (with censoring)
Table A.6: Type I error for the diﬀerent approaches and diﬀerent scenarios with Firth
correction. Simulations: 10,000. Sample size: 10,000.
Approach 1 Approach 2 Approach 3 Mean no. Scenario
β1 β2 β1 β2 β1 β2 events
0.050 0.048 0.050 0.048 0.050 0.048 8371
0.048 0.049 0.048 0.048 0.048 0.048 8176 diﬀerent biomarker prevalences
0.052 0.050 0.052 0.051 0.052 0.050 9189 Weibull shape 0.4 (no censoring)
0.050 0.048 0.050 0.048 0.050 0.048 9189 Weibull shape 1 (no censoring)
0.052 0.049 0.051 0.049 0.052 0.049 9189 Weibull shape 5 (no censoring)
0.052 0.050 0.052 0.051 0.052 0.050 7848 Weibull shape 0.4 (with censoring)
0.052 0.049 0.051 0.049 0.052 0.049 6053 Weibull shape 5 (with censoring)
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A.3. Selected R-Code
Sample size calculation for 3.2.
#######################################################################################
### estimate survival probabilities ###
t <- (accrual / 2) + followup
study_length <- accrual + followup
surv_prob_std <- sum((bio_prop * (1-rand.prob) / p_std) * exp(-lambda0 * t))
surv_prob_exp <- sum((bio_prop * rand.prob / p_exp) * exp(-lambda1 * t))
#######################################################################################
### estimate average hazard ratio and hazard rates ###
### for Z=0 ###
lambda_std <- -log(surv_prob_std) / t
### for Z=1 ###
HR_avg <- log(surv_prob_exp) / log(surv_prob_std)
lambda_exp <- HR_avg * lambda_std
lambda_star_std <- lambda_cens + lambda_std
lambda_star_exp <- lambda_cens + lambda_exp
eventrate_std <- (lambda_std/lambda_star_std) * (1 + (1/(accrual * lambda_star_std)) *
exp(-lambda_star_std * (study_length)) -
(1/(accrual * lambda_star_std)) * exp(-lambda_star_std * followup))
eventrate_exp <- (lambda_exp/lambda_star_exp) * (1 + (1/(accrual * lambda_star_exp)) *
exp(-lambda_star_exp * (study_length)) -
(1/(accrual * lambda_star_exp))*exp(-lambda_star_exp*followup))
eventrate <- p_std * eventrate_std + p_exp * eventrate_exp
#######################################################################################
### Schoenfeld ###
n_schoenfeld <- ceiling((qnorm(1 - beta) + qnorm(1 - alpha/2))^2 /
(p_std * p_exp * log(HR)^2 * eventrate))
#######################################################################################
### Palta & Amini ###
V_s <- rand.prob * (1 - (exp(-lambda1 * followup) -
exp(-lambda1 * study_length)) / (lambda1 * accrual)) +
(1-rand.prob) * (1-(exp(-lambda0 * followup) -
exp(-lambda0 * study_length)) / (lambda0 * accrual))
mu <- (sum(log(HR) * bio_prop * rand.prob * (1 - rand.prob) * V_s)) /
(sqrt(sum(bio_prop * rand.prob) * (1 - rand.prob) * V_s)))
n_palta <- ceiling((qnorm(1 - beta) + qnorm(1 - alpha/2))^2 / mu^2)
#######################################################################################
### Lachin & Foulkes ###
Phi <- function(lambda){
phi <- lambda^2 * ((lambda + lambda_cens * (1-(1/(accrual * (lambda+lambda_cens))) *
exp(-(lambda + lambda_cens) * followup) -
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exp(-(lambda + lambda_cens) * (accrual + followup)))) / lambda)
return(phi)
}
lambda_bar <- rand.prob * lambda1 + (1 - rand.prob) * lambda0
lambda0_bar <- sum(lambda0 * bio_prop)
lambda1_bar <- sum(lambda1 * bio_prop)
lambda_bar_mean <- sum(lambda_bar * bio_prop)
### initial sample size for sigma weights from Lachin formula ###
n_init <- ceiling(((qnorm(1-alpha/2) * sqrt(Phi(lambda_bar_mean) * ((1/rand.prob) +
(1/(1-rand.prob)))) + qnorm(1-beta) * sqrt(Phi(lambda1_bar) *
(1/rand.prob) + Phi(lambda0_bar) * (1/(1-rand.prob)))) /
mean(lambda1-lambda0))^2)
Psi0 <- Phi(lambda_bar) * (1/rand.prob + 1/(1 - rand.prob))
Psi1 <- Phi(lambda1) / rand.prob + Phi(lambda0) / (1 - rand.prob)
Sigma <- sum((bio_prop * Psi1) / (Psi0^2))
Omega <- sum(bio_prop / Psi0)
###sigma weights###
sigma0 <- Psi0 / (n_init * bio_prop)
w <- (1/sigma0) / ((1/sigma0[1]) + (1/sigma0[2]) + (1/sigma0[3]))
lambda_diff <- sum(w * (lambda1 - lambda0))
n_lachinfoulkes <- ceiling(((qnorm(1-alpha/2) * sqrt(Omega^(-1)) + qnorm(1-beta) *
sqrt(Omega^(-2) * Sigma)) / lambda_diff)^2)
#######################################################################################
###Lachin & Foulkes with sample size weigths###
w_ssize <- bio_prop
lambda_diff_ssize <- sum(w_ssize * (lambda1 - lambda0))
n_lachinfoulkes_ssize <- ceiling(((qnorm(1 - alpha/2) * sqrt(Omega^(-1)) +
qnorm(1 - beta) * sqrt(Omega^(-2) * Sigma)) /
lambda_diff_ssize)^2)
Data generation for Sections 3.2 and 3.3.
data <- data.frame(patientID=rep(NA, n), adm_cens_time=rep(NA, n),
biomarker_status=rep(NA, n), biomarker=rep(NA, n),
survival_time=rep(NA, n), cens_time=rep(NA, n), group=rep(NA, n),
arm=rep(NA, n), status=rep(NA, n), os=rep(NA, n))
### patients ###
data$patientID <- c(1:n)
#######################################################################################
### Draw biomarker status for each patient ###
data$biomarker_status <- sample(c(0:2), n, replace = T, prob = bio_prop)
nB0 <- length(data$biomarker_status[data$biomarker_status == 0])
nB1 <- length(data$biomarker_status[data$biomarker_status == 1])
nB2 <- length(data$biomarker_status[data$biomarker_status == 2])
#######################################################################################
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### Randomize within arms ###
Z0 <- rbinom(nB0, 1, rand.prob[[1]])
Z1 <- rbinom(nB1, 1, rand.prob[[2]])
Z2 <- rbinom(nB2, 1, rand.prob[[3]])
data$biomarker[data$biomarker_status == 0] <- 'B0'
data$group[data$biomarker_status == 0] <- Z0
data$biomarker[data$biomarker_status == 1] <- 'B1'
data$group[data$biomarker_status == 1] <- Z1
data$biomarker[data$biomarker_status == 2] <- 'B2'
data$group[data$biomarker_status == 2] <- Z2
data$arm[data$biomarker_status == 0 & data$group == 0] <- 'B00'
data$arm[data$biomarker_status == 0 & data$group == 1] <- 'B01'
data$arm[data$biomarker_status == 1 & data$group == 1] <- 'B11'
data$arm[data$biomarker_status == 2 & data$group == 0] <- 'B20'
data$arm[data$biomarker_status == 2 & data$group == 1] <- 'B21'
#######################################################################################
### Survival times ###
nB10 <- length(data$arm[data$arm == "B10"])
nB11 <- length(data$arm[data$arm == "B11"])
nB20 <- length(data$arm[data$arm == "B20"])
nB21 <- length(data$arm[data$arm == "B21"])
U1 <- runif(nB0, min = 0, max = 1)
U2 <- runif(nB10, min = 0, max = 1)
U3 <- runif(nB11, min = 0, max = 1)
U4 <- runif(nB20, min = 0, max = 1)
U5 <- runif(nB21, min = 0, max = 1)
data$survival_time[data$arm == 'B00'] <- (-(log(U1)/(lambda0[[1]])))^(1/shape)
data$survival_time[data$arm == 'B01'] <- (-(log(U2)/(lambda1[[1]])))^(1/shape)
data$survival_time[data$arm == 'B10'] <- (-(log(U2)/(lambda0[[2]])))^(1/shape)
data$survival_time[data$arm == 'B11'] <- (-(log(U3)/(lambda1[[2]])))^(1/shape)
data$survival_time[data$arm == 'B20'] <- (-(log(U4)/(lambda0[[3]])))^(1/shape)
data$survival_time[data$arm == 'B21'] <- (-(log(U5)/(lambda1[[3]])))^(1/shape)
#######################################################################################
### random censoring ###
if(p.rand.cens > 0 & p.rand.cens <= 1){
lambda.cens <- (p.rand.cens*sum(bio_prop*((lambda0+lambda1)/2)))/
(1-p.rand.cens)
data$cens_time <- rexp(n, rate = lambda.cens)
} else{
data$cens_time <- rep(Inf, n)
}
#######################################################################################
### staggered entry/administrative censoring ###
if(accrual > 0){
data$adm_cens_time <- runif(n, min = followup, max = accrual+followup)
} else{
data$adm_cens_time <- rep(Inf, n)
}
#######################################################################################
### overall survival ###
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data$os <- pmin(data$survival_time, data$cens_time, data$adm_cens_time)
#######################################################################################
### status 1=dead 0=alive ###
data$status[data$survival_time <= data$os] <- 1
data$status[data$survival_time > data$os] <- 0
Data analysis for Section 3.2
### Surv objects ###
Surv <- Surv(data$os, data$status)
SurvB0 <- Surv(data$os[data$biomarker_status==0], data$status[data$biomarker_status==0])
SurvB1 <- Surv(data$os[data$biomarker_status==1], data$status[data$biomarker_status==1])
SurvB2 <- Surv(data$os[data$biomarker_status==2], data$status[data$biomarker_status==2])
#######################################################################################
### (Stratified) asymptotic log-rank test ###
diff <- survdiff(Surv ~ group + strata(biomarker_status), data=data)
diffB0 <- survdiff(SurvB0 ~ group[data$biomarker_status==0], data=data)
diffB1 <- survdiff(SurvB1 ~ group[data$biomarker_status==1], data=data)
diffB2 <- survdiff(SurvB2 ~ group[data$biomarker_status==2], data=data)
#######################################################################################
### Log-rank pvalues ###
p.val <- (1 - pchisq(diff$chisq, length(diff$n) - 1))
p.valB0 <- (1 - pchisq(diffB0$chisq, length(diffB0$n) - 1))
p.valB1 <- (1 - pchisq(diffB1$chisq, length(diffB1$n) - 1))
p.valB2 <- (1 - pchisq(diffB2$chisq, length(diffB2$n) - 1))
nB0 <- length(data$biomarker_status[data$biomarker_status==0])
nB1 <- length(data$biomarker_status[data$biomarker_status==1])
nB2 <- length(data$biomarker_status[data$biomarker_status==2])
n <- nB0 + nB1 + nB2
#######################################################################################
### Stratified exact/approximate log-rank test ###
diff.exactLR <- logrank_test(Surv ~ factor(group)|factor(biomarker_status),
data=data, distribution=approximate(B=10000))
p.val.exactLR <- pvalue(diff.exactLR)[1]
#######################################################################################
### Frailty coxph (Gamma) ###
frail.coxph <- coxph(Surv ~ group + frailty.gamma(biomarker_status), data=data)
p.val.frail.coxph <- coef(summary(frail.coxph))[1,6]
#######################################################################################
### Frailty coxme (Gaussian) ###
frail.coxme <- coxme(Surv ~ group + (1|biomarker_status), data=data)
chisq.frail.coxme <- (fixef(frail.coxme))^2 / vcov(frail.coxme)
p.val.frail.coxme <- 1 - pchisq(chisq.frail.coxme, 1)
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#######################################################################################
### Stratified Cox ###
strat.cox <- coxph(Surv ~ group + strata(biomarker_status), data=data)
p.val.strat.cox <- coef(summary(strat.cox))[,5]
#######################################################################################
### Two-step procedure ###
fitB0 <- coxph(SurvB0 ~ group[data$biomarker_status==0], data=data)
fitB1 <- coxph(SurvB1 ~ group[data$biomarker_status==1], data=data)
fitB2 <- coxph(SurvB2 ~ group[data$biomarker_status==2], data=data)
fit_vec <- c(unname(fitB0$coefficients), unname(fitB1$coefficients),
unname(fitB2$coefficients))
HR_vec <- exp(fit_vec)
var_vec <- c(fitB0$var, fitB1$var, fitB2$var)
### ssize weigths ###
weights_ssize <- c(nB0/n, nB1/n, nB2/n)
### test statistic ###
twostep_HR <- exp(sum(fit_vec * weights_ssize))
twostep_coef <- sum(fit_vec * weights_ssize)
twostep_var <- sum(var_vec * weights_ssize^2)
twostep_wald <- (twostep_coef)^2 / twostep_var
p.val.twostep <- 1 - pchisq(twostep_wald, 1)
Data analysis for Section 3.3
### Surv objects ###
Surv <- Surv(data$os, data$status)
SurvB1 <- Surv(data$os[data$biomarker_status==1], data$status[data$biomarker_status==1])
SurvB2 <- Surv(data$os[data$biomarker_status==2], data$status[data$biomarker_status==2])
SurvB1B2 <- Surv(data$os[data$biomarker_status!=0],
data$status[data$biomarker_status!=0])
data$treatment <- data$biomarker_status * data$group
data$treatment1 <- as.numeric(data$treatment == 1)
data$treatment2 <- as.numeric(data$treatment == 2)
#######################################################################################
### Approach 3 (full model) ###
cox_full <- coxph(Surv ~ factor(biomarker_status) + treatment1 + treatment2, data=data)
beta.cox_full_gamma1 <- coef(summary(cox_full))[,1][1]
beta.cox_full_gamma2 <- coef(summary(cox_full))[,1][2]
beta.cox_full_trt1 <- coef(summary(cox_full))[,1][3]
beta.cox_full_trt2 <- coef(summary(cox_full))[,1][4]
#######################################################################################
### Approach 2 (no biomarker-negative patients) ###
cox_B1B2 <- coxph(SurvB1B2 ~ factor(biomarker_status) +treatment1 +treatment2,
data=data[data$biomarker_status!=0,])
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beta.cox_B1B2_gamma2 <- unname(coef(summary(cox_B1B2))[,1][1])
beta.cox_B1B2_trt1 <- unname(coef(summary(cox_B1B2))[,1][2])
beta.cox_B1B2_trt2 <- unname(coef(summary(cox_B1B2))[,1][3])
#######################################################################################
### Approach 1 (individual models) ###
cox_B1 <- coxph(SurvB1 ~ group, data=data[data$biomarker_status==1,])
beta.cox_B1 <- coef(summary(cox_B1))[,1]
cox_B2 <- coxph(SurvB2 ~ group, data=data[data$biomarker_status==2,])
beta.cox_B2 <- coef(summary(cox_B2))[,1]
#######################################################################################
### Approach 3 with Firth (full model) ###
cox_full_firth <- coxphf(Surv ~ factor(biomarker_status) + treatment1 + treatment2,
data=data, firth=T)
beta.cox_full_firth_gamma1 <- unname(cox_full_firth$coefficients[1])
beta.cox_full_firth_gamma2 <- unname(cox_full_firth$coefficients[2])
beta.cox_full_firth_trt1 <- unname(cox_full_firth$coefficients[3])
beta.cox_full_firth_trt2 <- unname(cox_full_firth$coefficients[4])
#######################################################################################
### Approach 2 with Firth (no biomarker-negatives) ###
cox_B1B2_firth <- coxphf(SurvB1B2 ~ factor(biomarker_status) + treatment1 + treatment2,
data=data[data$biomarker_status!=0,], firth=T)
beta.cox_B1B2_firth_gamma2 <- unname(cox_B1B2_firth$coefficients[1])
beta.cox_B1B2_firth_trt1 <- unname(cox_B1B2_firth$coefficients[2])
beta.cox_B1B2_firth_trt2 <- unname(cox_B1B2_firth$coefficients[3])
#######################################################################################
### Approach 1 with Firth (individual models) ###
cox_B1_firth <- coxphf(SurvB1 ~ group, data=data[data$biomarker_status==1,], firth=T)
beta.cox_B1_firth <- unname(coef(cox_B1_firth))
cox_B2_firth <- coxphf(SurvB2 ~ group, data=data[data$biomarker_status==2,], firth=T)
beta.cox_B2_firth <- unname(coef(cox_B2_firth))
Data imputation and analysis for Section 3.4
### Surv object ###
Surv <- Surv(sim.data$os, sim.data$status)
### additional variables ###
sim.data$biomarkergroup[sim.data$biomarker=="B0"] <- 0
sim.data$biomarkergroup[sim.data$biomarker=="B1"] <- 1
sim.data$biomarkergroup[sim.data$biomarker=="B2"] <- 2
sim.data$treatment <- sim.data$biomarkergroup*sim.data$group
sim.data$treatment1 <- as.numeric(sim.data$treatment==1)
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sim.data$treatment2 <- as.numeric(sim.data$treatment==2)
#######################################################################################
### data analysis for Section 3.4.4.2 ###
sim.dataB1 <- sim.data$os[sim.data$biomarker == 'B1'],
sim.data$status[sim.data$biomarker == 'B1']
sim.dataB1_noB2 <- sim.data$os[sim.data$biomarker == 'B1' & sim.data$B2= = 0],
sim.data$status[sim.data$biomarker == 'B1' & sim.data$B2 == 0]
SurvB1 <- Surv(sim.dataB1$os, sim.dataB1$status)
SurvB1_noB2 <- Surv(sim.dataB1_noB2$os, sim.dataB1_noB2$status)
#######################################################################################
### Model 1 ###
cox_B1_noB2 <- coxph(SurvB1_noB2 ~ group, data=sim.dataB1_noB2)
beta.cox_B1_noB2 <- coef(summary(cox_B1_noB2))[1,1]
#######################################################################################
### Model 2 ###
cox_B1 <- coxph(SurvB1 ~ group + B2:group, data=sim.dataB1)
beta.cox_B1 <- coef(summary(cox_B1))[1,1]
beta.cox_B1_int <- coef(summary(cox_B1))[2,1]
#######################################################################################
### Model 3 ###
cox_full_true <- coxph(Surv(os, status) ~ factor(biomarkergroup) + B1:treatment1 +
B2:treatment2 + B2:treatment1, data=sim.data)
beta.cox_full_true_gamma1 <- coef(summary(cox_full_true))[,1][1]
beta.cox_full_true_gamma2 <- coef(summary(cox_full_true))[,1][2]
beta.cox_full_true_trt1 <- coef(summary(cox_full_true))[,1][3]
beta.cox_full_true_trt2 <- coef(summary(cox_full_true))[,1][4]
beta.cox_full_true_int <- coef(summary(cox_full_true))[,1][5]
#######################################################################################
### Data imputation for Section 3.4.5.3
### data frames ###
data_true <- subset(sim.data, select=c(-B2_true))
data_true$B2 <- sim.data$B2_true
sim.data_miss <- subset(sim.data, select=c(-B2_true))
sim.data_imp <- subset(sim.data, select=c(-B2_true))
model <- imp.method[1]
method <- imp.method[2]
prop.miss <- as.numeric(imp.method[3])
sim.data_imp$nelsaal <- nelsonaalen(sim.data_imp, os, status)
#######################################################################################
### naive imputation ###
if(model == 'naive'){
sim.data_imp$B2 <- as.factor(sim.data_imp$B2)
ini <- mice(sim.data_imp, max=0, print=FALSE)
pred <- ini$pred
meth <- ini$meth
pred[c("B2"), c("treatment","os")] <- 0
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pred[c("B2"), c("nelsaal")] <- 1
meth["B2"] <- method
imp <- mice(sim.data_imp, meth=meth, predictorMatrix=pred, seed=1, m=prop.miss,
print=F, maxit=10)
cox_full_imp <- with(imp, {coxph(Surv(os, status) ~ factor(biomarkergroup) +
B1:treatment1 + as.numeric(B2):treatment2 +
as.numeric(B2):treatment1)})
cox_full_imputed <- summary(pool(cox_full_imp))
#######################################################################################
### JAV apporach ###
}else if(model == 'JAV'){
## create variables for interactions ###
sim.data_imp$B1trt1 <- as.factor(sim.data_imp$B1*sim.data_imp$treatment1)
sim.data_imp$B2trt2 <- as.factor(sim.data_imp$B2*sim.data_imp$treatment2)
sim.data_imp$B2trt1 <- as.factor(sim.data_imp$B2*sim.data_imp$treatment1)
sim.data_imp$B2 <- as.factor(sim.data_imp$B2)
ini <- mice(sim.data_imp, max=0, print=FALSE)
pred <- ini$pred
meth <- ini$meth
pred[c("B2", "B2trt1", "B2trt2"),c("treatment","os")] <- 0
pred[c("B2", "B2trt1", "B2trt2"),c("nelsaal")] <- 1
pred[c("B2trt2"),] <- pred[c("B2trt1"),]
pred[c("B2"), c("B2trt1")] <- 0
pred[c("B2trt1"), c("B2")] <- 0
pred[c("B2trt2"), c("B2")] <- 0
meth[c("B2", "B2trt1", "B2trt2")] <- method
imp <- mice(sim.data_imp, meth=meth, predictorMatrix=pred, seed=1, m=prop.miss,
print=F, maxit=10)
cox_full_imp <- with(imp, {coxph(Surv(os, status) ~ factor(biomarkergroup) +
as.numeric(B1trt1)+as.numeric(B2trt2)+as.numeric(B2trt1))})
cox_full_imputed <- summary(pool(cox_full_imp))
#######################################################################################
### stratify approach ###
}else if(model == 'stratify'){
sim.data_imp$B2 <- as.factor(sim.data_imp$B2)
### stratify data set variable 'treatment' ###
sim.data_imp_trt <- split(sim.data_imp, sim.data_imp$treatment)
sim.data_imp_trt0 <- sim.data_imp_trt[[1]]
sim.data_imp_trt1 <- sim.data_imp_trt[[2]]
sim.data_imp_trt2 <- sim.data_imp_trt[[3]]
ini <- mice(sim.data_imp, max=0, print=FALSE)
pred <- ini$pred
pred[c("B2"),c("treatment","os")] <- 0
pred[c("B2"),c("nelsaal")] <- 1
pred[c("B2"),c("B1")] <- 1
meth <- ini$meth
meth["B2"] <- method
imp1 <- mice(sim.data_imp_trt1, meth = meth, predictorMatrix = pred, seed = 1,
m = prop.miss, print = F, maxit = 10)
imp0 <- mice(sim.data_imp_trt0, meth = meth, predictorMatrix = pred, seed = 1,
m = prop.miss, print = F, maxit = 10)
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imp <- rbind(imp0, imp1)
### load modified 'with' function to add complete data set (sim.data_imp_trt2)
source('with_addcomplete.R')
cox_full_imp <- with_addcomplete(imp, {coxph(Surv(os, status) ~
factor(biomarkergroup) + B1:treatment1 +
as.numeric(B2):treatment2 +
as.numeric(B2):treatment1)},
data.complete = sim.data_imp_trt2)
cox_full_imputed <- summary(pool(cox_full_imp))
}
beta.cox_full_imputed_gamma1 <- cox_full_imputed[1, 1]
vamd.cox_full_imputed_gamma1 <- cox_full_imputed[1,10]
beta.cox_full_imputed_gamma2 <- cox_full_imputed[2, 1]
vamd.cox_full_imputed_gamma2 <- cox_full_imputed[2,10]
beta.cox_full_imputed_trt1 <- cox_full_imputed[3, 1]
vamd.cox_full_imputed_trt1 <- cox_full_imputed[3,10]
beta.cox_full_imputed_trt2 <- cox_full_imputed[4, 1]
vamd.cox_full_imputed_trt2 <- cox_full_imputed[4,10]
beta.cox_full_imputed_int <- cox_full_imputed[5, 1]
vamd.cox_full_imputed_int <- cox_full_imputed[5,10]
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